Flavonoid intake and breast cancer incidence and survival by Fink, Brian N.
  
 
Flavonoid Intake and Breast Cancer Incidence and Survival 
 
 
 
 
Brian N. Fink 
 
 
 
 
A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in 
partial fulfillment of the requirements for the degree of Doctor of Philosophy in the 
Department of Epidemiology, School of Public Health 
 
 
 
Chapel Hill 
2006 
 
 
 
        
 
 
 
 
 
 
 
 
  
        Approved by 
 
                                                                                           Advisor: Dr. Marilie D. Gammon 
                                                                                                    Reader: Dr. Jane Schroder 
                                                                                                    Reader: Dr. Susan Steck 
                                                                                                    Reader: Dr. Bob Millikan 
                                                                                                    Reader: Dr. Mary Wolff 
 
 
 
 ii
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2006 
Brian N. Fink 
ALL RIGHTS RESERVED 
 
 iii
 
 
 
ABSTRACT 
Brian N. Fink: Flavonoid Intake and Breast Cancer Incidence and Survival 
(Under the direction of Marilie D. Gammon) 
 
Background: Flavonoids are phytochemicals found in a variety of foods that have 
demonstrated anti-carcinogenic properties in experimental studies.  Two epidemiologic 
studies conducted in the Mediterranean have observed an inverse association between dietary 
intake of certain flavonoid classes and breast cancer incidence.  However, it is unknown 
whether a similar association is evident among American women.  Further, whether 
flavonoids affect breast cancer survival is unknown.  We investigated whether dietary 
flavonoid intake influences breast cancer incidence and survival among a population-based 
cohort of American women.  Methods: A population-based, case-control study was 
conducted among women ages 20-98 years who resided in Nassau and Suffolk counties in 
Long Island, New York.  Cases were newly diagnosed with a first invasive breast cancer 
between August 1, 1996 and July 31, 1997; controls were identified using random digit 
dialing and Health Care Finance Administration rosters.  Trained interviewers administered 
an in-person questionnaire to participants on known and suspected breast cancer risk factors.  
Participants also completed a self-administered food frequency questionnaire regarding their 
average frequency of food and beverage consumption in the prior 12 months.  For those with 
known menopausal status, 1,434 breast cancer cases and 1,440 controls provided adequate 
dietary responses.  Case medical records were obtained to assess tumor characteristics and 
initial course of treatment.  Cases were followed-up through 2002.  All-cause mortality (n = 
 iv
173) and breast cancer-specific mortality (n = 113) were determined through the National 
Death Index.  Results: Increasing intake of flavonols, flavones, flavan-3-ols, and lignans, as 
reported at the case-control interview, was associated with a reduced risk of incident post-
menopausal breast cancer among Long Island women.  All-cause mortality among post-
menopausal women was reduced for intake of flavones and isoflavones and similar results 
were observed for breast cancer-specific mortality.  Conclusion: Findings provide evidence 
for a beneficial effect of flavones, flavonols and lignans on breast cancer incidence among 
post-menopausal women.  Results from the follow-up study indicate that mortality among 
post-menopausal breast cancer patients is reduced in association with high intake of flavones 
and isoflavones near the time of diagnosis.  These findings suggest American women can 
consume sufficient levels of flavonoid-rich foods to benefit from their potential 
chemopreventive effects. 
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CHAPTER I: BACKGROUND AND INTRODUCTION 
 
Overview of Study Background, Specific Aims, and Hypotheses  
    In 2005, an estimated 211,240 new cases of invasive breast cancer were diagnosed and 
40,110 deaths among American women were attributable to breast cancer (1).  Migration 
studies and variation of international incidence and mortality rates suggest breast cancer is 
affected by lifestyle and environmental factors (2).   
    Analytic epidemiology studies have identified many reproductive and lifestyle factors that 
modestly influence breast cancer risk, and may influence survival.  The generally accepted 
reproductive risk factors for breast cancer development, such as the timing of menarche, age 
at first birth, and menopause, strongly implicate ovarian hormones, particularly the estrogens, 
in breast cancer development (3).   
In terms of breast cancer survival, many of the related clinical and non-clinical factors may 
also work through an estrogen pathway.  Poor prognosis is associated with large tumor size, 
axillary node involvement, stage at diagnosis, and estrogen receptor negative and 
progesterone receptor negative tumors (4-9).  Also influential on the time between diagnosis 
and mortality are the treatment undergone, including surgery, radiation, chemotherapy, and 
hormone therapy (9).   
    Of the non-clinical factors, obesity at the time of breast cancer diagnosis has been the most 
frequently recognized determinant of breast cancer survival among both pre-menopausal and 
post-menopausal women (10-30).  If obesity affects prognosis, so may other non-clinical 
factors.  Some follow-up studies have suggested that increased consumption of fruits and 
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vegetables may enhance breast cancer prognosis (31-33), and thus estrogen and oxidative 
stress pathways may be involved. 
    The effects of dietary practices on breast cancer have garnered a great deal of focus, 
particularly fruit and vegetable consumption.  While fruits and vegetables appear to reduce 
the risk of breast cancer incidence, the exact components driving this effect are unknown 
(34-36).  A common counterargument to their potential benefit is that people who eat plenty 
of fruits and vegetables tend to eat healthier overall diets and are less likely to smoke 
cigarettes, consume alcohol, and live a sedentary lifestyle (37).  Yet, certain components of 
fruits and vegetables are suspected to prevent various types of cancer (34, 36).  Fruits and 
vegetables are known to contain antioxidants and phytoestrogens, both of which have 
demonstrated effects on the estrogen pathway (38-42) and oxidative stress pathway (43-47).  
A previous analysis of case-control data from the Long Island Breast Cancer Study Project 
(LIBCSP) found that increased intake of fruits and vegetables was associated with a 
decreased risk of breast cancer (48).  This association remained even after adjustment for 
several, conventionally-evaluated antioxidants under study as well as supplement use, 
suggesting there may be additional chemopreventive agents involved, such as flavonoids 
(48).  Flavonoids are polyphenolic compounds that occur naturally in foods and beverages of 
plant origin including fruits, vegetables, chocolate, tea, and wine, and are hypothesized to be 
associated with a lower risk of breast cancer and improved prognosis (49). 
    It is suspected that flavonoids may operate through an estrogen pathway and oxidative 
stress pathway, the same pathways that many risk factors for breast cancer operate (38-47).  
For example, some flavonoids have demonstrated an ability to inhibit aromatase, a 
cytochrome p450 enzyme that synthesizes endogenous estradiol (50-53).  Flavonoids may 
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therefore reduce estradiol’s growth stimulatory effects in breast cancer cells (49).  
Additionally, some flavonoids have demonstrated the ability to inhibit tumor cell 
proliferation through enzyme inhibition (54, 55).  This may reduce the amount of reactive 
oxygen species (ROS), which are also believed to be catalysts of tumor promotion and 
progression of cancer (56-58).  Thus, there is a sound biologic rationale for studying 
flavonoids in relation to breast cancer risk and survival. 
    Using the USDA Database for the Flavonoid Content of Selected Foods and the modified 
Block food frequency questionnaire (FFQ) from the LIBCSP, the proposed study will be the 
first to examine whether flavonoids affect survival, and among the first to look at flavonoids 
in relation to breast cancer incidence.  In the two recently published studies using this 
database (59, 60), researchers assessed breast cancer incidence in a Greek population (59) 
and an Italian population (60), both with a high and wide range of intake of fruits and 
vegetables that provided enough heterogeneity to determine if there were beneficial effects.  
A decreased risk of breast cancer was found with increased intake of flavones, a class of 
flavonoids, in both populations (59, 60).  In the Italian study, a decreased risk of breast 
cancer was also found for flavonols (60).  However, there have been no published studies 
using this database on American populations.   
    The overall aim of the proposal was to evaluate the relationship between dietary intake of 
flavonoids and breast cancer risk and survival.  This project attempted to shed light on this 
area by examining specific dietary factors, in particular, flavonoids, assessed at breast cancer 
diagnosis and their associations with breast cancer incidence and survival.  To test this 
hypothesis, data from the case-control (N = 1,508 cases and 1,556 controls) and follow-up 
study (N = 1,273 invasive cases) of the LIBCSP were utilized.   
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    This study improved upon previous research by assessing intakes of flavonoids in a U.S. 
population and their association with breast cancer.  With the use of the USDA Database for 
the Flavonoid Content of Selected Foods and the USDA - Iowa State University Isoflavones 
Database, primarily, we can study all foods contained in the database which are also included 
in the modified Block FFQ used in the LIBCSP.  Flavonoid intake for seven classes of 
flavonoids that comprise a total of 30 individual flavonoids were estimated.   
 
Specific Aims and Hypotheses 
The specific aims of the proposed research are as follows. 
Aim 1.  To estimate intake of seven classes of flavonoids and total flavonoid intake among 
breast cancer cases and controls using the USDA Database for the Flavonoid Content of 
Selected Foods, the USDA - Iowa State University Isoflavones Database, additional literature 
sources, and the LIBCSP dietary data. 
Aim 2.  To examine the association among dietary intake of flavonoids and risk of breast 
cancer.  This will test the hypothesis that there is an inverse association between flavonoid 
intake and risk of breast cancer. 
Aim 3.  To examine the association among dietary intake of flavonoids and survival with 
breast cancer.  This will test the hypothesis of an inverse association between flavonoid 
intake and mortality following diagnosis with breast cancer. 
 
Epidemiology of Breast Cancer Incidence 
Introduction 
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    Breast cancer is the most common incident cancer among women except for non-
melanoma skin cancers (61).  It is the second leading cause of cancer death in women, 
exceeded only by lung cancer (61).  Currently, there are over 2 million women living in the 
United States who have been diagnosed and treated for breast cancer (61).  Death rates from 
breast cancer among American women are declining due to earlier detection and improved 
treatment while incidence rates have begun to plateau in women age 50 and older (61).   
    In rural Asian areas, this disease is relatively uncommon (62).  Some researchers, based on 
data from previous ecologic studies, have attributed this international heterogeneity in risk to 
the higher consumption of fruits, vegetables, and soy products in Asian countries (63).  
Migration studies and variation of international incidence rates suggest breast cancer is 
affected by lifestyle and environmental factors (64).   
    Breast cancer incidence rates have historically been 4 to 7 times higher in the U.S. than in 
China or Japan, but the reasons for this are not entirely clear (65).  In 1980, the breast cancer 
incidence rate for white women in the U.S. was 2.5 to 4 times that of women living in China, 
Japan, or the Phillipines (66).  The variation in risk is not due to underlying genetic 
differences because the rates of breast cancer in Asian-American women shift substantially 
toward those of white U.S. women within a few generations after migration (67). 
    A case-control study of breast cancer by Ziegler and colleagues (65) among women of 
Chinese, Japanese, and Filipino ethnicities, aged 20-55 years, was conducted in parts of 
California and Hawaii.  A six-fold gradient in breast cancer risk by migration patterns was 
observed.  Asian-American women born in the West had a breast cancer risk 60% higher 
than Asian-American women born in the East (65).  Migrants who had lived in the West for a 
decade or longer had a risk 80% higher than more recent migrants (65).  Furthermore, the 
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age-standardized incidence rates of breast cancer for Asian-Americans living in the U.S. 
(53.7 per 100,000 person-years in Chinese women, 69.0 per 100,000 person-years in 
Japanese women) were intermediate to the incidence rates of Asians (27.5 per 100,000 
person-years in China; 28.9 per 100,000 person-years in Japan; and 45.7 per 100,000 person-
years in Phillipines) and U.S. whites in California and Hawaii (91.8 per 100,000 person-
years) (65).   
    Similarly, using Surveillance, Epidemiology, and End Results (SEER) data, Stanford and 
colleagues studied breast cancer incidence in Asian residents of three U.S. geographic areas 
(68).  The rates in Asian-American women born in China or Japan and in their U.S.-born 
counterparts were approximately 50% and 75% (73 per 100,000 person-years in Asian born 
women; 117 per 100,000 person-years in U.S. born Asians) that of U.S.-born whites (159 per 
100,000 person-years), respectively (68).  This difference in rates between U.S. and Asia-
born women was present at all ages (68).  Compared with Chinese women living in the 
mainland, Singapore, and Hong Kong, Asian-born Chinese women living in the U.S. had a 
higher annual rate of breast cancer (47 per 100,000 person-years compared to 20-30 per 
100,000 person-years) and U.S.-born Chinese women had an even higher rate than this (59 
per 100,000 person-years) (68).  These results may help to explain those of Pineda and 
colleagues (69) who, also using SEER data, found that Japanese women had better overall 
survival (24.8% deaths from all causes) and better survival after breast cancer diagnosis 
(14.8% deaths from breast cancer) than all other races, including Chinese, Filipino, U.S.-born 
Asian Americans, and Caucasians (39.1% deaths from all causes and 20.1% deaths from 
breast cancer) (69). 
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    Additional studies of Asians and Asian migrants have had comparable findings with regard 
to breast cancer risk.  Chie and colleagues (70) calculated and compared age-specific and 
age-adjusted incidence rates and mortality rates of breast cancer patients from Taiwan to 
other cities and states in Asia and the U.S.  The lowest incidence rates of breast cancer 
among Chinese women were found in Taipei, Tianjin, and Shanghai while the highest rates 
were found in Los Angeles and Hawaii (70).  They concluded that lifestyle characteristics, 
especially the Westernization of dietary patterns may be the most important factors (70).   
    A study by Wu and colleagues (71) assessed breast cancer risks in relation to reproductive 
and menstrual histories in migrant and U.S.-born Asian Americans.  Using the same 
population as Ziegler (65), it was found that there were differences between each group (71).  
U.S.-born Asian Americans had an average age at menarche of 12.2 years, 1.4 years earlier 
than Asian women who migrated to the U.S. (71).  A slightly higher proportion of Asian 
American women breastfed compared with U.S. whites and the duration was longer in Asian 
migrants compared to U.S. whites (71).  However, the effects of these reproductive and 
menstrual factors were small and the ORs for migration variables changed only slightly after 
adjustment for these factors, suggesting the lower rates of breast cancer in Asians are 
primarily a result of environmental and lifestyle factors (71). 
    This wealth of research emphasizes the disparities between Asian, Asian-American, and 
American women with respect to reproductive, lifestyle, and environmental factors and 
subsequent breast cancer risk.  Since Americans tend to consume less flavonoid-rich fruits, 
vegetables, and soy products compared to Asians and Asian-Americans (72), it is possible 
that compounds in these products which have known biologic activity may decrease breast 
cancer risk and improve survival after diagnosis.  The lifestyle and environmental disparities 
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support the study of factors that may contribute to these differences, including dietary 
flavonoid intake.   
    Despite all of the previous research, only a few modifiable risk factors have been 
identified with which to make public health recommendations to reduce the risk of breast 
cancer.  Well-established risk factors include few or no pregnancies, oral contraceptive use, 
hormone replacement therapy (HRT), little or no breastfeeding, early age at menarche, late 
onset of menopause, late age at first birth, age, family history of a first-degree relative, high 
endogenous estrogen levels in serum, history of benign breast disease (BBD), lack of 
physical activity, high body mass index (BMI) in post-menopausal women, high 
socioeconomic status (SES), ionizing radiation, and alcohol consumption (64, 73) (Table 
1.1).   
    Possible relationships have been found with cigarette smoking, fat consumption, use of 
non-steroidal anti-inflammatory drugs (NSAIDs), and fruit and vegetable consumption (73).  
Elucidating the pathways in which potential protective compounds reduce breast cancer risk 
may clarify prior conflicting or weak study results.   
    The following pages address the epidemiologic rationale and biologic basis of the 
aforementioned risk factors for breast cancer incidence.  Consideration of whether flavonoids 
affect breast cancer risk and survival would be strengthened if it is consistent with our 
current understanding of the descriptive and analytic epidemiology of breast cancer (Figure 
1.1).   
 
Reproductive Risk Factors 
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    The reproductive risk factors have long been implicated in breast cancer incidence.  These 
factors appear to act through their effects on endogenous estrogen levels.  Because of 
flavonoids’ reported effects on the estrogen pathway, which will be described in more detail 
later, the impact of these risk factors must be assessed in the proposed analysis. 
 
Pregnancy 
    Pregnancy has been found to induce transient and permanent structural changes in breast 
tissue in laboratory animals (74).  Transiently, the hormonal influence of pregnancy may 
enhance the progression of cells that may have already started to undergo malignant 
transformation, and in the long term, it may cause stem cells to differentiate and become less 
susceptible to carcinogenesis (74).  The increased estrogen levels that occur in each full-term 
pregnancy may promote the growth of cells that have already undergone malignant 
transformation, resulting in an initial increase in breast cancer risk (75).   
    There is evidence of a transient increase in breast cancer risk after giving birth: some 
investigators have found an association between shorter interval since last birth and a higher 
risk of breast cancer (76, 77); others have found that uniparous women were at higher risk 
than nulliparous women in the period immediately after delivery (78, 79).  However, this risk 
dissipates and eventually reduces the lifetime risk of breast cancer because of the 
differentiation of additional breast cells with each pregnancy (75).  Liu and colleagues (80) 
investigated time-points when the elevated postpartum maternal breast cancer risk peaks.  
After conducting a nested case-control study within the Swedish Fertility Register, the 
researchers discovered that uniparous women had an increased risk of breast cancer 
compared to nulliparous women and that this risk peaked five years following delivery (OR = 
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1.49, 95% CI: 1.01-2.20) (80).  The biparous women had lower levels of estrogens in their 
second pregnancy compared to their first pregnancies (80). The differentiation of mammary 
cells induced by the first delivery may have lowered the short-term adverse effects of the 
second childbirth (80). 
    Over a lifetime, nulliparous women are at an increased risk for breast cancer in 
comparison with parous women (81).  In studies of white women, higher parity confers a 
reduced risk of breast cancer for women ages 35 and older (81).  In a study comparing the 
risk in U.S. women at all ages (82), the odds ratio (OR) for breast cancer in white women 
ages 35 to 49 ranged from 0.75 to 0.30 for number of full-term pregnancies ranging from 1 to 
5+ (82).   
    Number of pregnancies have also been recognized as reducing the risk of breast cancer 
(81).  A case-control study of Caucasian and African-American women found that both races 
of women had a decreased risk of breast cancer per full-term pregnancy (13% among women 
ages 35-49 years and 10% in women ages 50-64 years in Caucasians, 10% among women 
ages 35-49 years and 6% in women ages 50-64 years in African-Americans) (82).  Compared 
with women who had never had a full-term pregnancy, women who had experienced at least 
one pregnancy had an estimated 20-24% reduction in breast cancer risk (82).   
 
Oral Contraceptive Use 
    Oral contraceptives (OCs) were first introduced in 1960 and have since been used by an 
estimated 200 million women (83).  In 1992, the Collaborative Group on Hormonal Factors 
in Breast Cancer (CGHFBC) was formed to reanalyze available worldwide studies.  They 
conducted a meta-analysis of 54 studies and found that current OC users were at an increased 
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risk of breast cancer compared to never users (RR = 1.24, p-value = 0.00001) (84).  The risk 
estimate was only slightly attenuated for women who had stopped using OCs one to four 
years before diagnosis (RR = 1.16, p-value = 0.0001) (84).  Overall, there was a small 
increase in risk up to ten years from cessation of use (84).   
    The Women’s Lifestyle and Health Cohort Study, conducted in Norway and Sweden, also 
examined this association (85).  103,027 women provided information on contraceptive use 
and 1,008 primary breast cancers were diagnosed through 1999 (85).  An increased risk of 
breast cancer was observed among current/recent OC users RR = 1.6 (95% CI: 1.2, 2.1) (85).  
This result was similar for current/recent users of combined OCs (RR = 1.6 (95% CI: 1.0, 
2.0) and progestin-only pills (RR = 1.6 (95% CI: 1.0, 2.4) (85). 
    The theorized mechanism (“Estrogen Augmented by Progestogen Hypothesis”) behind 
combined OC use and breast cancer risk is that the combination of hormones induces more 
cell divisions than estrogen alone (86).  If there are adverse effects of OCs, these may appear 
in younger women whose risk may increase soon after exposure to exogenous hormones 
containing estrogen and progestin (87).  Concurrent with this information is a finding that 
OC use before age 30 was associated with increased post-menopausal breast cancer among 
women with the NAD(P)H Quinone Oxoreductase (NQ01) genotype, suggesting that the 
association may include products of estradiol and estrone metabolism (88).  This hypothesis 
predicts that estrogen replacement therapy will increase breast cancer risk, and that the 
addition of a progestogen will increase risk further (86).   
 
Hormone Replacement Therapy (HRT) 
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    For HRT, the most prominent concern on the part of health professionals and post-
menopausal women remains the possibility that HRT, especially if used for a long period of 
time, may contribute to the development of breast cancer (89).  Epidemiologic studies have 
reported an increased risk of breast cancer with HRT use for many years, with conjugated 
estrogens (90, 91) or estradiol compounds (92, 93) whereas others have failed to show any 
alteration of risk (94, 95).   
    Current use of HRT is associated with an increased risk of breast cancer according to three 
meta-analyses (RRs range from 1.21 to 1.40) (96-98).  This risk increased with longer 
duration of use (96-98).  These findings were confirmed by results from the Women’s Health 
Initiative, a randomized clinical trial that indicated the overall health risks of using estrogen 
and progestin for an average of 5.2 years (HR = 1.26, 95% CI: 1.00, 1.89) (99).  In fact, this 
trial was stopped because the test statistics indicated the risks, mainly for cardiovascular 
disease, were too great compared to the benefits of the hormone use (99). 
    Along this line of evidence, a 1997 meta-analysis of 51 studies found that breast cancer 
risk increases by 2.3% with each additional year of HRT use (100).  Since 1997, several 
case-control studies (101-105) and cohort studies (106-108) have assessed estrogen plus 
progestin regimens and all but one study (105) suggested an increased risk of breast cancer.   
    Estrogens strongly influence the growth of breast tissue (86, 109).  Estrogen receptors 
(ER) in breast tissue, which are well-known as prognostic indicators, provide further reasons 
to suspect the effects of using exogenous estrogens such as HRT (109).  The estrogen 
augmented by progestogen hypothesis predicts that HRT will increase breast cancer risk and 
that the addition of a progestogen will increase risk further (86).  Breast cancer incidence 
increases about 2.1% per year of age in the post-menopausal period (86).  This rise can be 
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attributed solely to endogenous estrogens (110, 111), so the breast cancer risk associated with 
HRT can be predicted by serum estrogen levels to the serum estrogen levels achieved during 
HRT (86).     
 
Breastfeeding 
    In a review by Willett and colleagues of 32 published studies (112), 16 of the studies 
showed a statistically significant reduction in risk with longer duration of breast feeding.  
Meta-analyses such as the one from the Collaborative Group on Hormonal Factors in Breast 
Cancer (100) support the reduction in breast cancer risk by breastfeeding, 4.3% with every 12 
months of having breastfed.  A study by Ursin and colleagues (82) noted a 5% reduction for 
every 12 months of having breastfed.  Another meta-analysis (113) indicated the risk of 
breast cancer was decreased for ever-breastfeeding women compared to never-breastfeeding 
women (OR = 0.90, 95% CI 0.86-0.94).  The decrease in risk continued as duration of 
breastfeeding increased, as the risk for those having breastfed at least 12 months was OR = 
0.75 (95% CI: 0.71-0.81) (113).  Similarly, a recent study of breastfeeding and breast cancer 
was conducted in Connecticut with women ages 30 to 80 years (114).  Parous women who 
reported ever lactation had a slightly reduced risk of breast cancer (OR = 0.83, 95% CI: 0.63-
1.09) (114).  For women who breastfed more than three children compared to those who 
never lactated, their OR = 0.53 (95% CI: 0.27-1.04) (114).  Women who breastfed their child 
for more than 13 months had an OR of 0.47 (95% CI: 0.23-0.94) (114).   
    While the mechanisms associated with the beneficial effects of lactation have not been 
completely elucidated, several have been proposed (82, 114).  Lactation may protect against 
breast cancer by postponing the resumption of ovulatory menstrual cycles after a pregnancy 
 14
and thus reducing exposure to cyclic hormones (82), by increasing the differentiation of 
breast tissue (115), by altering estrogen levels in the breast (116), or by allowing excretion of 
carcinogenic agents such as organochlorines from the breast ductal tissue (114, 117).  
 
Early Age at Menarche 
    Age at menarche is presumably a risk factor because it marks the beginning of ovarian 
menstruation and the cyclic flow of reproductive hormones (3).  Researchers have found that 
the risk of breast cancer decreases by 5 to 20% for each year the onset of menarche is 
delayed (81), (79).  A study by Brinton (118) and colleagues found that women with onset of 
menstruation at or after age 15 years had a 23% lower risk than those with an age at 
menarche of 12 years or younger.  In addition, because recall of age at menarche can be 
difficult, especially for older women, the strength of the association may be even stronger 
than reported (81).   
    The earlier the age at menarche, the earlier a young women experiences increased steroid 
hormone levels, which presumably means more exposure over a long period of time and this 
may increase a woman’s risk of breast cancer (112).  A series of reports on the hormonal 
patterns of a cohort of Finnish girls followed through puberty and into adulthood indicated 
that early menarche (before age 12) was associated with significantly higher estradiol levels 
in the adolescent period and with higher follicular phase estradiol levels in women aged 20-
31 years (119, 120).   
    Related studies have found differences in cycle lengths between breast cancer patients and 
control patients (121, 122).  Women in countries with different breast cancer risk were 
consistent with menstrual cycle length modulating breast cancer risk (122).  A study by 
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Kumar and colleagues (40) supports the hypothesis that soy consumption may alter 
circulating ovarian steroid hormone concentrations in pre-menopausal women and increase 
menstrual cycle length.  The average menstrual cycle length of women in Western 
populations is 26 to 29 days whereas it is longer for Asian populations (123-125).     
 
Late Age at Menopause 
    The later a woman’s age at menopause, the higher her risk of breast cancer (81, 112).  For 
every five-year difference in age at menopause, the risk of breast cancer changes by about 
17% (79).  On average, risk increases by about 3% per year that menopause is delayed (81).  
Moolgavkar and colleagues (126) found that menopause at 52 years of age carried a two-fold 
increased risk of breast cancer over menopause at 42 years of age.  This corresponds to a 7% 
increase in risk per year increase of age at menopause (126).  Among post-menopausal 
women, the increased risk associated with late age at menopause is generally not seen until 
after age 65, suggesting that the effect of age at menopause is not seen for 10 to 20 years 
after menopause (127).   
    Similar to many of the other risk factors, including early age at menarche, it is suggested 
that the longer the exposure to sex hormones during the reproductive years, the higher the 
risk of breast cancer (128).  Thus, the reduction in risk associated with an earlier menopause 
is likely due to the cessation of ovarian function and the resultant reduction in circulating 
hormone levels (112).      
 
Late Age at First Birth  
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    Late first full-term pregnancy is generally accepted as a major breast cancer risk factor 
(86).  MacMahon and colleagues (129), in their international case-control study, found that 
women who had their first full-term pregnancy under age 20 had approximately one-half the 
risk of breast cancer as nulliparous women.  However, nulliparous women did not have as a 
high a risk as women with a first full-term pregnancy after age 35 (129).  This is concurrent 
with findings from other studies indicating women who give birth to their first child after age 
30 have a higher risk of breast cancer compared to nulliparous women (130-132). 
    When the first birth occurs at an early age, fewer cells are likely to have been initiated and 
the period of protection, afforded by terminal differentiation of the breast glandular 
epithelium, covers a longer period of the woman’s remaining lifetime (112).  Further 
explanation for the increased risk includes a full-term pregnancy at an early age may reduce 
the likelihood of tumor initiation while a full-term pregnancy at a later age may promote the 
growth of existing tumor cells (129).   
 
Demographic Risk Factors   
Increasing Age 
    Breast cancer incidence continues to increase with age, however, there is a distinct slowing 
of the rate of increase around age 50, which is approximately the average age at menopause 
(86).  Incidence continues to climb after age 50, but the slope is less steep (86).  However, 
comparing older women to younger women, breast cancer incidence rates are considerably 
higher for older women (133).  For example, the incidence rate for breast cancer calculated 
from SEER data for 1987 to 1991 was 25.6 cases per 100,000 person-years for women ages 
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30-34 years (133).  However, for women ages 70 to 74 years, the incidence rate was 450.3 
cases per 100,000 person-years (133).   
 
Socioeconomic Status (SES) and Race 
    Breast cancer incidence rates generally have been found to increase as SES increases (134, 
135).  A cross-sectional study using breast cancer information for 37,921 cases diagnosed in 
New York City from 1986-1995 was conducted by Merkin and colleagues (136) to assess the 
association between a residential area’s SES, race, and advanced stage breast cancer.  After 
adjusting for age and year at diagnosis, living in areas with lower levels of education and 
income increased the odds of presenting with advanced stage breast cancer by 50% for 
African-American women and 75% for white women (136).  This is corroborated by findings 
from Schwartz and colleagues (137) that African-Americans are more likely than Caucasians 
to be diagnosed at an advanced stage of breast cancer.  This difference has been attributed to 
underutilization of screening services (138, 139) as well as living in socioeconomically 
disadvantaged neighborhoods (140-142).  
    Other risk factors such as nulliparity, late age at first birth, and late age at menopause 
(143-148) may be partially responsible for any increase in breast cancer risk because these 
characteristics are more prevalent among women of higher SES.  According to Gordon (149), 
SES factors have been associated with additional risk factors for breast cancer such as diet, 
lifestyle factors, physical characteristics, and tumor characteristics.  
 
Medical Risk Factors 
Family History of Breast Cancer 
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    In general, a family history of breast cancer in a first-degree relative has been associated 
with a two- to three-fold increase in risk of invasive breast cancer (150).  A relative risk of 
1.5 to 3.0 has generally been found when women whose mother or sister had breast cancer 
are compared to those whose first-degree female relatives did not have breast cancer (151).  
A meta-analysis found that individuals with a positive family history of breast cancer 
incidence had a RR of 2.1 (95% CI: 2.0-2.2) for breast cancer incidence (152, 153).  The 
prevalence of a family history of breast cancer has been estimated to range from 5% to 22% 
(154-157) but much of the variation is due to methodology and the study population.  Some 
studies included distant relatives whereas others used first-degree relatives in defining 
positive family history (153).    
    It is estimated that 5% to 10% of all breast cancers can be attributed to highly penetrant 
germline mutations (158).  The well-known BRCA1 and BRCA2 genes were identified in the 
1990s and have since been discovered to be responsible for 2% to 5% of all breast cancers 
(112).  These mutations, while rare in the general population, may be responsible for the 
early onset of breast cancer for high-risk breast cancer families (159, 160).  Up to age 40, 
women with BRCA1 are estimated to have a 20-fold greater risk of breast cancer compared 
to the general population and to have a lifetime risk of breast cancer of 60% to 85% (161).   
 
Endogenous Estrogen Levels 
    There is substantial experimental, epidemiologic, and clinical evidence that breast cancer 
risk is influenced by endogenous hormones (3).  According to Key (162), the evidence of 
ovarian hormones playing a role in breast cancer development is strong.  Estrogens modulate 
gene expression in breast cells through interaction with nuclear proteins (receptors) (163).  
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Estrogen and progesterone aid in maintaining breast cancer growths through paracrine and 
autocrine signaling (163).   
    After menopause, adipose tissue is the major source of estrogen production (112), (164, 
165).  This is a suspected reason why obese, post-menopausal women have both higher levels 
of estrogen and a higher risk of breast cancer than do non-obese, post-menopausal women 
(112).  Estradiol, which is considered to be the most biologically active endogenous estrogen, 
circulates free in the blood or bound to sex hormone-binding globulin (SHBG) or albumin 
(112).  Free estradiol is thought to be available to breast tissue and possibly more related to 
breast cancer risk than total estradiol (112).  Post-menopausally, estrone is the most abundant 
circulating estrogen (3, 166).  Estrone and estrone sulfate may be sources of intracellular 
estradiol (3, 112).  In post-menopausal women, there is a positive association between total 
estradiol and breast cancer risk (112). 
    In a meta-analysis of six prospective studies, breast cancer cases had mean estradiol levels 
15% higher than those of healthy controls (167).  Additional studies published since this 
meta-analysis found a positive association between plasma estradiol and the risk of cancer 
when comparing the top to bottom quartile (RR = 1.9) (168).  Among women with no prior 
use of post-menopausal hormone therapy, the association was even stronger (RR = 3.8) 
(168).  Endogenous estrogen levels are affected by both genetic and lifestyle factors (169). 
 
Estrogen Receptor (ER) / Progesterone Receptor (PR) Status 
    Whereas ER and PR have a well-established role in assessing the prognosis of breast 
cancer (as discussed below), their role in breast cancer etiology remains unclear (170-173).  
There is evidence that several risk factors related to hormones, including age at menarche, 
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parity, BMI, waist-hip ratio, and age at first live birth have been associated with ER+PR+ 
breast cancer, but not ER+PR- or ER-PR- breast cancers (172).  Giuffrida and colleagues 
(174) reported that breast cancer patients with a higher BMI, compared to those with a lower 
BMI, were more likely to have ER+PR+ tumors.  Similar to this, dietary fat intake has been 
positively associated with ER+PR+ breast cancer (173).   
    The only established risk factor known to be consistently associated with hormone 
receptor type is age (175).  For example, Yasui and colleagues (171) estimated age-specific 
incidence rates stratified by ER/PR status and found that all four receptor types (ER+PR+, 
ER+PR-, ER-PR+, ER-PR-) showed increasing risk with age, but only ER+ tumors were the 
only subtype to increase with age among Western women. 
Benign Breast Disease (BBD) 
    Benign breast disease (BBD) comprises a wide-spectrum of conditions whose pathology 
ranges from minor deviations of normal features to gross atypia falling short of malignancy 
(176).  A number of benign breast conditions have been evaluated in terms of their influence 
on subsequent breast cancer risk (177).  Results have been inconsistent and part of this 
problem may be due to an inconsistent definition of benign disease and the failure to consider 
different types of conditions as separate entities, given that not all confer an increased risk of 
breast cancer (178).  Recent studies have indicated that BBD increases the risk of breast 
cancer (179-182) but this risk varies by histopathological types (183). 
    Minami and colleagues (183) used a retrospective cohort design to investigate the risk of 
breast cancer development in Japanese women who were participants in a breast cancer 
screening program.  An elevated risk of breast cancer was observed in all women with BBD 
(RR = 3.26, 95% CI: 1.08-9.93) (183).  Women with proliferative BBD were at high risk for 
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breast cancer (RR = 8.48, 95% CI: 2.99-24.10), but no risk was observed for women with 
non-proliferative BBD (RR = 0.93, 95% CI: 0.11-7.66) (183).  It should be noted, however, 
that only 11 of the 1,876 women developed breast cancer during the follow-up period and 
this small number may be a key reason for such imprecise confidence intervals.  According 
to the authors, however, the results are consistent with those in high-risk countries for breast 
cancer (183). 
    Another study of histologic type of BBD and breast cancer was conducted among 2,731 
women in the San Francisco Bay Area (184).  The women were followed for an average of 
16 years after their first occurrence of biopsy-proven BBD between 1948 and 1973 (184).  
The cohort’s age-adjusted rate of breast cancer was 1.8 times that of the general population 
(RR = 1.8, 95% CI: 1.6-2.2) (184).  Among the different histologic types of BBD, rates were 
greatest for intraductal papilloma (RR = 3.9, 95% CI: 2.0-7.4) and adenosis (RR = 2.5, 95% 
CI: 1.2-4.9) (184).  Rates were also elevated for fibrocystic BBD (RR = 1.5, 95% CI: 1.1-1.9) 
(184).   
    The most common types of cancer chiefly occur within an organism’s most rapidly 
growing and least-differentiated tissues (185, 186), presumably because DNA is most 
vulnerable to initiation during periods of mitotic growth (186, 187).  In the breast, the rate of 
DNA synthesis is greatest in the epithelial cells that line the terminal ducts; the rate is 
intermediate in the larger ducts and is lowest in the alveoli (188-191).  Additionally, over 
90% of breast carcinomas are thought to arise within the terminal ducts (192, 193). In the 
study by Krieger and colleagues (184), the greatest risk of breast cancer was detected among 
types of BBD that chiefly involved ductal epithelial tissue. 
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Environmental and Lifestyle Risk Factors 
Post-menopausal Obesity and Weight Gain 
    A recent meta-analysis estimated a 3% increase in post-menopausal breast cancer risk per 
1 kg/m2 increase in BMI (194).  Additionally, the meta-analysis conducted by the Breast 
Cancer Collaborative Group, which included eight cohort studies of post-menopausal 
women, concurred with previous research indicating an increase in breast cancer risk with 
increasing BMI (195). 
    The association between body mass and breast cancer is modified by menopausal status, 
with higher weight or BMI at diagnosis associated with a decreased risk in pre-menopausal 
women and an increased risk in post-menopausal women (196).  The European Investigation 
into Cancer and Nutrition (EPIC) Study was designed to assess relationships between 
nutrition and cancer.  When studying body size and breast caner risk, post-menopausal 
women not taking exogenous hormones had a higher risk of breast cancer due to obesity (RR 
= 1.36, 95% CI: 1.06-1.75 for BMI ≥ 28.8 kg/m2) (196).  The relative risk and corresponding 
confidence intervals were nearly identical for women with a BMI in the 23.6 to 25.6 kg/m2 
range (RR = 1.35, 95% CI: 1.06-1.73) and the 25.7 to 28.7 kg/m2 range (RR = 1.38, 95% CI: 
1.08-1.76) (196).  Among pre-menopausal women, however, BMI was inversely associated 
with breast cancer risk (RR = 0.82, 95% CI: 0.59-1.14) (196).  The authors concluded that 
general obesity had a much stronger association with post-menopausal breast cancer risk than 
waist circumference or waist-to-hip ratio (WHR) (196). 
    Weiderpass and colleagues (197) used data from the aforementioned Women’s Lifestyle 
and Health Cohort and found that being overweight and obese (BMI > 25kg/m2) at 
enrollment was associated with a decreased risk of breast cancer in pre-menopausal women 
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(RR = 0.66, 95% CI: 0.40-1.07).  In post-menopausal women, as stated previously, 
circulating estrogens are mainly derived from extraglandular aromatization of plasma 
androstendione to estrone in adipose tissue (198).  Thus, estrogen production is correlated 
with body weight and obesity is associated with proportions of estrogens in circulation (198).  
Additionally, being overweight decreases women’s levels of SHBG and increases 
bioavailable estrogen, which increases the risk of breast cancer (112). 
    Some studies which have examined both adult weight gain and adult BMI in the same 
study population have found weight gain to be an equivalent (199, 200) or stronger predictor 
(164, 201-203) of post-menopausal breast cancer risk than BMI (198).  Total adult weight 
gain has strongly predicted breast cancer risk among former and never users of HRT (198).  
In the Cancer Prevention Study (CPS) II Nutrition Cohort, total adult weight gain was 
associated with breast cancer incidence in post-menopausal women who were not taking 
HRT, as a weight gain of 21-30 pounds had a rate ratio (RR) = 1.4 (95% CI: 1.1-1.8) (198).  
After accounting for weight gain, neither recent BMI or BMI at age 18 years predicted breast 
cancer risk (198).   
 
Alcohol Consumption 
    Although all studies do not report an association between alcohol consumption and breast 
cancer risk (204), there is accumulated evidence for a positive association from both cohort 
and cross-sectional studies (205-208).  The 1994 meta-analysis by Longnecker and 
colleagues (206) noted that overall, women who consumed two drinks per day experienced a 
20% increase in risk compared to non-drinkers and those consuming more than two drinks 
per day had a 40% increase in risk.  The Smith-Warner pooled analysis of cohort studies 
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(207) found the relative risk for each 10-gram increase in alcohol intake, compared to non-
use, was 1.09; women who consumed 30-60 grams per day had a 41% higher risk of invasive 
breast cancer.   
    Alcohol is proposed to be involved through its ability to increase circulating hormone 
levels in pre- and post-menopausal women, a direct carcinogenic effect of alcohol 
metabolites such as acetaldehyde and an antagonistic effect on folate absorption and 
metabolism (112, 209-211).  Moderate alcohol consumption increases some biomarkers of 
oxidative stress in post-menopausal women.  Alcohol also influences breast cancer by 
altering absorption and metabolism of protective antioxidants and increasing oxidative stress 
(212).     
    Hartman’s work with the Women’s Alcohol Study in post-menopausal women involved 
evaluating moderate alcohol consumption on potential risk factors for breast cancer and 
alcohol’s effect on antioxidants and other indicators of oxidative stress (212).  When post-
menopausal women consumed 30 grams per day during an 8-week period, there was a 5% 
increase in plasma isoprostane and a 4.6% decrease in plasma α-tocopherol concentration 
(212).  This suggests that chronic consumption of moderate alcohol amounts by post-
menopausal women may lead to significant changes in oxidative stress biomarkers (212).   
 
Physical Inactivity 
    Physical inactivity may be one of the main risk factors for breast cancer that can be 
modified through lifestyle/behavior change (213).  A 2002 review of the literature found that 
32 of the 44 studies conducted observed a reduction in breast cancer risk in women who were 
most physically active (213).  On average, this reduction in risk was 30% to 40% (213).  
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Coogan and colleagues (214) conducted a case-control study to evaluate the effect of 
occupational physical activity on breast cancer risk and found that women with heavy-
activity occupations had a lower risk than women with sedentary jobs (OR = 0.82, 95% CI: 
0.63-1.08).  This reduced risk was also found in women with jobs requiring medium activity 
(OR = 0.86, 95% CI: 0.77-0.97) and light activity (OR = 0.92, 95% CI: 0.84-1.01) (214).  
    Similarly, a case-control study of a Swedish population assessed leisure-time and 
occupational physical activity and breast cancer risk (215).  After adjustment for potential 
confounders, women in sedentary occupations during their reproductive years (25-44 years of 
age) had a 50% higher risk for post-menopausal breast cancer (OR = 1.5, 95% CI 1.0-2.2), 
compared to those with the most physically-demanding jobs (215).  Women with a 
combination of a sedentary job and lack of leisure-time exercise had a three-fold higher risk 
of breast cancer, compared to the most physically active both inside and outside the 
workplace (215).   
    A 2003 publication from John and colleagues (216) described a case-control study of 
breast cancer in Latinas, African-Americans, and whites ages 35-79 years to assess the 
association with lifetime histories of moderate and vigorous physical activity, including 
recreational activity, walking, bicycling, chores, and occupation.  Summing these activities 
over each woman’s lifetime, a reduced risk of breast cancer was found in both pre- and post-
menopausal women with the highest versus lowest tertile of average lifetime activity (OR = 
0.74, 95% CI: 0.52-1.05) (216).   
    Physical activity in girls can delay both menarche and the onset of regular menstrual 
cycles (112).  These effects reduce the number of ovulatory cycles a woman has in her life, 
which is an important determinant of breast cancer risk (128).  In women, strenuous activity, 
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such as running, can alter circulating hormone levels and increase the frequency of 
anovulation (112).  Physical activity may also reduce breast cancer risk by preventing weight 
gain or reducing body fat, which, as stated previously, is the primary source of estrogen 
production in post-menopausal women (216).     
 
Ionizing Radiation 
    Ionizing radiation is an established cause of breast cancer in both animals and humans 
(217, 218).  An increased risk has been consistently reported for radiation exposure from 
various sources, including the atomic bomb explosions in Japan (219, 220).  The effect of 
radiation on breast cancer is greatly dependent on age at exposure (221).  Among women 
under the age of 40 at exposure, a linear increase in breast cancer risk with increasing 
radiation dose has been consistently reported (221, 222).  Relative risks are small for 
radiation exposure after age 40 years and increase with decreasing age at exposure, with the 
highest risk for exposure before age 20 years (221-223).   
    The Life Span Study of a defined population of survivors of the atomic bombing of 
Hiroshima and Nagasaki demonstrated that radiation dose response corresponds to a linear 
model and the risk of breast cancer is closely associated with estimated breast tissue dose 
(224).  The age-adjusted excessive relative risk of developing breast cancer per Sv (Sievert, a 
weighted sum of doses used for different types of radiation such as the mixed gamma and 
neutron radiation from the atomic bombings (222)) was 1.56 (90% CI: 1.91-1.99) (223).  The 
incidence of breast cancer is 25% lower in Nagasaki than Hiroshima, the former being the 
city of lower radiation exposure (225).   
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Cigarette Smoking 
    Cigarette smoking has been inconsistently associated with breast cancer risk (226, 227).  
Case-control studies have been more likely to report a positive association while cohort 
studies have reported little or no relationship between smoking and breast cancer incidence 
(228, 229).  A recent analysis of 53 studies showed no risk of smoking in relation to breast 
cancer (230).  However, inconsistencies may be due to heterogeneity in risk according to 
timing of exposure, age at diagnosis, or genetic susceptibilities (231, 232), as well as poor 
recall (233).  Additionally, passive smoking was often not accounted for and since it may 
also be related to breast cancer risk, failing to account for it would dilute risk estimates for 
active smoking (232). 
    Reynolds and colleagues (232) examined breast cancer risk and active and passive 
smoking in the California Teachers Study (CTS) cohort and found that breast cancer 
incidence was higher in current smokers compared to never smokers (HR = 1.32, 95% CI: 
1.10-1.57) and passive smokers (HR = 1.25, 95% CI: 1.02-1.53).  This passive smoking 
finding is consistent with a meta-analysis result of RR = 1.43 (95% CI: 1.10-1.85) (234).  
Data from the LIBCSP, however, indicate a non-significant effect of passive smoking, active 
smoking, or joint exposure (OR = 1.15, 95% CI: 0.90-1.48) (233). 
    Smoking cigarettes generates free radicals, increases lipid peroxidation levels, and is 
associated with lower blood levels of antioxidants after controlling for dietary intake (212).  
Free radical derivatives of molecular oxygen (superoxide, hydrogen peroxide, and hydroxyl 
radical) are generated during normal metabolism and increased following cigarette smoking 
(235).  Cigarette smoking may increase the risk of breast cancer through exposure to known 
carcinogens, such as benzo[a]pyrene, which is present in tobacco products (112).  However, 
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smoking may decrease the risk of breast cancer through an anti-estrogenic effect by altering 
hormone metabolism or lowering the age by which women reach menopause (112).   
 
Fat Consumption 
    Overall, a relationship between fat intake and breast cancer is inconsistent, at best (236).  
For example, results from a cohort study conducted amongst women in the Nurses Health 
Study provided no evidence that lower intake of total fat or specific types of fat were 
associated with a decreased risk of breast cancer (237).  A total of 2,956 women were 
diagnosed with breast cancer over the 14-year follow-up period (237).  Women obtaining 
30.1% to 35% of their energy from fat, compared to those obtaining 20% or less of their 
energy from fat, had a RR for breast cancer of 1.15 (95% CI: 0.73-1.80) (237).    
    The studies which point towards a positive correlation tend to be migration studies 
comparing Asian populations to Asian-American and American populations (238, 239).  
Migrants from low-risk countries generally increase their risk after immigrating to higher-
risk countries (240), coinciding with data suggesting that these migrants have higher dietary 
fat patterns (241, 242).  International correlation studies conducted with incidence and 
mortality data from several countries support an association between dietary fat and breast 
cancer, with correlation coefficients between 0.7 and 0.9 (243-248).      
 
Non-steroidal Anti-inflammatory Drug (NSAID) Use  
    Use of aspirin and other NSAIDs has been shown to reduce risk of breast cancer in some 
epidemiologic studies (249-255).  Results from cohort studies have been inconsistent  as 
some have found a reduced risk while others have found no association (256).  In the Cancer 
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Prevention Study II Nutrition Cohort, Jacobs and colleagues found that neither current total 
NSAID use nor current aspirin use were associated with breast cancer incidence, RR = 1.07 
(95% CI: 0.96-1.21) for ≥ 60 NSAID pills per month compared with no reported use of 
NSAIDs.  Conversely, data collected from the LIBCSP (249) indicated that ever use of 
aspirin or other NSAIDs at least once per week for 6 months was associated with a reduced 
risk of breast cancer, OR = 0.80 (95% CI: 0.66-0.97).  It is thought that aspirin may suppress 
aromatase activity through its inhibition of cyclooxygenase (COX)-derived prostaglandins 
(249).  Thus, frequent use may reduce the amount of circulating estrogen and therefore 
reduce the risk of breast cancer (249). 
 
Fruit and Vegetable Consumption 
    Diets rich in fruits and vegetables are frequently recommended for the prevention of 
cancer.  Yet, similar to dietary fat, the relationship of consumption of fruits and vegetables 
and breast cancer remains unclear (48).  A review of 19 case-control studies and 3 cohort 
studies concluded that elevated fruit and vegetable consumption likely reduces the risk of 
breast cancer (257).  However, a 2001 meta-analysis of eight cohort studies found weak, non-
significant associations for total fruits (RR = 0.93, 95% CI: 0.86-1.00), total vegetables (RR 
= 0.96, 95% CI: 0.89-1.04), and total fruits and vegetables (RR = 0.93, 95% CI: 0.86, 1.00) 
with breast cancer risk (258).  It should be noted that these cohort studies were conducted in 
Western societies where the intake level of fruits and vegetables is relatively homogeneous, 
making it difficult to detect an effect (259).   
    Fruits and vegetables have a wide variety of compounds that have demonstrated potential 
anticarcinogenic effects in vivo (260).  These include carotenes, dithiolthiones, flavoids, 
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indoles, isothiocyanates, phenols, folic acid, and vitamins C and E (261).  The suspected 
cancer-preventive mechanisms of these compounds include antioxidant effects, carcinogen 
detoxification, alteration of estrogen metabolism, effects on DNA, and antiproliferative 
effects (261, 262).  Vegetarians or Asian women have higher 2-hydroxyestrone (2HE) / 16-
hydroxyestrone (16HE) levels in their urine in response to their low-fat, high-fiber diet (263).  
A high ratio of 2HE to 16HE may be associated with a decreased risk of breast cancer (263, 
264), though not all studies observe an association (265, 266).  Low values of this ratio in 
urine may be an endocrine biomarker for greater breast cancer risk (263).   
    Malin and colleagues (259) conducted a case-control study of women from the Shanghai 
Breast Cancer Study and found that the intake of many fruits and vegetables was associated 
with a decreased risk of breast cancer.  Of note in Shanghai, women eat lots of fruits and 
vegetables but do not use vitamin supplements much, if at all (259).  The researchers found 
no inverse association of carotene and breast cancer risk and concluded it was possible that 
other phytochemicals may explain the inverse association (259).  In fact, a wide variety of 
flavonoids in citrus fruits may act as antioxidants (43, 44). 
    Zhang and colleagues examined dietary carotenoid and vitamin intake for incident cases of 
breast cancer from the Nurses Health Study participants (45).  Strong inverse associations 
were found with alpha and beta carotene, vitamin C, vitamin A, and lutein among pre-
menopausal women with a family history of breast cancer (45).  Also, pre-menopausal 
women consuming 5 or more servings of fruits and vegetables per day had a decreased risk 
of breast cancer (RR = 0.77; 95% CI: 0.58-1.02) (45).  They suspected this result may be due 
to the fact that carotenoids and vitamin C can metabolize reactive oxygen species (ROS) and 
may decrease DNA damage and genetic mutations.  However, they also concluded that fruits 
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and vegetables contain many other phytochemicals, which include flavonoids, that are 
protective against cancer in in vitro models.  Thus, other constituents in fruits and vegetables 
may account for the inverse association.  
    Recently, a case-control study of women from the LIBCSP examined fruit and vegetable 
consumption in relation to breast cancer risk (48).  Among post-menopausal women, 
vegetable intake (OR = 0.63; 95% CI: 0.46-0.86) and leafy vegetable intake (OR = 0.66; 95% 
CI: 0.48-0.90) were inversely associated with breast cancer risk, adjusting for age and energy 
intake (48).  Risk was particularly decreased among post-menopausal women with estrogen 
receptor positive (ER+) breast cancer and progesterone receptor positive (PR+) breast cancer. 
The proportion of estrogen receptor positive (ER+)  breast tumors is reportedly higher among 
Caucasian than Asian women (112).  Breast cancer risk increases when there is over-
expression of estrogen receptor in surrounding, normal epithelium (267).   
     In the LIBCSP, adjusted odds ratios were also uniformly decreased in relation to high 
intakes of carotenoids, alpha and beta carotene, lutein, and lycopene (48).  The inverse 
association between fruits and vegetables and breast cancer remained after adjustment for the 
antioxidants and supplement use (48).  This, like previous studies’ conclusions, this suggests 
that other constituents in fruits and vegetables may be involved in the prevention of breast 
cancer incidence. 
 
Flavonoids 
    Flavonoids are one of the principal groups of phytoestrogens (72).  Phytoestrogens are 
plant-derived, organic, non-steroidal molecules possessing a weak estrogenic or anti-
estrogenic activity (72, 268).  These have demonstrated inhibitory effects on hormone-related 
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cancers (49, 63).  Flavonoids are a group of more than 4,000 polyphenolic compounds that 
occur naturally in foods of plant origin (49).  Evidence from laboratory studies and 
epidemiological investigations implicate flavonoids as chemopreventive agents (49, 51-58, 
269-277).   
    Flavonoids appear to act through two distinct pathways, the estrogen pathway (Figure A.1) 
and the oxidative stress pathway (Figure A.2).  The estrogenic activity of various flavonoids 
has led to many proposed mechanisms by which they may modify breast cancer risk.  
Because they are similar to estrogen in both structure and function, they modulate steroid 
hormones (40).  Some flavonoids, such as lignans (53, 278), have demonstrated an ability to 
reduce circulating hormone levels in the body through aromatase inhibition (41, 51, 52).  
This research has led to the hypothesis that flavonoids compete with estradiol for binding to 
estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) and thus inhibit cell 
proliferation and tumorigenesis via gene transcription (269).   
    Isoflavonoids have been shown to increase serum levels of  SHBG, which decreases the 
amount of bioavailable estrogen by decreasing levels of free estradiol  (42), (39, 279-282).  
The weak estrogenic effect of phytoestrogens can stimulate SHBG production, like 
tamoxifen can, in the liver (39).  Again, this increase in SHBG helps to decrease the ovarian 
steroid levels in the body.  This may be a cancer-preventive mechanism in that flavonoids 
could potentially counteract negative effects of oral contraceptive use.  SHBG and albumin 
determine the bioavailability of sex steroids to most tissue and the metabolic clearance of the 
steroids (279-283).  Phytoestrogens can convert endogenous estrogens to protective 2-
hydroxylated estrogens in women and thus may play a role in decreasing levels of 17α-
hyroxyestrone, which is a stimulant of breast proliferation (284-288). 
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    Isoflavones in soy protein, particularly genistein and daidzein, have demonstrated effects 
similar to that of breastfeeding through an ability to increase the length of the follicular phase 
and delay menstruation (289, 290).  They achieve this by suppressing luteinizing hormone 
(LH) and follicular stimulating hormone (FSH), which may decrease breast cancer risk (284, 
289, 290).  A change in menstrual cycle length alters the duration of mammary epithelial 
cells in the luteal phase of the cycle where breast cells are more proliferative (40) (291).   
    Some flavonoids have demonstrated an ability to reduce the number of ovulatory cycles 
and delay menstruation, potentially reducing the risk of breast cancer (40, 289-291).  Kumar 
and colleagues (40) observed an increase in cycle length and follicular cycle length in those 
who consumed soy supplements and concluded this may shorten the exposure of the breast 
epithelia to progesterone in the luteal phase.  If this occurs over a period of time with 
consistent soy consumption, then the relative time during which breast epithelia is stimulated 
to proliferate may be decreased (40).  After 12 weeks, SHBG levels had increased while 
levels of free estradiol and estrone decreased in many who consumed the soy supplements 
(40 mg of soy isoflavonoids per day) (40).  The theory is that the number of menstrual cycles 
in a woman’s lifetime can be reduced as well as her breasts’ exposure to estrogen. 
    According to Kris-Etherton and colleagues (277), flavonoids may act in a variety of ways 
to interfere with carcinogenesis, such as protecting DNA from oxidative damage, 
deactivating carcinogens, and inhibiting the expression of mutated genes and the activity of 
enzymes that promote carcinogenesis, and promoting detoxification of xenobiotics.  For 
instance, chocolate, a rich source of catechins, has demonstrated the ability to inhibit COX 
activity, hydrogen peroxide, and superoxide anion production (277).  As described earlier, 
anthocyanidins, which are present in fruits, vegetables, and red wine, have demonstrated 
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free-radical scavenging abilities as well as inhibition of xanthine oxidase (XO) in animal 
models (292, 293).  For example, apigenin, genistein, and kaempferol, which are rich in 
berries, soy, and citrus products respectively, have demonstrated the ability to inhibit pro-
oxidant enzymes such as COX-2 and inducible nitric oxide synthase (iNOS) (294). 
    Flavonoids contain a number of phenolic hydroxyl groups attached to ring structures, 
conferring their antioxidant activity (46).  They can act as reducing agents, hydrogen 
donating antioxidants, and singlet oxygen quenchers (46).  Numerous flavonoids, such as 
lignans (295) and flavan-3-ols (47), have demonstrated abilities to inhibit tumor cell 
proliferation through various antioxidant mechanisms .  The principal flavan-3-ols, 
epicatechin (EC), epigallocatechin (EGC), epicatechin gallate (ECG), and epigallocatechin 
gallate (EGCG) (47), act as antioxidants in vitro by scavenging ROS and nitrogen species, 
and chelating redox active metal ions (47).  They may also function as antioxidants through 
inhibition of redox-sensitive transcription factors, nuclear factor-kB and activator-protein-1; 
inhibition of pro-oxidant enzymes such as iNOS, lipoxygenases, COX, and XO; and 
induction of phase II and antioxidant enzymes such as glutathione-S-transferases and 
superoxide dismutases (47).   
    The flavonoids involved in antioxidant activities and the estrogen pathway can be 
measured by the modified Block FFQ, the USDA databases; and scientific literature and 
these issues will be described in more detail in the Methods section.    
 
Breast Cancer and Flavonoids 
    High intake of flavonoid-rich foods and beverages may reduce breast cancer risk and thus 
play an important role in the primary prevention of breast cancer, though this has scarcely 
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been researched.  Epidemiologic studies have indicated an inverse association between 
dietary flavonoid intake and the risk of cancer, including the breast (72, 295-297).  Most 
epidemiological studies have investigated whole foods rich in flavonoids while most in vitro 
studies have focused on individual flavonoids present within them.  A major concern of 
previous studies is the validity of the dietary measurement tool in assessing usual flavonoid 
intake.  Although many ecological and experimental studies have suggested a potential role 
of flavonoids in breast cancer prevention, results have been inconsistent in part due to the 
difficulty in measuring intake (72).   
    However, most human studies have only been able to quantitate intake of a small portion 
of flavonoids, or quantitate intake of a small portion of foods containing flavonoids, because 
of the lack of a flavonoid database.  A recent exception (59) examined the relationship 
among a Greek population with high fruit and vegetable intake utilizing the USDA Flavonoid 
Database for Selected Foods and discovered a reduction in breast cancer risk with flavone 
intake (OR = 0.87, 95% CI 0.77-0.97).  Bosetti and colleagues investigated this relationship 
in 2,569 women from a case-control study conducted in Italy (60).  A reduced risk of breast 
cancer was found for increasing intake of flavones (OR = 0.81, 95% CI 0.66-0.98 for the 
highest versus lowest quintile) and flavonols (OR = 0.80, 95% CI 0.66-0.98 for the highest 
versus lowest quintile) (60).  A recent analysis of the LIBCSP data (48) confirmed a reduced 
risk of breast cancer in relation to fruit (OR = 0.78, 95% CI 0.58,1.03) and vegetable (OR = 
0.63, 95% CI 0.46-0.86) intake.  However, no specific nutrient or antioxidant was strongly 
inversely related to breast cancer.  This analysis demonstrated that the study population 
consumed a diverse and rich amount of fruits and vegetables to address our hypotheses but 
suggested that constituents other than antioxidants may be driving the inverse link between 
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fruits and vegetables and breast cancer.  For example, lignans, a type of flavonoid, are found 
in many fruits and vegetables, as well as tea, coffee, seeds, and whole grains and have been 
associated with a reduced risk of pre-menopausal breast cancer (OR = 0.66, 95% CI 0.44-
0.98) (295).  
    Although soy and soy products are the richest source of certain phytoestrogens (mainly 
isoflavonoids), other flavonoid food sources may be more common in the United States, such 
as fruits and vegetables (e.g. apples and onions), and beverages (e.g. tea and wine) (295, 
298).  Daily human consumption of all flavonoids is estimated to be a few hundred 
milligrams to one gram (62, 270).  Conducting studies of flavonoid intake and cancer risk in 
the United States requires a database that captures these common American food sources.  
Thus, the USDA Database for the Flavonoid Content of Selected Foods is a logical choice.  
With the creation of this database, we now have a more comprehensive tool to assess dietary 
intake of flavonoids and their associations with breast cancer. 
 
Epidemiology of Breast Cancer Survival 
    The most important predictors of survival are characteristics of the tumor and treatment 
undergone and age (27, 299-301).  SES and race may also affect disease prognosis as lower 
SES and African-American race are associated with greater risk of death (149, 302).    The 
only other non-clinical parameter that is known to affect disease prognosis is obesity at 
diagnosis, which is known to adversely affect survival (10-30).  Other than avoiding weight 
gain prior to diagnosis, other modifiable factors that may potentially improve survival 
include improved diet and increasing exercise (37, 246, 303-306).  Use of oral contraceptives 
and reproductive history prior to diagnosis may also affect prognosis (300, 307-309).  
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However, little research to date has focused on these other modifiable factors. Researchers 
have recently turned to examining whether factors that influence the development of breast 
cancer also influence disease progression.  As mentioned earlier, results from previous 
studies have indicated that fruits and vegetables may reduce the risk of developing breast 
cancer (48).  Thus, it is plausible to consider whether fruit and vegetable intake influences 
survival, and to explore what components in these products may be involved in the biological 
pathways related to breast cancer development and progression.  
    Numerous studies, as recently reviewed by Page (5), have shown that the time between 
breast cancer diagnosis and recurrence, and subsequent death, is significantly decreased 
among women with tumors greater than 1 centimeter (cm) or 2 cm; with an increasing 
number of axillary node involvement and with increasing stage at diagnosis; and ER- tumors 
(6-9).  First, tamoxifen will be described because it is the predominant hormonal drug 
treatment following breast cancer diagnosis and surgery (310), followed by radiation and 
chemotherapy treatment.  The clinical and non-clinical prognostic factors will then be 
described (Table 1.2).   
 
Clinical and Non-Clinical Prognostic Factors 
Tamoxifen 
    Tamoxifen, a type I anti-estrogen which has mixed estrogenic and anti-estrogenic actions, 
has become the predominant drug treatment following breast cancer diagnosis and surgery 
(310).  The therapeutic effect of tamoxifen on ER+ breast cancer patients is more beneficial 
than on ER- breast cancer patients (311).  Patient with ER+ breast cancer have an increased 
reduction in death rate with longer duration of tamoxifen treatment, whereas patients who are 
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ER- do not benefit from tamoxifen, regardless of therapy duration (311).  Tamoxifen has 
been shown to increase the survival of patients with breast cancer and in 1994, the FDA 
approved the claim that tamoxifen prolonged the overall survival of the patient with breast 
cancer (312). 
    Tamoxifen seems to form a receptor complex that is converted incompletely to the fully 
activated form (313).  As a result of the imperfect changes, the ER complex is then only 
partially active in initiating the series of events necessary to orchestrate gene activation 
(314).  Studies demonstrate that high concentrations of anti-estrogens like tamoxifen can 
inhibit the replication of breast cancer cells (315).  Tamoxifen exhibits estrogen-like effects 
in the post-menopausal patient causing a partial decrease in LH and FSH and an increase in 
SHBG (316, 317).       
 
Radiation and Chemotherapy Treatment  
    Following breast cancer diagnosis, treatment with mastectomy or lumpectomy, followed 
by radiation and/or chemotherapy generally ensues (318-322).  Prospective, randomized 
trials confirmed that the combination of breast conservation surgery with whole breast 
radiotherapy (breast conservation therapy (BCT)) produces effective local control and 
equivalent survival when compared to radical or modified radical mastectomy (323-325).  
Additionally, thousands of women worldwide underwent high-dose chemotherapy (HDCT) 
with autologous hematopoetic stem cell support during the 1990s because it represented a 
standard of care for patients with high-risk primary or metastatic breast cancer (321).  These 
common treatments are undergone in attempt to minimize the chance of recurrence and 
improve prognosis.   
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    A randomized trial of locoregional radiation therapy compared with no further treatment 
after mastectomy among axillary lymph node-positive, pre-menopausal patients with breast 
cancer treated with adjuvant intravenous chemotherapy (326), indicated an improvement in 
overall survival with the radiation therapy (RR = 0.73, 95% CI: 0.55-0.98).  This finding 
corresponds to post-menopausal patients in the Danish Breast Cancer Cooperative Group 
where increased survival was found with a combination of radiation therapy and 
chemotherapy or hormonal therapy (327). 
 
Tumor Size at Diagnosis 
    In a study by Schairer and colleagues (301), probabilities of death from breast cancer and 
other causes were calculated according to stage, race, and age at diagnosis using SEER data 
of women diagnosed with breast cancer between 1973 and 2000.  Among white women with 
tumors 2 cm or less in diameter, the probability of death from breast cancer at the end of the 
follow-up period was 0.04 to 0.07 for patients with ER+ tumors and 0.09 to 0.10 for those 
with ER- tumors, depending on age (301).  For white women with tumors greater than 2 cm 
in diameter, the respective probabilities of death were 0.13 to 0.15 for ER+ tumors and 0.16 
to 0.23 for ER- tumors, depending on age (301).  These findings are consistent with those of 
Zhang and colleagues (306), that women with a tumor size ≥ 2 cm in diameter had a case-
fatality rate (CFR) of 5.2 deaths per 100 person-years, compared to a CFR of 1.7 deaths per 
100 person-years for women with a tumor < 2 cm in diameter.  
 
Stage at Diagnosis 
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    Survival after breast cancer is strongly related to stage at diagnosis (300, 328).  In the 
Schairer study (301), the probability of death from breast cancer increased with advancing 
stage; from 0.03 to 0.10 for patients with in situ disease to 0.70 to 0.85 for patients with 
distant disease, depending on age and race.  A case-only study including over 1,200 women 
diagnosed with breast cancer was conducted in London (300) and accordingly, the most 
important predictors of survival were clinical stage and nodal status (300).  As stage at 
diagnosis increased, the respective RR of death increased; RR = 1.52 (95% CI: 1.26-1.83) for 
Stage II, RR = 2.84 (95% CI: 2.31-3.48) for Stage III, and RR = 7.70 (95% CI: 4.47-13.25) 
for Stage IV (300).  Similar results were found in another case-only study of women in the 
Malmo Mammographic Screening Trial (329).  The respective mortality rates were the 
following, 443 cases per 100,000 person-years in women with Stage 0-I tumors, 2,225 cases 
per 100,000 person-years in women with Stage II tumors, 11,374 cases per 100,000 person-
years in women with Stage III tumors, and 32,927 cases per 100,000 person-years in women 
with Stage IV tumors (329).   
 
Node Involvement/Status 
    Nodal involvement is a key prognostic factor in breast cancer survival (27, 299-301, 330).  
In a retrospective analysis of 813 patients with locoregional or distant recurrence of primary 
breast cancer (331), the estimated median survival times were quite different depending on 
nodal involvement.  The median survival time after relapse in node-negative women was 42 
months (95% CI: 31-52 months), 20 months (95% CI: 16-24 months) in patients with 1-3 
axillary lymph node metastases, and only 13 months (95% CI: 12-15 months) in women with 
at least 4 axillary lymph node metastases (331).  In the Reeves study (300), the RR of dying 
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was much higher among women with node-positive disease than among those with node-
negative disease or with unknown status.  Those with node-negative disease (no nodal 
involvement) had a RR of dying = 0.48 (95% CI: 0.40-0.57) (301).  These results corroborate 
with the conclusion of Voordeckers and colleagues (332) that the percentage of positive 
lymph nodes in an axillary lymph node dissection is an important prognostic factor for breast 
cancer survival.   
 
Tumor Estrogen Receptor (ER) / Progesterone Receptor (PR) Status 
    ER and PR status of breast tissue are established clinical parameters in predicting 
prognosis of breast cancer (333).  Survival time differs by ER/PR status with ER-/PR- 
women having worse survival compared to ER+/PR+ women (333).  Estrogen binds to the 
ER, phosphorylation occurs, and the ER becomes transcriptionally active (310).  The 
Schairer study (301) indicated that the probability of death from breast cancer was higher in 
women with ER- tumors compared to those with ER+ tumors.  This is corroborated by 
findings from the Iowa Women’s Health Study that reported a CFR of 6.2 deaths per 100 
person-years for ER- women compared to a CFR of 2.5 for ER+ women (306).  Both of these 
studies corroborate with data collected from 4,473 breast cancer cases diagnosed in 1990-
1992 in Estonia, France, Italy, Spain, the Netherlands, and the United Kingdom (334).  The 
5-year relative survival of ER- women was 77% (95% CI: 73-81%), compared to 90% (95% 
CI: 88-92%) for ER+ women (334).  The 5-year relative survival of PR- women was 79% 
(95% CI: 75-83%) compared to 90% (95% CI: 88-92%) for PR+ women (334).  These 
findings persisted after adjustment for age and stage at diagnosis (334).  Similarly, women 
 42
who had given birth within 2 years of their breast cancer diagnosis were more likely to have 
tumors that were ER- (335). 
    All of these findings concur with the deductions of Putti (336, 337) and Maynard (337) 
that better-differentiated tumors are likely to be ER+  and that ER+ tumors have relatively 
better prognosis.  Conversely, ER- tumors are more likely to be of higher histological grade 
and the patients tend to have a decreased overall survival depending on age and nodal status 
(338).   
 
Obesity at Diagnosis 
    Obesity or overweight at diagnosis is associated with poorer prognosis in the majority of 
studies examining these factors and breast cancer (29, 306, 339).  A meta-analysis by 
Goodwin and colleagues (27) found that increasing body weight exerted a negative 
prognostic effect.  Nine of the 13 cohort studies reported statistically significant associations 
between a measure of body size at diagnosis and prognosis; that the greater the body size at 
diagnosis, the poorer the prognosis (27).  The RR or OR estimates of death for those with a 
large body size ranged from 1.12 to 4.17, with most estimates in the range of 1.5 to 2.0 (27).  
When these analyses were adjusted for other clinical risk factors such as tumor size, nodal 
status, and stage at diagnosis, body size remained an adverse prognostic factor (27). 
    A more recent meta-analysis (340) found that 17 of 26 studies detected a high BMI or 
body weight at diagnosis as a significant risk factor for breast cancer recurrence, death, or 
both.  In those studies which found the positive association between overweight and poor 
breast cancer prognosis, women categorized in the higher (versus lower) levels of obesity 
exhibited a 30% to 540% increased risk of death (29, 340).  A study (306) included in the 
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review by Rock and Demark-Wahnefried (29), analyzed breast cancer mortality rates in a 
cohort of 698 post-menopausal patients with unilateral breast cancer.  After adjustment for 
age, women in the highest tertile of BMI had a 1.9-fold (95% CI: 1.0-3.7) higher risk of 
dying than those in the lowest tertile (306).  This association remained after adjusting for 
stage and tumor size (RR = 1.5, 95% CI: 0.7-2.9).  Also included in the review was a study 
by Jain and colleagues (339), which among 676 incident cases of invasive breast cancer from 
the National Breast Screening Study (NBSS) in Canada, found that the only nutritional 
factors affecting breast cancer prognosis were total energy intake and obesity (RR = 1.64, 
95% CI: 0.99-2.73). 
    To examine the impact of BMI at diagnosis on breast cancer prognosis, Barclaz and 
colleagues (341) studied 6,792 patients in trials of the International Breast Cancer Study 
Group (IBCSG).  They found that patients with “ideal” BMI (≤ 24.9 kg/m2) had significantly 
longer overall survival (OS) and disease-free survival (DFS) than patients with intermediate 
(25-29.9 kg/m2) or obese BMI (≥ 30 kg/m2) (341).  The HR for obese DFS  = 1.17 (95%: CI: 
1.07-1.28) while that for obese OS = 1.25 (95% CI: 1.13-1.38) (341).  Again, this association 
remained after adjustment for other factors which included treatment, tumor size, nodal 
status, ER status, menopausal status, hormone use, and chemotherapy (HR = 1.11, 95% CI: 
1.10-1.20 for obese OS) (341). 
    According to Zhang and colleagues (306), there are a few explanations for poor prognosis 
after breast cancer diagnosis among those women who are overweight.  First, obesity may 
make breast cancer more difficult to detect and therefore it is more advanced at diagnosis.  
Second, the increased endogenous estrogen level of obese women may accelerate tumor 
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spread.  And, finally, obesity is a marker of potentially adverse dietary contributors, such as 
excess fat intake (306).   
 
Socioeconomic Status (SES), Race, and Age 
    SES is a significant predictor of both disease-free and overall survival (149).  Differences 
in survival risk factors for black and white women have been observed, but the differences 
are not uniform among all studies (149).  Some studies indicate that white patients, who tend 
to have higher survival rates than black patients (342), have, on average, a higher SES (343-
346).  In the review by Gordon and colleagues (149), women with lower social class indices 
were more likely to have ER- tumors (High School Education: OR = 1.98, 95% CI: 1.43-
2.73; Living below the poverty line: OR = 1.76, 95% CI: 1.28-2.42).  SES continued to be a 
marker of lower survival even after adjustment for ER status (149). 
    The effects of patient and tumor characteristics on breast cancer survival were examined 
with SEER data from 1973 to 1998 (302).  Larger tumor size and higher tumor grade were 
found to have large negative effects on survival, as did African-American race (HR = 1.47, 
95% CI: 1.39-1.58) (302).  Accordingly, the effect of race is most likely due to a combination 
of other biological and social factors that are not recorded in the SEER database (302). 
    Breast cancer in adolescence and early adulthood is a rare condition (347).  However, 
invasive ductal carcinoma occurring in young women has a more aggressive biological 
behavior and a worse prognosis than breast cancer in older, pre-menopausal women (348).  
Studies and reports have indicated that women younger than 35 years of age have more 
advanced disease at diagnosis and a poorer 5-year survival than older, pre-menopausal 
women (349-353).  Similarly, a study of breast cancer cases in France (354) indicated that in 
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women age 40-54 years, therapeutic treatment strategies may have been more selective 
compared to women under age 40 years, leading to a better prognosis.  Relative survival 
figures indicated that poor prognosis in women over 75 years was essentially due to natural 
mortality (354).  It is hypothesized that breast cancer may be better diagnosed in women age 
40-54 years because they and their doctors may pay more attention to any modifications of 
the breast at this time of life (354).   
 
Potential Prognostic Factors 
Physical Activity 
    Physical activity has been associated with weight loss and weight maintenance among 
healthy individuals (355, 356), and a few recent studies have suggested a favorable effect of 
exercise on body weight among breast cancer survivors (357, 358).  In a study of energy 
balance during the first year after breast cancer diagnosis, Demark-Wahnefried and 
colleagues (359) found that physical activity throughout the year was low and that weight 
gain during chemotherapy was associated with an increase in fat mass.  They concluded that 
reduced physical activity is the primary cause of this weight gain (359).  It is hypothesized 
that physical activity aids in weight maintenance and loss, as well as decreasing adiposity, 
thus reducing the amount of bioavailable estrogen produced endogenously (360).   
 
Cigarette Smoking 
    A study that followed women diagnosed with breast cancer for twelve years indicated that 
the risk of death from breast cancer in cigarette smokers (RR = 1.44, 95% CI: 1.01, 2.06) and 
ex-smokers (RR = 1.13, 95% CI: 0.66,1.94) was greater than that for non-smokers (329).  
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This relationship remained statistically significant after adjustment for age and stage at 
diagnosis (RR = 2.14, 95% CI 1.47, 3.10).  Smokers may have a less favorable prognosis 
than non-smokers because smoking may promote the development of more aggressive ER- 
tumors (329). 
 
Dietary Fat and Energy Intake 
    Several studies have associated decreased survival with pre-diagnosis fat intake (31, 33, 
361), whereas others have failed to detect any association (304, 362).  Saxe and colleagues 
(30) followed women who had been diagnosed with primary breast cancer for five years and 
found that both total energy intake (HR = 1.58, 95% CI: 1.05-2.38) and saturated fat intake 
(HR = 1.19, 95% CI: 1.05-3.04) were associated with an increased risk of breast cancer 
recurrence.  Both saturated and polyunsaturated fats were also associated with an increased 
risk of death for each additional 10 grams per day in the diet (HR = 1.84, 95% CI: 1.09-3.13 
for polyunsaturated fat) (30).  Energy intake is highly correlated with fat intake and in this 
study, energy intake was found to be an important independent risk factor for both recurrence 
and death (30). 
 
Alcohol Consumption 
    The known and potential prognostic risk factors of breast cancer may all have influences 
on estrogen and insulin resistance and hyperinsulinemia (363).  Pre-morbid alcohol 
consumption of at least one drink per week was associated with a 2.7 fold increase in risk of 
death in a study by McDonald et al. (364).  Alcohol consumption may be a surrogate for 
decreased fruit and vegetable consumption (364), indicating decreased flavonoid intake.  
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Alcohol effects estrogen concentration and metabolism as well as alcohol dehydrogenase 
(ADH) and ROS (364).  Other studies have demonstrated at least a slight increase in risk of 
mortality from breast cancer due to alcohol consumption (362, 365).  Post-menopausal 
women may decrease their risk by avoiding or minimizing their consumption (365).    
 
Oral Contraceptive Use 
    The literature on oral contraceptive use and breast cancer survival remains inconclusive as 
most studies are based on small and heterogeneous patient populations (308).  Studies since 
that time have improved, including one by Reeves and colleagues (300) that examined the 
relationship between all-cause mortality and various hormonal and other factors in 1,208 
women with breast cancer.  Oral contraceptives were found to influence survival in women 
with breast cancer, even after adjustment for stage and nodal status, though the results were 
not statistically significant (HR = 0.88, 95% CI: 0.63-1.22 for 10+ years since last OC use, 
compared to never use) (300).   
 
Reproductive Patterns 
    In a study of childbirth and breast cancer survival conducted among breast cancer cases 
from the Australian Breast Cancer Family Study (ABCFS) (335), researchers found that 
those who had given birth within two years before their breast cancer diagnosis were more 
likely to have tumors that involved axillary lymph nodes.  This finding is supported by Olson 
and colleagues (366), who found an adjusted relative risk of 3.1 (95% CI: 1.8-5.4) comparing 
women who had given birth within two years before breast cancer diagnosis and nulliparous 
women.  These women have been found to have more axillary nodes involved as well as ER-
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/PR- tumors of a high grade (335, 366).  Age at menarche, age at menopause, and oral 
contraceptive use were not associated with survival in a study of women under age 71 with 
stage I, II, or III breast cancer (367).  The most obvious host factor potentially mediating the 
adverse prognostic effect of recent childbirth is the hormonal milieu of pregnancy, which 
may result in increased estrogen and progesterone levels stimulating pre-existing breast 
cancer clones (335).   
 
Fruit and Vegetables  
    Some studies have indicated that fruits and vegetables, as well as micronutrients such as 
Vitamin C and carotenoids, may enhance breast cancer survival (30-33, 37).  In those studies 
that found an inverse relationship with survival and intake of fruits, vegetables, and related 
nutrients, the estimates ranged from a 20% to 90% reduction in risk of death (31-33, 37).  
However, variability in these findings and in the vegetable-related dietary factors have been 
examined in these studies and these data do not provide conclusive evidence for a beneficial 
effect (31-33, 37). 
    The study by Jain and colleagues (33), which was described earlier, found a decreased risk 
of dying from breast cancer in the highest quartiles of beta-carotene intake (HR = 0.48, 95% 
CI: 0.23-0.99) and Vitamin C intake (HR = 0.43, 95% CI: 0.21-0.86).  The authors also 
mentioned that diets high in saturated fat, which were associated with an increased risk of 
death (HR = 1.44, 95% CI: 1.16-1.78), may be lower in fruit and vegetable intake and 
therefore lower in carotenes and Vitamin C, which may implicate excess fat intake and 
inadequate fruit and vegetable intake as playing roles in decreased survival after breast 
cancer diagnosis (33).  Similarly, the study by Rohan and colleagues (31) found a decreased 
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risk of death with increasing intake of beta-carotene (HR = 0.68, 95% CI: 0.36-1.27) and 
Vitamin C (HR = 0.74, 95% CI: 0.42-1.30) among cases from the South Australian Central 
Cancer Registry (SACCR), but confidence intervals were wide.  The association for beta-
carotene consumption and Vitamin C consumption was strong and there was found to be 
improvement in tumor differentiation with increasing consumption of these nutrients (32). 
    Additional studies have also assessed fruits and vegetables and their potential associations 
with breast cancer survival.  A study of 149 patients diagnosed with primary breast cancer 
between 1989 and 1991 were followed up for 5 or more years from the University of 
Michigan Medical Center (30).  Fruit (HR = 1.06, 95% CI: 0.69-1.63) and green and yellow 
vegetables (HR = 0.97, 95% CI: 0.70-1.35) did not appear to reduce the risk of breast cancer 
recurrence and death (30).  However, when stratified by menopausal status, fruit appeared to 
enhance survival among pre-menopausal women (HR = 0.17, 95% CI: 0.01-1.86) and 
decrease survival for post-menopausal women (HR = 1.23, 95% CI: 0.79-1.91) (30), though, 
again, neither was precisely estimated. Green and yellow vegetables had no appreciable 
association for pre-menopausal (HR = 0.96) or post-menopausal women (HR = 0.95) (30).   
    Hebert and colleagues (368) studied the effect of diet and body weight on recurrence and 
death in 472 women with early stage breast cancer and noticed the dietary effects were found 
in post-menopausal women only.  A decreased risk of death was found for each increase of 
100 mg in Vitamin C intake (RR = 0.48, p = 0.14) and for each serving of vegetables 
consumed (RR = 0.31, p = 0.08) (368).  These results are similar to those from a study of 
female registered nurses from the Nurses Health Study who had been diagnosed with breast 
cancer (369).  Increased intake of vegetables was associated with a decreased risk of death in 
the third (HR = 0.80, 95% CI: 0.59-1.08) and fourth quintile (HR = 0.81, 95% CI: 0.59-1.11), 
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though neither estimate was statistically significant (369).  Similar to the conclusions of Jain 
and colleagues (33), these authors felt the inverse associations could reflect part of an overall 
healthy diet rather than just vegetable intake alone (369). 
    To improve upon this prior research, it would be useful to add flavonoids to the list of 
components to be measured.  If flavonoids’ effects are stronger than those of fruits, 
vegetables, and antioxidants such as vitamins C and E, then there would be evidence 
indicating flavonoid intake may be beneficial with regard to survival following breast cancer 
diagnosis.  These thoughts have been echoed by other researchers who feel that examination 
of various constituent phytochemicals would be useful (29, 368, 370). 
 
Flavonoids and Background Summary 
    Flavonoids are hypothesized to be associated with a lower risk of developing breast cancer 
and in decreasing the probability of death (49).  In particular, the proposed study was the first 
to examine whether flavonoids affect survival, and among the first to look at flavonoids in 
relation to breast cancer incidence.  As stated earlier, there have been no published studies 
conducted on American populations using the USDA Flavonoid Database for Selected 
Foods.  In the two published studies using this database (59), researchers assessed breast 
cancer incidence in a Greek population (59) and an Italian population (60), both with high 
and wide ranges of fruit and vegetable intake, providing enough heterogeneity to determine if 
there were beneficial effects; which there were.  The large sample size of the LIBCSP study 
population has this same variability and consumption pattern, making it possible to determine 
if flavonoids may reduce breast cancer risk among American women and enhance survival 
after diagnosis.   
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    Improved understanding of carcinogenesis and cancer progression, and uniform results, 
can lead to consistent public health messages that will help women enhance their survival 
following the diagnosis of breast cancer.  Since these messages are currently unknown and 
thus, lacking, now is a perfect time to conduct research that start to answer these important 
questions. 
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Tables and Figures 
Table 1.1.  Known and potential risk factors for breast cancer incidence. 
Known and Potential Risk Factors for Breast Cancer Incidence 
Reproductive Risk Factors Demographic Risk Factors 
Pregnancy Increasing age 
Oral contraceptive use Race 
Hormone replacement therapy 
(HRT) 
Socioeconomic status (SES) 
Little or no breastfeeding  
Early age at menarche Potential Risk Factors 
Late age at menopause Cigarette smoking 
Late age at first birth Fat consumption 
 Non-steroidal anti-inflammatory 
drug (NSAIDs) use 
Medical Risk Factors Fruit and vegetable consumption 
Family history of breast cancer in 
sister or mother 
 
Endogenous estrogen levels  
Benign breast disease (BBD)  
  
Environmental/Lifestyle Risk 
Factors 
 
Post-menopausal obesity and weight 
gain           
 
Alcohol consumption  
Physical inactivity  
 Adapted from Adami (112) and Kelsey (64). 
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Table 1.2.  Known and potential prognostic factors for breast cancer survival. 
Known and Potential Prognostic Factors for Breast Cancer Survival 
Known Prognostic Factors Potential Prognostic Factors 
Tamoxifen Physical activity 
Age Cigarette smoking 
Radiation and chemotherapy treatment Dietary fat and energy intake 
Tumor size at diagnosis Alcohol consumption 
Stage at diagnosis Oral contraceptive use 
Node involvement/status Reproductive patterns 
Tumor estrogen receptor (ER) / 
progesterone receptor (PR) status 
Fruits and vegetables 
Obesity at diagnosis  Flavonoids 
Socioeconomic status (SES) and race  
Adapted from Jain (299), Schairer (301), Reeves (300), Rosen (6-8), and Fisher (9). 
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Figure 1.1.  Reproductive risk factors proposed mechanism behind breast cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Few or no pregnancies    Oral contraceptive use 
Hormone replacement therapy (HRT)  Breastfeeding 
Early age at menarche     Late age at first birth 
Late age at menopause 
Estrogen 
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Figure 2.1. Proposed DAG of potential confounders to the association between 
flavonoid intake and breast cancer incidence. 
Flavonoid Intake BC Incidence
pregnancy OC use HRT
parity breastfeeding Early age at menarche
SES
Late age at menopause Late age at 1st birth
Age
Family History Endo. Estrogen Levels BBD Physical Activity BMI/Body Size/Wt. Alcohol intake
Smoking Radiation Fat intakeFruit&VegIntake
 
 
 
 
 
 
 
  
 
CHAPTER II: RESEARCH METHODS AND DESIGN 
Overview of Study Methods 
    To study the associations of flavonoid intake with breast cancer risk and survival, existing 
data collected as part of the LIBCSP was used.  The LIBCSP is a population-based study of 
women of Nassau and Suffolk counties in Long Island, New York; the case-control 
component was conducted in 1996-1998 and the follow-up was conducted in 2002-2004.    
Dietary intake in the year prior to the case-control interview was collected utilizing a 
modified version of the 100-item Block food frequency questionnaire (FFQ).  98.2% (N = 
1,481) of the cases and 97.6% (N = 1,508) of the controls self-completed the FFQ in an 
average of 36 minutes immediately after the main questionnaire had been completed (371).  
The dietary intake of respondents (which was collected as part of the case-control study) was 
coupled with the USDA Database for the Flavonoid Content of Selected Foods, the USDA – 
Iowa State University Database on the Isoflavone Content of Selected Foods, and Statistical 
Analysis Software (SAS) to obtain a measure of flavonoid intake.  For the two lignans that 
are precursors to enterolactone and enterodiol, matairesinol and secoisolariciresiol (372), 
respectively, intake were estimated from dietary phytoestrogen concentrations of food (373).  
Unconditional logistic regression was used to study risk, and proportional hazards modeling 
and survival analysis techniques was used to study survival.      
 
Exposure Assessment 
Modified Block FFQ (LIBCSP Food Questionnaire) 
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    The original Block FFQ was developed using dietary data from 11,658 adult respondents 
to the Second National Health and Nutrition Examination Survey (NHANES II) (374).  Food 
items were selected on the basis of their contribution to the total population intake of energy 
and each of 17 nutrients in the NHANES II data, and represent over 90% of each of those 
nutrients (374).  Associated nutrient composition values were determined from the NHANES 
II database using frequency of consumption data in that survey (374).   
    The Block FFQ included a food list to ensure adequate assessment of dietary fiber intake, 
intake of cruciferous vegetables, foods and beverages with suspected health benefits (e.g., 
tea), and foods important in geographic and ethnic subgroups (e.g., chili peppers) (374).  
Some fruits were separated into “fresh, in season” and “canned/frozen” because respondents 
had difficulty with a combined item (374).  Additionally, the questionnaire has an open-
ended question where the respondent can indicate other frequently eaten foods, permitting 
the capture of foods important to a particular individual or demographic group (374).  
Questions on special diets and vitamin supplements were also included (374).   
    The Block FFQ was modified by Potischman and colleagues (375) to include questions 
differentiating low and high fat dairy items, low and high caffeine beverages with and 
without artificial sweeteners, separation of items that differed in fat or fiber content, as well 
as sections for foods relevant to their study population and an open-ended section to include 
foods consumed more than once per week that were missing from the food list. 
    For the LIBCSP, the Block FFQ was further modified; the portion size question for each 
food (with an average serving size as a guide), was followed by three possible choices for the 
respondent’s serving size; less, average, or more.  Additional food items that contain 
phytoestrogens were also added to this FFQ (376).  A private research firm, Intercontinental 
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Marketing Services (IMS), located in Bethesda, Maryland, derived estimates for each serving 
size choice for each food and beverage in grams and milliliters, respectively.   
 
USDA Database for the Flavonoid Content of Selected Foods  
    The recent interest in the potential anticarcinogenic and antioxidative properties of 
flavonoids by the scientific community led to the development of the USDA Database for the 
Flavonoid Content of Selected Foods (377).  The Nutrient Data Laboratory (NDL) and the 
Food Compostion Laboratory (FCL) of the Beltsville Human Nutrition Research Center 
(BHNRC) of the Agricultural Research Service (ARS) and U.S. Department of Agriculture 
(USDA), along with epidemiology and nutrition groups from universities, institutes, and 
corporations collaborated on the two-phase project (377).  The first phase consisted of an 
extensive survey of the literature for articles containing data on the flavonoid content of food.  
Data from analytical studies which used only acceptable procedures defined as those which 
lead to good separation of flavonoid compounds, such as column chromatography or high-
performance liquid chromatography (HPLC), were used (377).  Papers that contained data 
generated by thin layer or paper chromatography, radioimmunoassay (RIA), pH differential 
methods, or only spectrophotometric quantitation were not retained because of the lack of 
specificity of these methods (377).  This database was created through great attention to 
detail to produce the most comprehensive tool available to study the potential link between 
flavonoids and human health.  It is the new standard for flavonoid research and was used to 
help answer the questions posed and be a building block for future flavonoid databases.   
    The USDA Database for the Flavonoid Content of Selected Foods contains values for five 
classes of flavonoids: flavanols, flavones, flavanones, flavan-3-ols, and anthocyanidins.  
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Twenty-six individual flavonoids comprise these classes and they are measured in 225 foods 
and beverages.  Values are reported as mg/100g of fresh weight of edible portion of food and 
values of beverages were adjusted by their respective gravities and are reported as served.  
Values of tea are given as mg/100ml (100g weight) of tea infusions (as consumed).  This 
database was linked to the dietary data from the modified Block FFQ used in the LIBCSP to 
estimate individual and total flavonoid intake in these women.  In addition to identifying 
which group (cases or non-cases) consumes, on average, more total flavonoids and classes of 
flavonoids, it was determined whether greater total and individual flavonoid intakes are 
inversely associated with breast cancer risk and mortality.  Table 2.1 displays the five classes 
of flavonoids assessed in the USDA Database for the Flavonoid Content of Selected Foods, 
the individual flavonoids which make up these classes, and the main dietary sources of these 
flavonoid classes.   
USDA - Iowa State University Database on the Isoflavone Content of Selected Foods 
 
    Prior to the creation of the USDA Database for the Flavonoid Content of Selected Foods, a 
database for isoflavones, another class of flavonoids, was developed and introduced in 1999.  
The USDA - Iowa State University Database on the Isoflavone Content of Selected Foods 
was a collaborative effort between the FCL and NDL of the ARS/USDA and the Department 
of Food Science and Human Nutrition of the Iowa State University (378).  The main dietary 
sources of isoflavones are soybeans and soyfoods. Some other food legumes contain very 
small amounts of isoflavones (378).  Data for isoflavone contents of foods were collected 
from scientific articles published in refereed journals and by extensive sampling of soy-
containing foods and subsequent analyses at the Iowa State University (378). 
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    Data for the isoflavones, genistein and daidzein, have been added to the database to 
measure flavonoid intake from tofu, beans, and peas.  Tofu is a flavonoid-rich food that is 
listed on the FFQ but not the USDA Flavonoid Database, hence its addition.  The USDA - 
Iowa State University Database on the Isoflavone Content of Selected Foods was used to add 
this data because it contains genistein and daizein content of 14 different kinds of tofu.  The 
modified Block FFQ used in the LIBCSP inquired about tofu consumption but it was labeled 
only as ‘Tofu’.  Thus, the values of genistein and daidzein (in mg per 100 g) added to the 
flavonoid database for analysis were derived by taking the average content of these 
isoflavones in the 14 kinds of tofu. 
 
Additional Isoflavone and Lignan Values Obtained from the Literature 
    Since isoflavones and lignans, two additional classes of flavonoids, also occur in various 
fruits, vegetables, beverages, nuts, and grain products (379-382) (though in respectively 
smaller amounts compared to soy), additional data were obtained (379-382).  This 
supplementation of the two USDA databases ensured inclusion of as many flavonoid-
containing products as possible in the database to be used for analysis.  The manuscript that 
describes the creation of this enhanced database is in Appendix 2.  These sources are the 
result of previous analyses and compilations of the literature (382), including chemical 
analyses of foods and beverages in laboratories (379-381).  De Kleijn and colleagues (382) 
located published laboratory analysis data by searching the medical (Medline) and 
agricultural (Agricola) scientific literature and through contact with several experts in the 
field of phytoestrogens.  Values for lignans for some foods were also obtained via an isotope 
dilution gas chromatography/mass spectrometry method in the laboratory (382).   
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    In the laboratory analyses of Liggins and colleagues (379-381), foods were obtained from 
supermarkets, freeze-dried, milled, dessicated, and eventually assayed to obtain their contents 
of daidzein and genistein.  The values obtained from two of these laboratory investigations 
(379, 380) were recently used by Bosetti and colleagues (60) in their study assessing 
flavonoids and breast cancer risk in Italy.  
 
Classification of items using the Modified Block FFQ and USDA Database for the 
Flavonoid Content of Selected Foods 
 
    Descriptive analysis of the dietary data from the LIBCSP was conducted to determine the 
mean intake of each food and beverage item that was assessed in the study.  Table 2.2 
displays categories of foods and beverages which were listed on the modified Block FFQ.  
Foods and beverages consumed in ‘high’ quantities in the LIBCSP were considered to be 
those with a mean consumption of at least 15 g per day.  Foods and beverages consumed in 
‘small’ quantities therefore had a daily mean consumption of less than 15 g.  ‘Large’ 
contributors of flavonoids were considered to be foods and beverages which contained at 
least one flavonoid at 5 mg or greater per 100 g of the respective food or beverage.  ‘Small’ 
contributors of flavonoids therefore did not contain at least one flavonoid at 5 mg or greater 
per 100 g.  
    This table demonstrates the ability of the modified version of the Block FFQ used in the 
LIBCSP to reflect consumption of many flavonoid-rich foods and beverages, which 
represented the bulk of the content of the newly-constructed flavonoid database.  It was 
difficult to quantify flavonoid content for mixed dishes, which were assumed to include 
spaghetti; hamburgers, beef burritos, and meatloaf; pizza; and vegetable soup.  However, 
they are all relatively small contributors of flavonoid content (377) and thus any 
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misclassification should have a negligible effect on estimation.  The handling of ‘large’ and 
‘small’ contributors of flavonoids that were not listed on the modified Block FFQ, but are 
listed on the USDA Database for the Flavonoid Content of Selected Foods, are described in 
more detail later.   
    The contribution of herbs and spices, such as basil and oregano, were not considered when 
assessing flavonoid content.  This is because standard containers of basil and oregano contain 
1 oz. (28 g) and 1.2 oz. (34 g), respectively.  Since flavonoid content for all items on the 
USDA Database for the Flavonoid Content of Selected Foods are reported in mg per 100 g, it 
was unnecessary to estimate a trivial amount of these products in mixed dishes because it 
would take approximately 3 containers to have 100 g of basil or oregano. 
 
Overview of the Long Island Breast Cancer Study Project (LIBCSP)   
    The LIBCSP was a group of projects funded by the National Cancer Institute and National 
Institute of Environmental Health Sciences in response to federal legislation (Public Law 
103-43, June 10, 1993), which mandated that an epidemiologic study be conducted to assess 
environmental and other potential risk factors contributing to the incidence of breast cancer 
in the Long Island counties of Nassau and Suffolk in New York (371).  The primary study of 
the LIBCSP was a population-based case-control study undertaken to determine whether the 
risk of breast cancer among women residing on Long Island was associated with polycyclic 
aromatic hydrocarbons (PAHs) and organochlorine compounds, such as DDT and 
polychlorinated biphenyls (PCBs) (371).  To assess these primary exposures of interest, the 
study involved a comprehensive in-person questionnaire, biologic sample collection of blood 
and urine, and collection of environmental home samples of dust, water, and soil at the time 
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of the personal interview (371).  The following description of the is derived from Gammon 
and colleagues (371). 
 
Case-Control Study Population Identification 
    For the case-control study, cases were women with newly diagnosed, primary in-situ or 
invasive breast cancer between August 1, 1996 and July 31, 1997, confirmed by the 
physician and medical record, who were residents of either Nassau or Suffolk counties in 
Long Island, New York (371).  All cases were over the age of 20 years and English-speaking.  
Cases were ascertained using a rapid reporting network developed with 33 hospitals and 450 
physicians known to treat or diagnose breast cancer for the women of Long Island (371).  To 
facilitate collection of blood samples from cases prior to chemotherapy, a “super-rapid” 
identification network was established to ascertain potentially eligible case women with 
newly diagnosed breast cancer (371).  Study personnel contacted the pathology departments 
of all 28 hospitals on Long Island, as well as three large tertiary care hospitals in New York 
City, at least two to three times per week.  Seven institutions in the Long Island – New York 
City area with the largest numbers of newly diagnosed breast cancer cases among Long 
Island women were contacted daily (371). 
    Physicians of the potentially eligible case women were then contacted to confirm the 
subject’s diagnosis, the date of her diagnosis, and for permission to contact the subject.  To 
promote physician cooperation prior to initiating subject identification, over 400 physicians 
who as general practitioners, internists, surgeons, or oncologists on Long Island, who had the 
potential to diagnose or treat women with breast cancer, were mailed a packet describing the 
study which allowed them to indicate their willingness to participate in the study in writing.  
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No physician refused to participate.  A total of 2,271 women were initially identified and 
considered as potentially eligible cases.  Of these, 2,030 were determined likely to be eligible 
by the physician and physician consent was obtained for 1,837 (90.5%).  Physician refusal 
for contact was generally based on a subjects’ poor health status, which was often due to age-
related co-morbidity. 
    Control women were a sample of current residents of Nassau and Suffolk counties who 
spoke English, did not have a personal history of breast cancer, and who were frequency-
matched to the expected distribution of the case women by 5-year age group (371).  Controls 
were identified using random digit dialing (RDD) for women under the age of 65 years and 
Health Care Finance Administration rosters for women 65 years or older (371).  HCFA 
selection occurred twice during the 12-month identification period that coincided with the 12 
months of case ascertainment.  RDD selection began July 1, 1996 and continued in eight 
waves over the following 12 months.  The response rate to the RDD telephone screener was 
77.9% (371). 
 
Subject Recruitment in the Case-Control Study 
    Potentially eligible controls and cases with physician consent were first contacted by the 
study team via an overnight letter.  Due to concerns about the overnight service in some 
potential control women who were 65 years of age or older, subsequent older potential 
controls were contacted by a regularly mailed letter.  A recruitment letter explained the 
purpose of the study, the various components of the study interview, and that participation in 
the study was completely voluntary.  They could choose to participate in any or all of the 
components for which they were selected.  Along with this letter, in the packet of 
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information sent to potential participants, was a flyer that answered commonly asked 
questions about the study and a form letter signed by the Long Island Breast Cancer Network 
members, a community-based organization, explaining that the LIBCSP case-control study 
was a direct result of the community’s activism and it urged women to consider participating.  
Study recruiters contacted the study subjects to answer questions and arrange for an 
interview.  For most of the women, the recruiters contacted potential respondents by 
telephone.  For some control women who were difficult to contact by telephone, they were 
approached by recruiters in person.  Written, signed informed consent was obtained from 
participants prior to conducting any component of the interview. 
 
Case-Control Subject Participation  
    The main questionnaire was completed by 1,508 (82.1%) of the eligible case women (N = 
235 with in situ and 1,273 with invasive breast cancer) and 1,556 (62.7%) of the eligible 
control women (371).  The reasons for non-response to the interview among cases and 
controls included subject refusal (218 (12.4%) and 573 (21.6%)); too ill, cognitively 
impaired, or deceased (76 (4.1%) and 193 (7.8%)), and unlocatable, moved out of the area, or 
other (26 (1.4%) and 195 (7.9%)) (371).  Study subjects ranged in age from 20 to 98 years 
and response to the interview varied with the age of the respondents, with 88.9% of the cases 
and 76.1% of the controls under age 65 years participating versus 71.6% and 43.3%, 
respectively, among those age 65 years and older (371).  The average length of time between 
the referent date (date of diagnosis for cases and date of identification for controls) and 
interview date was 96 days for cases and 167 days for controls (371).    
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    For case women, final study eligibility was based upon thorough review of the medical 
record, which could only be obtained with a signed medical record consent form (371).  This 
form was signed by the cases themselves and it allowed study personnel to, in addition to 
determining final eligibility, determine the clinical characteristics of the breast cancer 
diagnosis (e.g., stage of disease and hormone receptor status).  Signed medical record release 
forms were obtained for 1,473 (97.7%) case respondents and records were successfully 
located and abstracted for 1,402 (95.2%).  Due to the fact that a goal of this study was to 
collect blood samples prior to chemotherapy, most case women were interviewed prior to the 
completion of their course of treatment.  Thus, complete treatment information is not 
available on the majority of case subjects at the time of the case-control interview. 
    The final eligibility of controls was obtained through direct contact with the subject (371).  
It is therefore possible that the interview response rates may be underestimates as they 
include in the denominator 25 potentially eligible case women and 193 potentially eligible 
control women for whom study subject eligibility could not be determined because they were 
never located or had moved out of the area (371). 
 
Case-Control Study Interview 
    The interview consisted of five components, which were administered in the following 
order: (1) signed informed consent; (2) the interview-administered main questionnaire; (3) 
collection of biologic samples (blood and urine) and administration of a specimen checklist; 
(4) administration of a modified Block FFQ; and (5) among a sub-sample of long-term 
residents, collection of environmental home samples (soil, dust, and water).  The first four 
components required between two to three hours to complete.  For those subjects who 
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completed the fifth component, an additional 30 to 60 minutes was required.  Completion of 
all components of the interview was done in the respondent’s home.  Interviewers, who were 
certified to collect blood samples in the state of New York, received a one-week, 
standardized, intensive training course in all aspects of interview administration.  
    The interviewer explained the contents of the written informed consent form to each 
eligible subject, and if the participant wished to continue, she was asked to read and sign the 
form.  Upon receiving physician and participant consent, cases and controls were 
administered an in-home interview with a trained nurse (371).  The main case-control 
questionnaire, which took approximately 100 minutes to administer, was administered 
focusing on known and suspected risk factors for breast cancer such as reproductive history, 
residence, physical activity, hormone use, and environmental exposures.    Subjects were also 
administered a modified version of the Block FFQ to assess dietary intake (371).  Most of the 
modifications were validated against six 24-hour recalls over a twelve month period (375, 
383).  A total of 1,508 (82.1%) eligible cases and 1,556 (62.7%) eligible controls completed 
the main questionnaire.  Of the women who completed the main case-control questionnaire, 
98.2% of cases and 97.6% of controls completed the FFQ.  This instrument was completed in 
an average of 36 minutes immediately following the completion of the main questionnaire.  
Response for the FFQ did not vary with age of the respondent. 
 
Demographic and Risk Factor Description of the Case-Control Population 
    There was no age limit for participation in the LIBCSP and this allowed for a wide age 
range of women to be included for study.  519 cases (34.4%) and 440 controls (28.3%) were 
at least 65 years of age or older.  2,840 (1,411 cases and 1,429 controls) (92.7%) of the 3,064 
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combined cases and controls reported themselves as Caucasian, 154 (5.0%) as African-
American, 67 (2.2%) as ‘Other’, and 3 women had missing racial status.  The education level 
of the population ranged from less than high school to post-graduate status.  More than one-
fourth of both cases and controls (28.0% and 29.7%, respectively) were college graduates or 
current or former post-graduate students.  Likewise, income level spanned a wide array as it 
ranged from less than $15,000 in 8.9% and 6.4% of the cases and controls, respectively, to 
greater than $90,000 in 13.1% and 21.5% of the cases and controls, respectively. 
     
 
Results of Established Risk Factors for Breast Cancer in the Case-Control Population 
 
    Many established risk factors for breast cancer that have been identified in previous 
studies (384), including parity (OR = 0.63, 95% CI 0.48-0.82 for 4+ children versus none), 
breastfeeding (OR = 0.70, 95% CI 0.53-0.89 for 14 months versus none), age at first birth 
(OR = 1.36, 95% CI 1.10-1.69 for 28+ versus < 22 years), and family history of breast cancer 
in a mother or sister (OR = 1.66, 95% CI 1.36-2.02 for family history versus no family 
history) , were confirmed to affect risk among women of all ages on Long Island (371).   
 
Potential Biases and Effects of Study Participation in the Case-Control Study 
 
    Response rates were lower among controls than in cases, which was driven by poor 
participation among elderly control women (371).  Co-morbidity among the elderly and the 
protective efforts of the subjects’ families prevented full study participation among these 
older women (371).  If the older respondents differed systematically from older non-
respondents, results based on this segment of the study population may be biased and 
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therefore should be interpreted cautiously as they may not be generalizable to all older 
women (371).   
    Additionally, a low screener rate obtained during RDD contributed to the lower 
participation rate of the controls and it affected results based on women under the age of 65 
years (371).  RDD has been an effective and common technique to identify a pool of 
potential eligible population-based controls since the technique was introduced by Waksberg 
(385).  However, with the increasing use of telephone answering machines and caller ID, 
particularly in high-income areas such as Long Island where residents were subjected to 
extensive telephone marketing, the RDD technique may be less effective (371). 
    As stated previously, there was a difference between cases and controls in the time lag 
between the reference date and the interview date, with cases interviewed on average within 
about 3 months of diagnosis and the controls within about 5.5 months of identification (371).  
This is a common feature of case-control studies when cases are deliberately recruited more 
quickly than controls, to enhance accurate recall of events prior to diagnosis (371).  This 
strategy was also employed to facilitate collecting blood samples before the initiation of 
chemotherapy treatment among case women.  For most factors in this study, cases and 
controls were asked to recall lifetime or historical exposures that occurred prior to the 
reference date, which was the date of diagnosis for cases and date of identification for 
controls (371).  The modified Block FFQ required cases and controls to recall their dietary 
practices in the year prior to the interview date when the FFQ was administered.   
 
Overview of the LIBCSP Follow-Up Study  
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    The LIBCSP follow-up study was conducted among the breast cancer cases who 
participated in the LIBCSP case-control study who had given study personnel permission to 
re-contact them (n = 1,414) (371).  Because case women were rapidly identified for the case-
control study, many women were still receiving treatment at the time of the case-control 
interview.  Often care was not at the institution where a case obtained her diagnosis and thus 
study personnel were unable to identify from which hospital to obtain the necessary 
treatment information.  Thus, five years after the initial diagnosis, subjects were re-contacted 
to obtain the necessary data on treatment for their initial breast cancer.  The proposal was to 
follow-up the population-based case participants from the original case-control study in order 
to assess their overall survival 5 years after diagnosis of their first primary breast cancer.  
The analyses reported here are restricted to women diagnosed with a first primary breast 
cancer at the time of the case-control study (n = 1,273).   
 
Subject Recruitment for the Follow-up Study 
    There were a total of 1,508 case women interviewed as part of the case only study.  
Potentially eligible subjects for the follow-up study were those who indicated at the case-
control interview that it was permissible to contact them in the future (n = 1,414).  The 
eligible case participants or their next of kin were re-contacted first by mail approximately 5 
years after the initial diagnosis, and then by telephone, and invited to participate in a 60-
minute telephone interview.  Informed consent was obtained verbally by telephone.  
Extensive efforts were made to contact and interview the next of kin because a large 
proportion of non-response could have been due to mortality.  Sixty of the 1,414 case women 
replied to the first mail contact and indicated refusal to participate, leaving 1,354 case women 
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(1,273 invasive case women and 81 in situ case women) available to be contacted by 
telephone.  Reasons for non-response included refusal to participate when contacted by 
telephone (n = 65), refusal to participate due to illness (n = 18), lost-to-follow up (n = 55), 
multiple contacts yet unable to complete the interview (n = 22), and deceased with no proxy 
to contact (n = 96).  Thus, 1,098 total interviews (93 with proxies) via telephone (1,066 
complete and 32 partial) were conducted.   
    
 Data Collection at Follow-up 
    At the 5-year follow-up, two sources were used to determine treatment and outcome data 
of the initial breast cancer diagnosis: (1) subject interviews and (2) medical record 
abstraction.  Cases were interviewed via telephone, by a trained interviewer, to assess two 
types of information: (1) treatment modalities undergone for the initial breast cancer 
diagnosis with the aim of obtaining the name(s) and location(s) of the treating physician(s) 
and institution(s), and dates of the treatment(s); and (2) outcomes and treatments for the 
outcomes since the initial breast cancer diagnosis date, with the aim of obtaining the name(s) 
and location(s) of the diagnosis and treatment physician(s) and location(s).  For case women 
(or their proxy) who provided a signed medical record release form (n = 598), all relevant 
medical records with regard to the initial breast cancer diagnosis and outcomes were 
requested; those successfully retrieved were systematically abstracted by trained abstractors. 
 
Case Interviews: Exposure Ascertainment  
    The cases were asked to recall the names of the hospitals, any other institutions, and 
treating physicians associated with all treatments undergone since the diagnosis date of their 
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initial breast cancer.  Although the case-control interview attempted to ascertain this 
information, most women had not yet finished their treatment regimen.  In the follow-up 
interview, more detailed information could now be obtained because the first course of 
treatment was now complete.  In order to facilitate recall, subjects were systematically 
queried about procedures they may have undergone including: surgery (needle biopsies, 
tumor biopsies, modified mastectomy, radical mastectomy, node removal); radiation; 
chemotherapy (specific combinations undergone, if possible); and hormone treatments 
(tamoxifen, etc.). For each type of procedure, the subjects were asked to recall the number of 
times the procedure was performed, the frequency, the date(s), the treating physician(s), and 
the location of the institution, office, or free-standing facility where each procedure was 
performed. The subject was also asked to complete another medical record release form 
giving the study staff permission to access their records. 
    From information collected in the case-control interview, treatment and co-morbidity data 
exists for the entire sample of cases (n = 1,508).  During the follow-up interview, detailed 
information on treatment and co-morbidity was obtained from most of these cases (n = 
1,098).  This information was then collected a third time through medical record abstraction, 
to confirm the interview data, and is available for women who signed a medical record 
release form (n = 598).   
Retrieval and Abstraction of Medical Records 
    Additional medical record release forms were obtained from the follow-up subjects by 
mail.  During the follow-up interview, subjects were asked to recall any relevant information 
regarding: (1) treatment they may have undergone for the initial breast cancer; and (2) study 
outcomes of interest and any treatment undergone for those outcomes.  For the proxy 
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interviews and self-respondents, relevant medical records regarding treatment (surgery, 
radiation, chemotherapy, hormone therapy, etc.) and outcomes (death) were retrieved from 
the appropriate hospitals.  Using a standardized form, trained abstractors reviewed and 
abstracted all medical records to determine each subject’s treatment regimen for their initial 
breast cancer and to determine relevant outcome information.    
 
Potential Biases and Effects of Study Participation in the Follow-up Study 
 
    The next-of-kin (proxy) questionnaire was identical to the instrument used to interview a 
breast cancer case other than the wording was modified to reflect that the questions referred 
to the case and not the proxy.  However, the ability of a proxy to recall treatment and 
outcome data of the initial breast cancer diagnosis for the case may not be as accurate as a 
self-report from the case herself.  This could result in more thorough and complete data 
collection from cases which may bias results of subsequent analyses.   Correspondingly, a 
review on the use of proxy respondents noted that some exposures are measured with less 
misclassification than others and that, in general, the misclassification is due to 
underreporting of the exposure by the proxy as compared with directly-reported responses 
(386).  
 
Case Outcome Ascertainment (Death) 
    The NDI, a central computerized index of death record information on file in the State 
vital statistics offices (387), was established by the National Center for Health Statistics 
(NCHS) to aid epidemiologists and other health and medical investigators with their 
mortality ascertainment activities.  The NDI contains state-mandated death records from 
1979 to present, as it is updated 12 months after the end of each year (388).  Data which 
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included  participant identification number, first and last name, city, state, date of birth, 
Social Security number, last contact, gender, reference date, race, and marital status, obtained 
from the telephone interview, were combined into a spreadsheet and converted into an ASCII 
file for NDI (389).  This list of information was matched with the NDI search, which 
includes matching algorithms on first and last names, middle initial, father’s surname, Social 
Security number, birth date, and gender (388), to provide a list of names of the invasive cases 
that did not match any death records or a list that could be considered a match.   
    The NDI is currently considered the “gold standard” of mortality ascertainment (389).  The 
ability of the NDI to ascertain deaths of study participants was tested with information 
regarding 197 participants whose deaths had been reported and 1,997 participants who were 
known to be alive, all from the Nurses’ Health Study (388).  Information was sent to the NDI 
and a newly-developed service, the Equifax Nationwide Data Search.  The sensitivity of the 
NDI to accurately report deaths was 98.0% compared to just 79.2% for the Equifax service 
(388), making the NDI a preferred method to search for deaths in prospective cohort studies 
(388).   
    More recently, in a study of 31,223 subjects with unconfirmed vital status in an ongoing 
occupational cohort mortality study, information was submitted to the Health Care Finance 
Administration (HCFA), Social Security Administration (SSA), and Pension Benefit 
Information Company (PBI) to obtain death certificate numbers (390).  The NDI provided 
exact matches for 92-96% of deaths identified by each of the three services (390).  The 
effectiveness of the NDI has also been tested by identifying participants in the oldest cohort 
of the Australian Longitudinal Study on Women’s Health (ALSWH) who had died between 
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1996 and 1998 (391).  The sensitivity of the NDI for identifying known deaths was 95% 
(391).   
    In the LIBCSP Follow-up, the all-cause mortality rate was 13.0% (196 deaths amongst 
1,508 cases).  Of the 196 cases that died, 123 died from breast cancer (breast cancer-specific 
mortality rate of 62.7%).  Therefore, there are two possible methods for assessing the 
outcome of death, all-cause mortality or breast cancer (disease-specific) mortality.  Of the 
1,273 invasive cases, 188 (14.8%) died during the follow-up period.  Table A.1 provides a 
list of the number of deaths and causes of death for the 1,273 invasive cases.  121 of the 
invasive cases (64.4%) died from breast cancer.  Among older women, the increasing 
probability of developing other debilitating conditions or diseases is an issue.  However, for 
the 32.4% (n = 387) pre-menopausal invasive cases, co-morbidity is less likely to have an 
effect on death from breast cancer.   
 
 
Flavonoid Database Construction for Analysis 
    The traditional construction of a database for analysis involves linking subject responses to 
the FFQ, specifically frequency and portion size, with an existing database for the 
components being studied.  This was the first study using both the USDA Database for the 
Flavonoid Content of Selected Foods and USDA – Iowa State University Database on the 
Isoflavone Content of Selected Foods to assess flavonoid intake with an American 
population.   
 
Weighting Foods from the Modified Block FFQ 
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    The first step in constructing the database for analysis was to weight foods and beverages 
listed on the USDA Database for the Flavonoid Content of Selected Foods.  This procedure 
was necessary because some food items on the modified Block FFQ include multiple foods 
or beverages rather than single foods (e.g., ‘Cauliflower or brussel sprouts’).  Weights 
(percentages) were assigned to the respective USDA Database items (e.g., give equal weight 
to both foods by assigning 0.50 to ‘Cauliflower, raw’ and 0.50 to ‘Brussel sprouts, raw’).  
These weights were then linked with the modified Block FFQ food item, ‘Cauliflower or 
brussel sprouts’, providing the flavonoid contribution of that FFQ item.  These weights are 
estimates of the proportion of each food or beverage consumed by the LIBCSP per item 
listed in the modified Block FFQ.  In order to assign these weights, the Foods Commonly 
Eaten in the United States: Quantities Consumed Per Eating Occasion and in a Day, 1994-
1996 was used (392).  This report was authored by Helen-Smiciklas-Wright, Diane Mitchell, 
Sharon Mickle, Annetta Cook, and Joseph Goldman.  The report contains estimates of food 
intakes by individuals residing in households in the entire United States (392).  The estimates 
were based on information from 14,262 non-breast fed individuals ages 2 and above for 
whom 2 days of dietary intake information was obtained in the 1994-1996 Continuing 
Survey of Food Intakes by Individuals (CSFII 1994-96), which was conducted by the United 
States Department of Agriculture (USDA) (392).  Food intake data were collected by in-
person interviews from 1994 through 1996.   
    The CSFII 1994-96 has two tables of information (392), one which provides quantities 
consumed per eating occasion in grams (Table Set 1) and another which provides estimates 
for the quantities of 96 foods and food groups eaten per individual per day (Table Set 2).  
Since the LIBCSP participants consist of females ages 20 and older, only information 
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pertaining to females in the following age categories listed on the tables was used: Age 20-
39, Age 40-59, and Age 60 and older.  The quantities consumed by users in Table Set 2 are 
reported in terms of gram weights.  Both table sets were used in this weighting process.   
 
USDA Database for the Flavonoid Content of Selected Foods Adjustments: Repeated Food 
and Beverage Items 
 
    Some foods and beverages from the modified Block FFQ used in the LIBCSP were listed 
on the USDA Database for the Flavonoid Content of Selected Foods multiple times yet in 
different forms.  For example, ‘Apples, Applesauce, and Pears’ is listed on the FFQ, but six 
items on the USDA Flavonoid Database contain at least one of these products (e.g., ‘Apples, 
raw, with skin’; ‘Apples, raw, without skin’; ‘Pears, with skin, raw’; ‘Pears, without skin, 
raw’; ‘Pears, without skin, cooked’; and ‘Applesauce, canned, unsweetened, without added 
ascorbic acid’).  For these occurrences, the CSFII 1994-96 (392) was used to provide 
estimates of the proportion consumed (weights) of each USDA Database item.  
 
New Variable Creation in Excel from the Modified Block FFQ Foods and Beverages 
 
    The data from the USDA Database for the Flavonoid Content of Selected Foods was 
placed into an Excel spreadsheet for ease of formula and variable creation.  New variables 
were created for each of the items on the modified Block FFQ.  For example, the ‘Apples, 
Applesauce, and Pears’ item on the FFQ was created into one variable called ‘FFQapple’.  
Next, seven columns (Total Flavonoid Intake / Day, Total Flavonols / Day, Total Flavones / 
Day, Total Flavanones / Day, Total Flavan-3-ols / Day, Total Anthocyanidins / Day, and 
Total Isoflavones / Day) were added to the right of each of these new variables.  An 
additional column for Total Lignans / Day was added to those foods and beverages which are 
shown to contain lignans from the phytoestrogen concentrations of food items (382).  
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Formulas were created in Excel to calculate the totals for each new variable.  Next, these new 
variables’ respective total flavonoid and flavonoid class values were entered into a new Excel 
spreadsheet. 
    The Excel spreadsheet contains a column for the identification number (ID) of each 
LIBCSP participant.  Each Excel spreadsheet had this same column of information to 
facilitate merging of data into one SAS dataset.  To the right of each ID number were the 
total flavonoid and total flavonoid class per day variables (e.g. appletotalday and 
appleflavone) and their respective values.  The values for each variable were identical for 
each participant in order to estimate flavonoid intake based on their actual intake of the food 
or beverage (Table 2.3). 
    When assessed separately, the total lignan intake per day variable was multiplied by 1000 
so that all values were in micrograms (µg) per day.  This was done because the levels of 
lignan intake are typically estimated to be in µg per day (393, 394).  The Excel spreadsheets 
were imported into SAS and merged by ID with an existing dataset which includes the gram 
per day variables and values for the modified Block FFQ items, as well as the data obtained 
from the other LIBCSP Case-Control and Follow-Up Study exposure assessment tools.    
 
New Variable Creation in SAS   
    The USDA Flavonoid Database for the Flavonoid Content of Selected Foods and the 
USDA – Iowa State University Database on the Isoflavone Content of Selected Foods report 
flavonoids in mg per 100 g of food or beverage.  Thus, within the Program Editor of SAS, 
the gram per day variables created from the modified Block FFQ data were to be divided by 
100, creating new variables which represent the number of 100 g servings of each item on the 
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FFQ.  Next, these new variables were multiplied by the total flavonoid per day intake 
variable and total flavonoid class intake variables, respectively, to obtain estimates which 
represented the actual intake (in mg per day) of total flavonoids and each flavonoid class per 
day by the women in the LIBCSP. 
    Next, new variables were created which represent the grand total of flavonoid intake and 
flavonoid class intake.  This was accomplished by taking each of the variables created in the 
previous step and summing them together (within their own class: e.g. the anthocyanidins, 
flavones, etc.) to create new variables that represent the grand total (in mg per day) of 
flavonoids (total flavonoids and each flavonoid class) consumed for all the women in the 
LIBCSP.   
 
USDA Database for the Flavonoid Content of Selected Foods Adjustments: Foods and 
Beverages Omitted 
 
    The USDA Database for the Flavonoid Content of Selected Foods contains many foods 
and beverages which are not commonly consumed in the American diet and are small 
contributors to American consumption of flavonoids (377, 392).  These products are not 
inquired about on the modified FFQ used in the LIBCSP and include the following, apple 
cider (European); avocados; bee pollen; bilberries; bilberry soup; black currant juice; blood 
orange juice; bog whortle berries; buckwheat flour, groats; capers; celeriac; celery hearts; 
chicory greens; chicory roots; chokeberries; cloudberries; corn poppy leaves; cowberries; 
cress, garden, raw; crowberries, juice; crown daisy leaves; currants; dock leaves; 
elderberries; endive; gooseberries; gourd; Greek greens pie; Hartwort leaves; Horseradish 
root, whole; kohlrabi; leeks; lemon balm leaves; lemons; licorice root; lingonberries, juice; 
lovage leaves; mangos, raw; marrowfat pea; olives; parsnips; peppermint; perilla leaves; 
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pummelo juice; purslane; Queen Anne’s lace; radishes; raisins; rhubarb; rowanberries; 
rutabagas; saw thistle, leaves; sour orange juice; sweet potato leaves; tangelo juice; tangerine 
juice; tangor juice; vinegar (cider, wine, red, white); water spinach; and water cress.  Because 
these foods are rarely consumed in the American diet (392), it would be difficult for them to 
contribute to the daily intake of flavonoids in the LIBCSP.  Therefore, an assumption was 
made that the effect of misclassification of flavonoid exposure related to intake of these 
foods and beverages was trivial and thus would not have an impact on study results. 
 
Specific Variable Definitions and Confounders 
    Many of the risk factors for breast cancer incidence that were described in the Background 
section may also affect flavonoid intake, thus confounding the association between flavonoid 
intake and breast cancer incidence.  These confounders may act on flavonoid intake directly 
or indirectly through another risk factor, such as SES.  In the literature, these confounders are 
generally described in relation to diet, which typically are fruit and vegetable intake and fat 
intake.  The main studies of flavonoids have been conducted on soy-derived isoflavones (e.g. 
daidzein and genistein) (395, 396) whereas the information about the other classes of 
flavonoids found in the principal aliments of the Western diet is still scarce (397).  Therefore, 
in the following discussion of these confounders, they will often be referred to through their 
effects on diet and these products, which will serve as proxies for flavonoids.  These 
confounders were assessed in the main questionnaire of the LIBCSP and subsequent 
variables have been derived from this information and used in the proposed study of 
flavonoid intake and breast cancer. 
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Socioeconomic Status (SES) 
    As stated previously, many of the potential confounders of the association between 
flavonoid intake and breast cancer incidence may work through a pathway involving SES.  
Surveys describing social differences in dietary habits indicate that subjects of lower SES are 
more likely to eat less healthily (398, 399).  For example, a review of surveys conducted 
between 1985 and 1999 in 15 European countries, higher SES was associated with greater 
consumption of both fruit and vegetables (400, 401).  The pooled estimate of the difference 
in intake of fruit was 33.6 grams/day (95% CI: 22.5-44.8) and vegetables was 13.4 grams/day 
(95% CI: 7.1-19.7) for women (400).  Likewise, other studies have shown that groups with 
high SES adopt healthier dietary behavior than lower SES groups (402-404).   
    Additionally, living in a disadvantaged community may affect BMI and obesity in at least 
two ways (405).  First, poorer communities may lack the resources necessary to support a 
healthy diet and sufficient physical activity (405).  Disadvantaged communities also present 
fewer opportunities and more constraints to eat healthy foods (405).  Wealthy and 
predominantly white neighborhoods have over four times the number of large supermarkets, 
which tend to have low food prices and an abundant selection of healthy foods such as fresh 
fruits and vegetables, compared to poor and predominantly black neighborhoods (406). 
    Assessment of income was derived from the LIBCSP Main Questionnaire, where subjects 
were asked to indicate the range of their total household income before taxes for the last 
calendar year.  This income included that provided by a spouse or partner, as well as any 
other person living in the household.  This variable, like those that will soon be described, 
was used in the assessment of its effects on the association between flavonoid intake and 
breast cancer risk.   
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Hormone Replacement Therapy (HRT) 
    Similar to pregnancy, HRT use may affect flavonoid intake indirectly through SES (407).  
Additionally, HRT use may affect flavonoid intake because of its potential correlation with 
physical activity (408-410).  In a cross-sectional study of women ages 60 to 79 years from 
the British Women’s Heart and Health Study (411), the association between SES and HRT 
use was assessed.  Indicators of a low SES; measured by income, education, and job status; 
were associated with reduced odds of using HRT (411).  All indicators of low childhood SES 
were also associated with reduced odds of ever using HRT (OR = 0.72, 95% CI: 0.58-0.89) 
(411).  Likewise, a cross-sectional survey of women ages 50 to 79 years in Vermont (412) 
indicated that those with a moderate to high income were three times more likely to use HRT 
than those with a low income.  This corroborates with results of another U.S. survey of post-
menopausal women (413) which indicated that both income level and education were 
associated with an increased likelihood of HRT counseling being obtained, comparing 
women earning at least $50,000 per year to women earning less than $30,000 per year (OR = 
2.9, 95% CI: 1.7-4.8) (413). 
    American prospective cohort studies have found that before they started to do so, women 
who used HRT were better educated, had a lower BMI, and were more physically active than 
women never using HRT (408-410).  Other American studies have found that women who 
use HRT are healthier or report better health than non-users, indicating that women with a 
better health prognosis are selected for HRT (414, 415). 
    Subjects were asked to report their hormone medication history in the main questionnaire.  
They were initially asked if they had ever used any of the medications listed on a card 
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provided to them during the interview.  If they responded ‘yes’ to any of the medications, 
they were prompted to provide further information regarding the hormone use such as the 
name of the hormone, when it was first used, how often it was used, and when it was no 
longer used.  This data was converted to a dichotomous variable which indicated if HRT was 
ever or never used. 
 
Family History and Benign Breast Disease (BBD) 
    The literature on family history of breast cancer and diet is scarce.  However, it is 
reasonable to infer that if a first-degree relative of a woman has or had breast cancer, then the 
woman may tailor her lifestyle in a healthful manner.  In fact, general anxiety and depression 
were clear predictors of consuming a low-fat diet in a study of affect and health behaviors in 
1,366 U.S. women ages 18 to 74 years (416).  Negative affect has been shown to be a 
determinant of eating behavior for women (417).  A study of first-degree relatives of breast 
cancer patients with high perceived risk were more likely to engage in leisure physical 
activity (418).  Both a family history (154-157) of breast cancer and having BBD (179-182) 
increase a woman’s risk of developing breast cancer.  Thus, if a woman knows she is at an 
increased risk of developing breast cancer, she may modify her dietary intake and amount of 
physical activity. 
    During administration of the main case-control questionnaire, the subjects completed a 
section devoted to family history.  They were asked about their immediate blood relatives 
(parents, grandparents, siblings, and children) and their respective cancer histories.  This 
information included the type of cancer and when it was diagnosed.  If breast cancer was 
reported, they were asked if one breast or both breasts were involved.  A variable was created 
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from this reported information that indicated whether or not the subject had a mother, sister, 
or daughter with breast cancer.  Information regarding BBD was abstracted from a section of 
the main questionnaire which inquired about the subject’s medical history.  Similar to family 
history, a dichotomous variable was created to indicate whether or not a subject had a history 
of BBD. 
 
Physical Activity 
    Women who exercise may follow different diets than non-exercisers (419).  Furthermore, 
physical activity may be associated with other healthy behaviors besides dietary intake; 
including alcohol intake, weight maintenance, and not smoking (213).  Similarly, low levels 
of physical activity are often associated with other unhealthy lifestyle factors such as 
smoking and alcohol consumption (420, 421).  In a study of the EPIC population in Spain 
(36), vegetable intake increased with education and physical activity.  These findings make 
sense with what most people would assume, that women who are more physically active, on 
average, consume healthier diets which include fruits and vegetables.  As stated by Gerber 
and colleagues (422), the better-informed and increasingly health-conscious population of the 
present day are seeking to identify and eliminate the putative carcinogenic risk factors and to 
exploit the preventive effects attributed to certain dietary components. 
    Subjects were asked to report their physical activity history in a section of the main case-
control questionnaire.  Information on the type of activity, when the activity began and 
ceased, as well as the frequency of activity were collected.  Additionally, the date of the 
subject’s first menstrual period and the reference date were abstracted from the questionnaire 
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to create a variable which provided the average hours per week of physical activity from 
menarche to the reference date. 
 
BMI, Obesity, Weight, and Weight Gain 
    These body size risk factors are affected by dietary intake and visa versa.  In a study 
documenting BMI and knowledge regarding obesity as a risk factor for breast cancer (423), 
the authors noted of the African, Caribbean, and European-American women that their 
dietary habits and those of the population at large put them at risk of becoming overweight.  
Excess body weight is one of the most readily preventable risk factors (424, 425) for breast 
cancer and estimates suggest it can directly explain at least 10% of female cancers (194).  In 
characterizing obesity as a risk factor for breast cancer, other contributory effects should be 
considered (422).  Some women not only consume poor diets, but are also less physically 
active, from a lower SES class, and have other detrimental habits such as smoking (426-430).  
Thus, for obese people, diet and lifestyle modification is widely considered the primary 
means to control weight (431). 
    In the section of the questionnaire which inquired about body size and physical activity, 
subjects were asked how tall they were (in feet and inches) and how much they weighed (in 
pounds) at age 20 and at their reference date.  These data were converted to meters squared 
(m2) and kilograms (kg) so BMI could be calculated in kg/m2. 
 
Alcohol Consumption 
    Alcohol consumption is an important constituent of the American diet (432).  In addition, 
dietary and lifestyle characteristics may differ for consumers of specific alcoholic beverages 
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and non-consumers which may have important implications for studies of alcohol and disease 
(433).  For example, a cross-sectional study of data from the Malmo Diet and Cancer Study 
(434) indicated that intakes of alcoholic beverages were positively associated with fat intake 
in women.  This held true for beer, wine, and spirits but the majority of the alcohol came 
from beer (434).  Fruit and vegetable intake was also lower among the high-fat consumers 
(434).  Thus, high fat intake and low fruit and vegetable intake were markedly pronounced in 
the high alcohol consumers (434).   
    Similarly, a series of case-control studies (433) of alcohol use and different types of 
cancer, including breast, in western New York indicated that wine drinkers had higher 
education and household incomes, lower prevalence of current smoking, lower total fat 
intakes, and higher intakes of fruits and vegetables than consumers of other beverages.  
Conversely, beer and liquor drinkers tended to have lower education and household incomes, 
higher rates of current smoking, higher fat intakes, and lower intakes of fruits and vegetables 
(433).  Thus, alcoholic beverage preference may encompass other health-related behaviors 
such as diet and SES (433). 
    Information on subjects’ alcohol intake was collected from a section in the main case-
control questionnaire.  Subjects were asked to report the frequency of consumption (e.g. 
times per day) and amount consumed (such as 12 ounces (oz.) of beer) of beer, wine, and 
liquor.  To facilitate subject recall, these questions were divided into six age groups ranging 
from ‘Under 20 years old’ to ‘Age 60 or older’.  The frequencies and amounts of each 
alcoholic beverage consumed (12 oz. beer, 4 oz. wine, and 1.5 oz. shots of liquor) were 
averaged over the decades to obtain the grams of intake per day.       
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Specific Variable Definitions of Other Risk Factors 
    These well-known or potential risk factors of breast cancer incidence were assessed in the 
LIBCSP.  This section describes how these risk factors were assessed and how variables 
were created from the information provided to allow for subsequent data analysis.  
 
Menopausal Status 
    According to Gammon and colleagues (371), menopausal status was defined using 
information provided by the subject during the case-control interview on her date of last 
menstrual period, prior surgical information on hysterectomy or oophorectomies, her 
smoking status, and use of hormone replacement.  A subject was defined as post-menopausal 
if her last menstrual period was more than 6 months before the reference date or if she had 
both ovaries removed prior to reference date (371).  If a subject was taking hormone 
replacement therapy or had a hysterectomy without removal of both ovaries, her menopausal 
status was initially classified as unknown (11.81% of subjects).  To reduce the number of 
subjects with unknown menopausal status, information was utilized about the subject’s 
reference age (371).  That is, any smoker with unknown menopausal status was categorized 
as post-menopausal if her age at reference was ≥ 54.8 years (90% percentile for natural 
menopause among smoking controls), and any non-smoker with unknown menopausal status 
was categorized as post-menopausal if her age at reference was ≥ 55.4 years (90% percentile 
for natural menopause among non-smoking controls) (371).  Subjects whose final 
classification of menopausal status was missing was 3.04% (371). 
 
Age at Menarche 
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    In the main case-control questionnaire, subjects were asked about their menstruation and 
menopause history.  The first question of this section asked for the month and year (or age) 
of their first menstrual period.  Because of the proposed link of hormones to breast cancer, 
this variable was useful in determining lifetime exposure to reproductive hormones. 
 
Age at First Birth and Parity 
    Subjects completed a section in the main case-control questionnaire which inquired about 
their pregnancy history.  Information was collected by questions regarding the type of 
pregnancy (live birth, stillbirth, miscarriage, abortion, or ectopic pregnancy), gender of the 
newborn, length of the pregnancy, and what date the pregnancy ended upon.  Any pregnancy 
which lasted at least 6 months was considered to be a full-term pregnancy.  From this 
information, age at first birth and parity (number of full-term live births) could be 
determined.   
    Age at first birth was derived from the date of the first full-term pregnancy’s endpoint and 
the date of birth of the mother.  This was initially a continuous variable in the dataset but was 
then centered for ease of use in data analysis.  The youngest age of a subject at first birth was 
the amount of years subtracted from all ages at first birth, thus making the youngest age at 
first birth equal to zero.  Parity was derived by adding the number of full-term live births 
together.   
 
Oral Contraceptive Use 
    In the main case-control questionnaire, subjects were asked about their contraceptive 
history.  The first question in this section asked if they had ever used pills, shots, or implants 
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as methods of birth control.  The remainder of the section inquired about the type of birth 
control method used and the start and stop dates of use for each.  The variable that was 
created to assess oral contraceptive use came from the first question, a dichotomized 
assessment of ever or never use of oral contraceptives. 
 
Race 
    The main case-control questionnaire contained a Background section which asked subjects 
the category that best described them; White, Black/African American, Asian/Pacific 
Islander, American Indian/Aleut/Eskimo, or Other (Specify).  The majority of the LIBCSP 
population reported themselves as White (94%).   
 
Passive/Active Cigarette Smoking 
    Subjects were inquired about their cigarette smoking behavior in a section of the main 
case-control questionnaire.  Subjects were first asked to indicate if they had ever smoked 
cigarettes, age when they started to smoke, age they stopped smoking (if ever), as well as 
amount and frequency of cigarettes smoked.  A current active smoker was defined as 
smoking within the 12 months prior to the reference date (date of diagnosis for the invasive 
cases) (233).  A former active smoker was defined as a smoker who reported quitting more 
than 12 months prior to the reference date (233).  Passive smoking data was defined as 
exposure to cigarette smoke in the household (which included caregivers).  A passive smoker 
was defined as either a current or former smoker or non-smoker who reported ever living 
with an active smoker; and a never smoker was defined as a non-smoker who also did not 
report living with an active smoker (233).  The relationship to the subject of the cigarette 
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smoker was inquired, in addition to the subject’s first age of exposure to this household 
member’s smoke, the age of last exposure to this smoke (if ever), and how many years the 
subject was exposed to the smoke.  From this data, two variables was created; one to assess 
their current active smoking status and one to assess their current passive smoking status as, 
both as current, past/former, or never.      
 
Fruit and Vegetable Consumption 
    As described by Gaudet and colleagues (48), individual fruits and vegetables were 
categorized into nine food groups: any fruits, fruit juices, and vegetables; any fruits; fruit 
juices; citrus fruits; any vegetables; leafy vegetables; yellow vegetables; and cruciferous 
vegetables.  The food groups were based on published literature from Potischman (435) and 
Frudenheim (44).   
 
Statistical Methods and Data Analysis 
 
    Preliminary descriptive statistics of the study population were generated, including means, 
medians, standard errors and t-tests (comparing cases and controls) for continuous variables 
such as flavonoid intake, fat intake, alcohol intake, age, BMI, age at menarche and age at 
menopause; and frequencies and Chi-square tests (comparing cases and controls) for 
categorical variables such as stage at diagnosis, race, socioeconomic status (SES), education, 
parity, hormone replacement therapy use, and family history of breast cancer.  The average 
intakes of dietary variables included total energy, fat, fruits, vegetables, and fiber for cases 
and controls.  This is common in breast cancer nutrition papers and allows for facilitated 
comparison of each group’s dietary practices.   
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Aim 1: To estimate intake of seven classes of flavonoids and total flavonoid intake among 
breast cancer cases and controls using the USDA Flavonoid Database for the Flavonoid 
Content of Selected Foods and LIBCSP dietary data. 
    To address this aim, univariate and frequency procedures were conducted to calculate the 
mean, median, minimum, maximum, and standard deviation of each of the classes of 
flavonoid intake, as well as total flavonoid intake, among cases and controls.  Flavonoid 
intake was quintiled to better assess the actual distribution of intake in the cases and controls.  
The individual flavonoids which make up each class were summed together to total class 
values.  Additionally, total flavonoid intake was estimated through summation of all the 
individual flavonoids for cases and controls, respectively.  The final database was designed 
to estimate all of these measures, making Aim 1 fairly easy to achieve. 
 
Aim 1 Analysis and Results 
Flavonoid Intake 
    The distribution of flavonoid intake among the breast cancer cases and controls is 
presented in Tables 3.1 and A.2.  Overall, cases consumed a lower amount of total flavonoids 
per day than controls among both post-menopausal (mean = 220.74 mg/d and 242.66 mg/d, 
respectively) and pre-menopausal women (mean = 211.12 mg/d and 212.19 mg/d, 
respectively), though the differences were more pronounced among post-menopausal 
women.  Flavan-3-ols were the largest contributor to total intake and were most disparate 
between post-menopausal cases (mean = 163.29 mg/d) and post-menopausal controls (mean 
= 182.68 mg/d).  Geometric means of flavonoid intake for pre- and post-menopausal cases 
and controls are presented in Table A.3.   
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    A list of the foods and beverages containing each class of flavonoids is presented in Table 
A.4.  Flavonols and lignans are the most prevalent classes of flavonoids in the items.  Tables 
A.5 and A.6 present the intakes of each class of flavonoids for cases and controls by ER/PR 
status.  Women who were ER-PR+ consumed the greatest daily intake of flavonoids per day, 
though this was the smallest hormone receptor group (n = 48).  The distribution summary of 
cases and controls within each quintile of flavonoid intake, stratified by menopausal status, is 
presented in Table A.7.   
       
Aim 2: To examine the association between each class of flavonoid intake and total dietary 
intake of flavonoids and risk of breast cancer.  This tested the hypothesis that there is an 
inverse association between flavonoid intake and risk of breast cancer. 
    To address this aim, data from the case-control study was used and unconditional logistic 
regression was used to calculate ORs and 95% confidence intervals (CI) of breast cancer in 
relation to quintiles of flavonoid intake.  All ORs and CIs assessed the association between 
flavonoids and risk of breast cancer.  Each class of flavonoid intake and total flavonoid 
intake was also assessed.  Age-adjusted ORs and corresponding 95% CIs were calculated, as 
well as ORs adjusting for potential confounders to examine the main effects of flavonoid 
intake on breast cancer risk (436).  In building regression models, backward elimination 
processes was used to determine effect measure modifiers and confounders to be included in 
the models.  Effect measure modification, for example, by BMI, which is a risk factor for 
post-menopausal breast cancer and may be related to flavonoid intake, was assessed with 
interaction terms and the Likelihood Ratio Test (LRT) comparing a full model which 
included the interaction term and a reduced model which excluded the interaction term.   
 93
    Other potential effect measure modifiers included physical activity, family history of 
breast cancer in a mother or sister, and menopausal status.  Potential confounders (age, 
family history of breast cancer in a mother or sister, BBD, physical activity, BMI, SES, HRT, 
and alcohol consumption, fruits, vegetables, and micronutrients) were evaluated by crude 
ORs and adjusted ORs which are adjusted by the potential confounder.  A 10% change or 
greater between these two effect measures resulted in retaining the potential confounder in 
the model (436).   
 
Aim 2 Analysis and Results 
Description of Exposures 
    This study found a decreased risk of breast cancer for post-menopausal women and 
women with high parity (≥ 3 births).  An increased risk was observed for those with a family 
history of breast cancer and those with a history of BBD.  No association was observed for 
BMI, education, alcohol, cigarette smoking, oral contraceptive use, income, physical activity, 
age at menarche, race, religion, marital status, and HRT use.  As demonstrated in the 
summary of this preliminary analysis, detailed in Table A.8, only age and menopausal status 
showed evidence of effect modification between flavonoid intake and breast cancer 
incidence.  None of the evaluated factors showed evidence of confounding the flavonoid-
breast cancer association (Table A.8).   
Crude Results 
    Among post-menopausal women, breast cancer risk was decreased in relation to intake of 
all flavonoids except for flavanones and isoflavones (Tables 3.2 and A.9).  ORs (95% CIs) 
were reduced by 25% among post-menopausal women in the highest fifth of intake of total 
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flavonoids (OR = 0.75, 95% CI = 0.56-1.01), by nearly 40% for flavones (OR = 0.61, 95% 
CI = 0.45-0.83), by nearly 50% for flavonols (OR = 0.54, 95% CI = 0.40-0.73), and by 30% 
for lignans (OR = 0.69, 95% CI 0.51-0.94).  In contrast, among pre-menopausal women, 
there was no evidence for a decreased risk of breast cancer for any class of flavonoids. 
    When stratified by ER/PR status, there was little or no heterogeneity in breast cancer risk 
in relation to flavonoid intake for post-menopausal women (Tables 3.3 and A.10).  A 
consistent trend towards a reduced risk was found for all hormonal receptor types in relation 
to flavonols, flavones, and total flavonoids. 
Fruit and Vegetable-adjusted Results    
    Table A.11 presents the associations between each class of flavonoid intake and breast 
cancer risk, adjusted by age, energy, fruits, vegetables, and micronutrients.  The results are 
similar to the age and energy-adjusted results in Tables 3.2 and A.10. 
ER/PR Stratified Results 
    Table A.12 presents the odds ratios and 95% confidence intervals for post-menopausal 
women by each of the four hormone receptor types.  Table A.13 presents these results among 
post-menopausal women in a slightly different form, by comparing those who are ER+PR+, 
ER-PR-, or ER-PR+, to those who are ER-PR-.  Neither table provided useful information for 
the formal analysis.  Stratification by each hormone receptor type caused small numbers in 
the ER+PR- and ER-PR+ groups and therefore results were imprecise.   
 
Aim 3: To examine the association between each class of flavonoid intake and total dietary 
intake of flavonoids and survival with breast cancer.  This tested the hypothesis of an inverse 
association between flavonoid intake and mortality following diagnosis with breast cancer. 
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    To address this aim, dietary intake assessed at the time of the original case-control study 
interview, which reflectd intake in the year prior to the reference date, was examined as the 
primary exposure.   
    The endpoint was time to death, which was considered to be all-cause mortality or breast 
cancer mortality.  Kaplan-Meier survival curves were constructed to give actuarial estimates 
of the 5-year cumulative incidences for the endpoint of interest (437).  Cox regression 
models were used with exact handling of ties to assess the associations of each death with the 
covariates under study (437).  Differences between the cumulative incidence curves for the 
different exposure categories were assessed with a log-rank test.  If there was a greater than 
10% difference, subsequent analyses were performed using stratified Cox models.  To assess 
the proportional hazards assumption of the Cox model, graphical and formal tests were 
performed.   
    Log-minus-log survival curves were examined for different stratifying variables created 
from the covariates of interest.  If the resulting curves showed substantial non-parallelism, 
then the assumption of proportional hazards was assumed to be violated.  All models were 
specified with a time-varying “proportional” hazards constant to reflect the change in 
magnitude of relative risks in the two strata with follow-up time.  Further tests of the 
proportional hazards assumption could also have been conducted by adding a time-dependent 
covariate representing the interaction of an original covariate and time. 
    The covariates of interest were determined by evaluation of potential confounders and 
effect measure modifiers.  Data for these covariates were generated from the main case-
control questionnaire but the data regarding treatment history was also generated from the 
follow-up interview and medical record abstraction.  Effect measure modification, for 
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example, by obesity, a poor prognostic factor for post-menopausal breast cancer survival 
which may be related to flavonoid intake, was assessed with interaction terms and the 
Likelihood Ratio Test (LRT) comparing a full model which included the interaction term and 
a reduced model which excluded the interaction term.  Other potential effect measure 
modifiers included age, radiation therapy, chemotherapy, family history of breast cancer in a 
mother or sister, tumor ER/PR status, cigarette smoking, SES, and physical activity.  
Potential confounders (age, family history of breast cancer in a mother or sister, menopausal 
status, physical activity, BMI, SES, parity, alcohol consumption, radiation therapy, 
chemotherapy, and fruits, vegetables, and micronutrients) were evaluated by crude HRs and 
HRs adjusted by the potential confounder.  A 10% change or greater between these two 
effect measures resulted in retaining the potential confounder in the model (436).   
 
Aim 3 Analysis and Results 
Description of Exposures 
    Tables A.14 and A.15 display a comparison of characteristics for all invasive cases (n = 
1,273) and the sub-sample of case women with dietary data available for the survival analysis 
reporte here (n = 1,210).  Based on crude, unadjusted analyses, post-college education, HRT 
use, and income ≥ $70,000 was associated with a decreased risk of mortality, and black race 
was associated with an increased risk of mortality.  The distribution of these 1,210 invasive 
cases by quintile of flavonoid intake is presented in Table A.16.  The majority of invasive 
cases were white, post-menopausal, married, and non-smokers.  Approximately 20% had a 
family history of breast cancer in a first degree relative.   
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Crude Results 
    Among post-menopausal women, risk of all-cause mortality was decreased in relation to 
flavones (HR = 0.59, 95% CI: 0.35-0.99) and isoflavones (HR = 0.44, 95% CI = 0.24-0.81), 
comparing the highest quintile of intake to the lowest quintile (Tables 4.2 and A.17).  Total 
flavonoids (HR = 0.78, 95% CI = 0.49-1.25) and anthocyanidins (HR = 0.66, 95% CI = 0.40-
1.08) were also associated with a modest reduction in mortality.  Flavones (HR = 0.64, 95% 
CI = 0.42-0.98) and anthocyanidins (HR = 0.62, 95% CI = 0.40-0.94) also reduced the risk of 
mortality when both pre- and post-menopausal women were analyzed together.  
    Among pre-menopausal women, similar reductions in all-cause mortality were observed 
for flavones (HR = 0.69, 95% CI = 0.32-1.47), isoflavones (HR = 0.71, 95% CI = 0.34-1.48), 
and anthocyanidins (HR = 0.62, 95% CI = 0.27-1.40).  Total flavonoids (HR = 1.77, 95% CI 
= 0.91-3.46), flavonols, flavan-3-ols, and lignans were positively associated with mortality; 
however, estimates were imprecise and no clear dose-response trends were evident.  
    As shown in Tables 4.3 and A.18, results for breast cancer-specific mortality were similar 
to those for all-cause mortality, including an inverse association with mortality for flavones 
among post-menopausal women (HR = 0.49, 95% CI: 0.24-0.99) and all women (HR = 0.50, 
95% CI = 0.29-0.87), comparing the highest quintile of intake to the lowest quintile.  Total 
flavonoids (HR = 0.62, 95% CI = 0.33-1.16), anthocyanidins (HR = 0.62, 95% CI = 0.33-
1.18), and isoflavones (HR = 0.79, 95% CI = 0.43-1.44) were also associated with a modest 
reduction in breast cancer mortality.   
Similar reductions in breast cancer mortality were observed among pre-menopausal 
women for flavones (HR = 0.45, 95% CI = 0.17-1.19) and anthocyanidins (HR = 0.81, 95% 
CI = 0.35-1.89).  Total flavonoids (HR = 1.75, 95% CI = 0.82-3.72), flavanols, flavan-3-ols, 
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and lignans were positively associated with mortality, though no dose-response relationship 
existed. 
    Table A.19 lists the preliminary analysis of confounding and effect measure modification 
for the survival study.  Again, only age and menopausal status showed evidence of effect 
measure modification.  No factors confounded the association between flavonoids and 
survival.     
Fruit and Vegetable-adjusted Results          
    Table A.20 presents the associations between each class of flavonoid intake and breast 
cancer survival, adjusted by age, energy, fruits, vegetables, and micronutrients.  The results 
are similar, yet more modest compared to those in Table 4.1.      
ER/PR Stratified Results 
    Table A.21 presents the hazard ratios and 95% confidence intervals for invasive cases by 
each of the four hormone receptor types.  Table A.22 provides the same measures for breast 
cancer-specific mortality.  Stratification by each hormone receptor type caused small 
numbers in the ER+PR- and ER-PR+ groups and therefore results were imprecise. 
 
Study Size and Power  
    Since flavonoid intake was categorized, power calculations for the second specific aim 
were based on the assumption of quintile distribution.  For the second specific aim, power 
was calculated with NQuery software.  For the third specific aim, a web-based program from 
Johns Hopkins University (438) was used.  For this study, each quintile was assumed to have 
approximately 300 women for cases and controls, respectively.  Hypothesized odds ratios 
and proportions of cases and controls comparing the lowest quintile of intake to the highest 
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quintile of intake were explored for the study’s 1,481 cases and 1,508 controls, using an 
estimate of 600 total subjects per quintile.  A two-sided alpha value of 0.05 was presumed for 
these estimates.  The sample size of our study had adequate power (> 80%) to detect an odds 
ratio of 0.70 (Table 2.4). 
 
    For the survival analysis, the sample size of the study had relatively adequate power (75%) 
(Table 2.5) to detect a hazard ratio of 0.50 (439, 440).  Of the 1,273 invasive cases, 186 
(14.6%) died during the follow-up period.  The primary aim of the survival analysis was to 
examine the association between each class of flavonoid intake and total dietary intake of 
flavonoids and survival with breast cancer. 
 
Study Strengths  
    At the time the women were diagnosed, between August 1, 1996 and July 30, 1997, the 
U.S. retail of soy-based foods was approximately $1.4 billion (441).  As of 2002, the U.S. 
retail had nearly tripled at $3.7 billion (441).  Soy isoflavone consumption has been 
estimated to range from 25-45 mg/day in Asian populations compared to < 5 mg/day in 
Western populations (442).  Fruit and vegetable intake has remained significantly higher as 
the mean frequency of daily consumption was 3.66 servings per day of fruits and vegetables 
in women in 1996 (443).  This number has stayed relatively constant over the years at 
approximately 3.6 (443).  The LIBCSP population consumed a diverse amount of fruits and 
vegetables (48), 3.94 ½ cup servings per day, which made it possible to determine if 
flavonoids may reduce breast cancer risk and enhance survival after diagnosis.  Thus, while 
the FFQ is not perfect, the major sources of flavonoids in the LIBCSP population diet were 
able to be measured.     
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    The study design, sample size, and comprehensive interview data for the LIBCSP Case-
Control Study and Follow-Up Study provided us with an efficient opportunity to examine 
important yet unresolved questions in breast cancer research.  In addition, the flavonoid 
intake and survival question had yet to be addressed in published research.  Thus, a new area 
of breast cancer survival research was studied.   
    The Block FFQ is a validated and reliable dietary assessment tool for estimating usual 
food group intake and ranking individuals into categories of intake (374, 375, 383).  While it 
was not originally designed to measure flavonoid intake, the impact of missing foods was 
assessed by comparing those listed on the FFQ to those in the USDA database, as well as the 
addition of genistein and daidzein composition of tofu, fruits, vegetables, and grain products 
from this database and other sources from the literature.  Widely available fruits and 
vegetables, chocolates, and tea were included on the instruments; thus providing some 
assurance that commonly-consumed flavonoid-rich products were assessed in this 
population.  Additionally, while several studies have examined the association between 
flavonoids in relation to breast cancer risk, only two studies to date had examined flavonoids 
with the USDA Database, and those were in a Greek population (59) and Italian population 
(60), respectively.  By examining the effect of flavonoids with this database on a U.S. 
population, it was possible to observe a stronger association.    
 
Study Limitations 
    While the FFQ has recognized limitations in assessing diet, it was the best method 
available for conducting large epidemiologic studies such as the LIBCSP.  The Block FFQ 
was originally designed to estimate fat intake and while there have been modifications made 
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to incorporate additional nutrients and foods, it does not assess all sources of flavonoids 
listed in the USDA Database for the Flavonoid Content of Selected Foods.  Also, tofu is the 
only soy-based product on the LIBCSP Block FFQ and soybean products are the primary 
food source listed on the USDA – Iowa State University Database on the Isoflavone Content 
of Selected Foods.  However, with the use of additional databases (from Dr. Mary Wolff and 
those found in the literature from other experts in the field), the inclusion of isoflavone-
containing fruits, vegetables, nuts, beverages, and grain products were performed to ensure 
the most accurate estimates of flavonoid intake possible.  Additionally, the FFQ did inquire 
about numerous flavonoid-rich fruits and vegetables, as well as tea, wine, and chocolate, all 
of which are commonly consumed products in the United States (392), so the amount of 
underestimation was minimal. 
    Other limitations include recall of past diet.  There are many forms in which recall can be a 
problem with the use of FFQs.  First, responses are dependent upon subjects’ ability to 
remember food consumption over the past accurately, which varies in an unsystematic way 
from person to person (444).  In addition, the diagnosis of breast cancer may have influenced 
how cases responded to the FFQ, possibly attributing their diagnosis to certain components 
of their diet, which could lead to a vast difference in diet between cases and controls and, 
perhaps, portray flavonoids as more protective than they really may be.  The third issue 
related to recall is the desire of some to report a healthier diet.  This could have lead to an 
underreporting of fat and sweets intake and over-reporting of fruit and vegetable intake 
because they believed this would be acceptable in the eyes of the interviewer; it was possible 
that this type of recall problem would make the cases and controls appear more homogeneous 
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with respect to dietary intake and make it difficult to detect an effect of flavonoids on breast 
cancer incidence and survival. 
    Additionally, the LIBCSP Block FFQ measured dietary intake in the year prior to the 
interview.  Like many chronic diseases, it is hypothesized that breast cancer is a result of an 
accumulation of exposures and changes within the body, which can take many years to 
develop before a diagnosis is made.  Thus, the FFQ may not have assessed the period of time 
most relevant to the development of breast cancer.  This means the diet reported in the FFQ 
was assumed to be similar to not only the diet in the year proceeding diagnosis for cases, but 
also the years following diagnosis.  However, diet does change over time, especially more 
likely after a diagnosis of breast cancer when lifestyle changes are often made in an attempt 
to prevent recurrence (445-447).  This problem may have been more pronounced with the 
flavonoid intake and survival analysis because it could be inferred that women consumed 
more fruits and vegetables following diagnosis (445-447).  This would have resulted in the 
FFQ underestimating their post-diagnosis flavonoid intake and perhaps make it easier to find 
a beneficial effect of flavonoids when consumed at very low levels. 
    Finally, with regard to survival, the advent of surgical and drug treatment has made 
immense improvements in the prognosis of breast cancer cases.  Thus, these improvements 
alone, rather than flavonoids, may have been important for improving breast cancer survival.  
The best way to address this problem was to adjust for chemotherapy and radiation treatment 
so that the effect of flavonoids could be better observed.    
 
Summary 
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    Although several studies have examined flavonoids in relation to breast cancer risk, most 
have involved isoflavones in soy, and none have been published thus far with regard to breast 
cancer survival.  Various classes of flavonoids have been reported to inhibit breast cancer 
cell replication, estradiol activity, and mammary tumorigenesis.  However, except with 
respect to isoflavones, there is no sufficient evidence, experimental or otherwise, linking 
particular flavonoids or classes of flavonoids to specific actions in the process of mammary 
carcinogenesis (59).  Consequently, the biologic plausibility of any inverse, protective 
associations found in the other classes of flavonoids and breast cancer risk and survival, were 
considered no more than suggestive (59).   
    The fundamental reason for conducting this analysis was to examine what components in 
particular foods and beverages, primarily fruits, vegetables, and tea; have biological 
mechanisms that impact the development of breast cancer.  The hypotheses included the 
following, that the controls consume more flavonoids than the breast cancer cases, that 
increased flavonoid intake reduces the risk of breast cancer incidence, and that increased 
flavonoid intake improves the prognosis for breast cancer cases following diagnosis.  While 
there are limitations to the FFQ, the amount of underestimation was likely to be minimal.  
The study population was sufficiently large to detect differences between cases and controls 
and it may be the first study published using an American population with the USDA 
Database for the Flavonoid Content of Selected Foods. 
    Because this area of research is vastly unexplored, results will hopefully provide reasoning 
for additional research that continues to focus upon what in the diet truly influences the 
progression, and perhaps suppression, of breast cancer.  Flavonoids may play a pivotal role in 
this process.  Eventually, in addition to simply adding to the literature regarding diet and 
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breast cancer, the possibility of discovering these dietary components could have a large 
public health impact in terms of prevention and survival.     
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Tables 
 
Table 2.1.  Classes and Dietary Sources of Flavonoids. 
Flavonoid Class Representative Flavonoids Main Sources 
Flavonols Quercetin, Kaempherol, 
Myricetin, Isorhamnetin 
Onions, Cherries, Apples, 
Broccoli, Tomato, Tea, 
Red Wine, Berries 
Flavones Luteolin, Apigenin Parsley, Thyme, Cereal 
Flavanones Hesperetin, Naringenin, 
Eriodicyol 
Citrus Fruits, (e.g., Oranges,
Grapefruit, Tangerines),  
Cumin, Peppermint 
Flavan-3-ols (Catechins) (+)-Catechin, (+)-
Gallocatechin,  
(-)-Epicatechin,  
(-)- Epigallocatechin,  
(-)-Epicatechin 3-gallate, 
(-)-Epigallocatehin 3-
gallate, Theaflavin, 
Theaflavin 3-gallate, 
Theaflvain 3’-gallate, 
Theaflavin 3,3’ gallate, 
Thearubigins 
Apples, Tea, Chocolate, 
Red Wine, Hops, Nuts 
 
Anthocyanidins Cyanidin, Delphinidin, 
Malvidin, Pelargonidin, 
Peonidin, Petunidin      
Blueberries, Cherries, 
Elderberries, Raspberries 
Isoflavones Genistein, Daidzein Tofu 
Lignans Matairesinol, 
Secoisolariciresinol 
Flaxseeds, Legumes, Whole 
Grains, Fruits, Vegetables 
 Adapted from Ren (49), Dwyer (448), and Ososki (449).  
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Table 2.2.  Classification of FFQ Food and Beverage Contribution of Flavonoid Intake. 
Category 1.  Foods and beverages consumed in high quantities which are large                  
                      contributors of flavonoids 
Apples, Applesauce, and Pears                                         Tea 
Grapefruit                                                                          Wine 
Oranges 
Broccoli 
Orange Juice and Grapefruit Juice 
Category 2.  Foods and beverages consumed in high quantities which are small  
                      contributors of flavonoids 
Tomatoes and Tomato Juice                                              Spaghetti 
Green Salad                                                                       Vegetable Soup 
Category 3.  Foods and beverages consumed in small quantities which are large                 
                      contributors of flavonoids 
Cherries                                                                              Tofu, Frozen Tofu 
Fresh Peaches, Apricots, and Nectarines                           Chocolate Cake, Brownies, Cookies 
Kale, Collards, and Turnip Greens                                    Chocolate Candy 
Category 4.  Foods and beverages consumed in small quantities which are small                 
                      contributors of flavonoids 
Strawberries                                                                       Beans 
Canned Peaches and Apricots                                           Cauliflower and Brussel Sprouts 
Green Beans                                                                      Spinach (raw and cooked) 
Peas                                                                                   Coleslaw and Cabbage 
Carrots                                                                               Red and Green Peppers 
Hamburgers, Beef Burritos, and Meatloaf                        Pizza 
Beer                                                                                 
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Table 2.3.  Example of Flavonoid Data in Excel Spreadsheet. 
ID strawberrytotalday strawberryflavonol 
 
strawberryflavone 
 
Strawberryflavan-
one 
 
 
10027 7.538300 1.440000 0.000000 0.000000 
10043 7.538300 1.440000 0.000000 0.000000 
10056 7.538300 1.440000 0.000000 0.000000 
10072 7.538300 1.440000 0.000000 0.000000 
ID strawberryflavan3ol 
 
Strawberryantho- 
cyanidin 
 
 
strawberryisoflavone 
 
strawberrylignan 
 
 
10027 4.470000 0.000000 0.050200 1.578100 
10043 4.470000 0.000000 0.050200 1.578100 
10056 4.470000 0.000000 0.050200 1.578100 
10072 4.470000 0.000000 0.050200 1.578100 
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Table 2.4.  Minimum Detectable Odds Ratios in the Proposed Case-Control Study of 
the LIBCSP Population,  Alpha = 0.05. 
Specific Aim Estimated Prevalence 
of Exposure Among 
Controls (Percent) 
Power Minimum Detectable 
Odds Ratio 
Aim #2. Based on Modified Block FFQ and Case-Control Data: To examine the association 
between each class of flavonoid intake and total dietary intake of flavonoids and risk of 
breast cancer.   
Quintile 5 vs. 
Quintile 1 (highest 
vs. lowest intake) 
 
 
20% 
 
 
0.49 
 
 
0.80 
 20% 0.70 0.75 
 20% 0.87 0.70 
 20% 0.96 0.65 
 20% 0.99 0.60 
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Table 2.5.  Power calculations (expressed as %) assuming different true hazard ratios of 
breast cancer mortality for certain variables of interest.* 
 
 
 
 
 
 
 
 
*All calculations assume the survival rate in the unexposed group (lowest quintile of intake) 
is 0.85, based on the 186 deaths (14.6%) amongst the 1,273 invasive cases. Type 1 Error rate 
was assumed to be 5%.  The accrual period was one year and the minimum follow-up time 
was five years.  The percentage lost-to-follow-up was assumed to be 4%, based on the 55 
cases (3.9%) of the 1,414 cases who gave permission to be re-contacted.  The comparison for 
the hazard ratio is the lowest quintile of flavonoid intake to the highest quintile of flavonoid 
intake, amongst the invasive cases only. 
 
 
 
 
 
 
Variable Hazard Ratios 
(n = 186 deaths among  
1,273 invasive cases) 
 0.9 0.8 0.7 0.6 0.5 0.4 
Flavonoid Intake 7 16 31 53 75 90 
 
 
 
 
 
Chapter III: DIETARY FLAVONOID INTAKE AND BREAST CANCER RISK 
AMONG WOMEN IN THE LONG ISLAND BREAST CANCER STUDY PROJECT 
 
 
Abstract 
Background: Flavonoids are phytochemicals found in a variety of foods that have 
demonstrated anti-carcinogenic properties in experimental studies.  Few epidemiologic 
studies have examined whether flavonoid intake is associated with breast cancer in humans.  
This study investigated whether dietary flavonoid intake is associated with a reduced risk of 
breast cancer among a population-based sample of American women.  Methods: A case-
control study was conducted among women ages 20-98 years who resided in Nassau and 
Suffolk counties in Long Island, New York.  Cases and controls were interviewed in-person 
about known and suspected breast cancer risk factors, and were asked to complete a self-
administered food frequency questionnaire (FFQ) regarding their average frequency of food 
and beverage consumption in the prior 12 months.  For those with known menopausal status, 
1,434 breast cancer cases and 1,440 controls provided adequate dietary responses.  Results: 
Breast cancer risk was decreased for the highest quintile of flavonol intake in post-
menopausal women (odds ratio = 0.54, 95% confidence interval = 0.40, 0.73), but not pre-
menopausal women (OR = 1.38, 95% CI = 0.88-2.15).  Among post-menopausal women, 
risk was also decreased for flavones (OR = 0.61, 95% CI = 0.45-0.83), flavan-3-ols (OR = 
0.74, 95% CI = 0.55-0.99), and lignans (OR = 0.69, 95% CI = 0.51-0.94).  Conclusion: 
Intake of flavonols, flavones, flavan-3-ols, and lignans is associated with a reduced risk of 
incident post-menopausal breast cancer among Long Island women.  These results coincide 
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with previous studies conducted among Mediterranean women.  Our results suggest 
American women can consume sufficient levels of flavonoids to benefit from their potential 
chemopreventive effects.  
Introduction 
    Flavonoids are a group of more than 4,000 polyphenolic compounds that occur naturally in 
fruits, vegetables, and beverages of plant origin (49, 72)  In numerous laboratory studies, 
flavonoids have demonstrated the ability to decrease lifetime estrogen exposure (50-53), 
inhibit tumor cell proliferation (54, 55), and inhibit reactive oxygen species (ROS) (56-58), 
all of which are mechanisms thought to influence breast cancer development (46, 47, 51-55, 
72, 268).  Further, dietary intake of certain flavonoids has been reported to potentially protect 
humans from developing certain types of cancer (450-453), including breast cancer (59, 60).   
    Until very recently, epidemiologic research regarding flavonoids and breast cancer 
development in women was limited, primarily due to the difficulty in estimating flavonoid 
intake.  Previous hospital-based, case-control studies in Greece (59) and Italy (60) have had 
their respective dietary data linked with two flavonoid databases from the United States 
Department of Agriculture (USDA) (377, 378).  Reduced risks of breast cancer were 
observed for intake of two flavonoid classes, flavones (59, 60) and flavonols (60).  Whether 
similar risk reductions are detectable among American women, for whom intake of 
flavonoid-rich foods is traditionally lower than in Mediterranean women, is unknown (454-
456).     
    This analysis investigated whether breast cancer risk in a population-based case-control 
study of women in the Long Island Breast Cancer Study Project (LIBCSP) was reduced in 
relation to flavonoid intake.   
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Materials and Methods 
Participants 
    The Long Island Breast Cancer Study Project was conducted on Long Island, New York, 
in Nassau and Suffolk counties (26). Cases were English-speaking women with newly-
diagnosed in situ or invasive breast cancer between August 1, 1996 and July 31, 1997. Cases 
were identified using a rapid reporting system developed specifically for the study.  Controls 
were randomly selected through random-digit-dialing methods for those under age 65 and 
Health Care Finance Administration lists for those age 65 years or older  and frequency-
matched to cases in 5-year age groups (371).  The institutional review boards of all the 
participating institutions approved the study protocol, and the individual women all signed 
informed consent forms.  
    In-person interviews were completed for 1,508 breast cancer cases (81.2% of eligible 
cases) and 1,556 controls (62.8% of eligible controls). Reasons for non-participation included 
subject refusal, too ill, cognitively impaired, unlocatable or moved out of area, and deceased 
(26). 
Exposure Assessment  
    Women were administered a standardized questionnaire and asked to report on a variety of 
known and suspected breast cancer risk factors.  Cases who signed a medical record release 
form at the interview had their medical records reviewed for clinical and pathologic 
characteristics related to the breast cancer diagnosis and treatment, including estrogen (ER) 
and progesterone (PR) tumor receptor status.   
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Cases and controls were asked to recall their diet history in the previous 12 months, 
including assessment of frequency and portion size, with a modified version of the Block 
food frequency questionnaire (FFQ) (435).  1,481 cases (98.2%) and 1,518 controls (97.6%) 
completed this self-administered instrument.  To facilitate comparison of our results with 
other studies, 18 cases and 18 controls with daily energy intakes above or below 3 standard 
deviations of the log-transformed mean in kilocalories per day (kcal/d) were excluded from 
the analysis (48).  An additional 29 cases and 60 controls were excluded because their 
menopausal status was unknown, resulting in a total of 1,434 cases and 1,440 controls.   
Dietary Flavonoid Intake Assessment 
Food and beverage content of total flavonoids and seven classes of flavonoids (flavonols, 
flavones, flavan-3-ols, flavanones, anthocyanidins, isoflavones, and lignans) were estimated 
with a database created for use in the LIBCSP (457).  The LIBCSP database included both 
the USDA Database for the Flavonoid Content of Selected Foods (377) and the USDA – 
Iowa State University Database on the Isoflavone Content of Selected Foods (378).  
Additional sources (270, 298, 379-382, 458-461) were utilized to include isoflavone content 
provided by fruits, vegetables, nuts, and grains, which are important dietary contributors 
among American women (392).  These sources also provided content information for lignans, 
a class of flavonoids not included in the USDA databases, but for which laboratory evidence 
has demonstrated potential anti-carcinogenic properties (72, 462-466).   
Using this database, a total of 50 items listed on the modified Block FFQ were found to 
contain measurable amounts of at least one flavonoid class.  Individual foods and beverages 
were listed under each class they contained from the richest source to the smallest source (top 
to bottom) (457). The richest sources of total flavonoids include ‘tea, including herb tea’ 
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(111.41 grams (g) of flavan-3-ols per 100 milligrams (mg)), ‘cherries’ (116.31 g of 
anthocyanidins per 100 mg), and ‘grapefruit’ (54.50 g of flavanones per 100 mg) (377).   
Statistical Analysis 
    Odds ratios (OR) and 95% confidence intervals (CI) were estimated using unconditional 
logistic regression (436), including terms for energy intake (kcal/d) and age (in five-year age 
group).  Total flavonoids and each flavonoid class were categorized as quintiles or deciles 
based on the distribution of intake by controls, but produced similar results; thus, only the 
results for quintiles are reported here.  Tests of trend were conducted using the continuous 
values in milligrams/day (mg/d).   
    Confounding was assessed using backward elimination with multivariable models. 
Potential confounders included menopausal status (pre- and post-menopausal), lifetime 
alcohol intake (grams/day), cigarette smoking (current, former, never), family history of 
breast cancer in a mother or sister, benign breast disease, average physical activity levels 
from menarche to reference date (hours/day), body mass index (BMI) [weight (kg) / height 
(m)2] at reference date (date of interview), household income, education, parity, 
mammography use, oral contraceptive use, and fruits, vegetables, and antioxidants consumed 
in the previous 12 months.  None of the potential confounders altered the estimates of effect 
by greater than 10%.   
Effect modification was first examined through use of stratified analysis and then by 
comparing the log likelihood-statistic for regression models that included a multiplicative 
interaction term to those without (437).  From the covariates listed above, only menopausal 
status was found to modify the association between flavonoid intake and breast cancer risk.  
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For the analyses, menopause-specific quintiles were created based on the respective intakes 
of pre- and post-menopausal control women.    
    Differences in risk estimates by hormone receptor status of case tumors were examined 
with stratified analyses.  ER+PR+ cases were considered as one group and compared with all 
other hormonal receptor types combined (ER+PR-, ER-PR+, ER-PR-).   
 
Results 
    The distribution of flavonoid intake among the breast cancer cases and controls is 
presented in Table 1.  Overall, cases consumed a lower amount of total flavonoids per day 
than controls among both post-menopausal (mean = 220.74 mg/d and 242.66 mg/d, 
respectively) and pre-menopausal women (mean = 211.12 mg/d and 212.19 mg/d, 
respectively), though the differences were more pronounced among post-menopausal 
women.  Flavan-3-ols were the largest contributor to total intake and were most disparate 
between post-menopausal cases (mean = 163.29 mg/d) and post-menopausal controls (mean 
= 182.68 mg/d).   
    As shown in Table 2, among post-menopausal women, breast cancer risk was decreased in 
relation to intake of all flavonoids except for flavanones and isoflavones.  ORs (95% CIs) 
were reduced by 25% among post-menopausal women in the highest fifth of intake of total 
flavonoids (OR = 0.75, 95% CI = 0.56-1.01), by nearly 40% for flavones (OR = 0.61, 95% 
CI = 0.45-0.83), by nearly 50% for flavonols (OR = 0.54, 95% CI = 0.40-0.73), and by 30% 
for lignans (OR = 0.69, 95% CI 0.51-0.94).  There was a significant decreasing trend across 
quintiles for total flavonoids, flavonols, flavones, and lignans.  In contrast, among pre-
 116
menopausal women, there was no evidence for a decreased risk of breast cancer for any class 
of flavonoids.   
    When stratified by ER/PR status, there was little or no heterogeneity in breast cancer risk 
in relation to flavonoid intake for post-menopausal women.  A consistent trend towards a 
reduced risk was found for all hormonal receptor types in relation to flavonols, flavones, and 
total flavonoids (Table 3).  The number of pre-menopausal women in the limited our ability 
to stratify by hormone receptor status in these younger women.   
 
Discussion 
    Inverse associations were found for intake of total flavonoids and most flavonoid classes 
with breast cancer risk in post-menopausal women only.  These results are consistent with 
two previous hospital-based, case-control studies conducted in Greece (21) and Italy (60) that 
found a slightly more modest reduction in risk with increasing flavones (59, 60) and 
flavonols (60).  Both used the same two USDA databases (377, 378) to measure flavonoid 
intake and each had a study population size similar to ours.  Our enhancement of these 
American databases to more fully capture intake of flavonoid-rich foods may have improved 
our ability to detect a stronger association between flavonoid intake and breast cancer risk in 
our American population.   
    In contrast, our data do not support an inverse association between isoflavones and breast 
cancer risk.  Previous studies have also not observed an association (238, 370, 467-470), 
including a study conducted in a multiethnic population in the San Francisco Bay Area (470).  
The diet history instrument used in the LIBCSP was limited in its coverage of soy products, 
which may have resulted in a slight underestimation of intake of isoflavone-rich foods.  This 
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non-differential misclassification would result in masking any potential beneficial effects of 
these compounds.  
    While previous efforts have been made to estimate the isoflavone content of soy-based 
products in the U.S. (298, 471), the continued growth of new soy products on the market, as 
well as non-traditional sources of soy such as soy flour in doughnuts and soy protein in fast 
food hamburgers, demonstrate the need for their inclusion in future dietary assessment tools.  
Furthermore, the Block FFQ did not include blueberries and raspberries, both rich sources of 
anthocyanidins (377).  Omission of these berries may have contributed to the lower 
anthocyanidin intake reported in our study compared to those in Greece (59) and Italy (60), 
although neither of these studies found a risk reduction with anthocyanidins.   
    Additionally, flavonoid content in foods is variable, in part influenced by environmental 
conditions (472).  Particularly, in fruits and vegetables, flavonoid content varies due to 
different cultivars, cultural practices, climatic conditions and geographic location, degree of 
ripeness, storage conditions, and industrial processing (292, 473-476).  Thus, it is possible 
that there are differences in flavonoid content in the products consumed by the Long Island 
study population compared to those for which estimates were taken from and used in the 
creation of databases.  However, it is unknown how large or small these differences were and 
where all products, especially fruits and vegetables, were grown or produced.      
    Our study did, however, expand the coverage of flavonoids compared to previous studies 
of flavonoids and breast cancer risk (59, 60) by including lignans, which are typically found 
in the woody portions of plants, the seed coat of seeds, and the bran layer in grains (382, 
477).  Lignans are thought to act through the same mechanisms as other flavonoids in 
preventing breast cancer (477).  Our finding of a reduced breast cancer risk for increasing 
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lignan intake among women on Long Island supports data reported in animals (478-481) and 
humans (72, 295, 396, 462, 466, 482, 483).   
    Given the hypothesized anti-carcinogenic effects of flavonoids (46, 47, 50-58, 72, 268), 
consumption would be expected to benefit both pre- and post-menopausal women.  However, 
the biological mechanism for the effect modification by menopausal status observed in our 
data is unclear.  A previous study of fruit, vegetable, and micronutrient intake in the LIBCSP 
(48) found a decreased risk of breast cancer among post-menopausal women with increasing 
levels of vegetable intake and many micronutrients, including alpha and beta-carotene.  Our 
findings suggest that the impact of flavonoids may also be greater in post-menopausal 
women.  Further research based on large numbers of both pre- and post-menopausal women 
is needed to help clarify this issue.  
Flavonoids are in numerous products, including fruits and vegetables, thus flavonoid 
consumption may reflect part of an overall healthy diet and lifestyle (33, 369).  Furthermore, 
many lifestyle factors that may potentially confound the relationship between flavonoids and 
breast cancer are highly correlated with flavonoids (48, 484, 485), making it difficult to 
firmly establish their independent effects (486).  The LIBCSP main questionnaire extensively 
assessed exposures over the life course including recreational physical activity levels from 
menarche to age at diagnosis, lifetime active and passive smoking exposure, and lifetime 
alcohol consumption (48).  However, when these were controlled mutually or individually, 
our results were not substantially altered.  
    Our study relied on retrospective reporting of dietary intake, which is subject to error, 
particularly in the reporting by breast cancer cases, compared to controls.  The controls may 
have over-reported consumption of flavonoid-rich foods, such as fruits and vegetables, in an 
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attempt to appear socially correct.  This would overemphasize the benefits of flavonoids.  
However, if this had actually occurred, it would be expected that over-reporting would occur 
among all control women, regardless of menopausal status.  The lack of an association in 
pre-menopausal women argues against this possibility.  An additional concern with errors in 
recall is that case reports of food intake may be affected by whether they have initiated 
chemotherapy by the time of the study interview (375).  However, in the LIBCSP, most of 
the case women were interviewed prior to any chemotherapy, and among those that had 
started, reported intake levels were not found to differ from those who had not started (48).   
Very few studies have addressed the impact of dietary flavonoid intake on the risk of 
breast cancer, particularly in an American population.  Only studies in Greece (59) and Italy 
(60) have used the USDA Database for the Flavonoid Content of Selected Foods and 
USDA – Iowa State University Database on the Isoflavone Content of Selected Foods 
together.  Our work combined these two databases with additional literature (270, 298, 379-
382, 392, 458-461) to provide a more comprehensive instrument for assessing flavonoid 
intake, including total flavonoids and lignans. 
This study had the advantage of a large sample size with a population-based design, 
reducing selection bias and allowing for greater generalizability of results compared with 
hospital-based studies.  The LIBCSP population consumed a wide variety and significant 
amounts of flavonoid-containing products, such as fruits, vegetables, and tea, enabling us to 
address our specific aims.  Furthermore, the Block FFQ utilized in this study is a validated, 
reliable dietary assessment tool for estimating usual food group intake and ranking 
individuals into categories of intake (375, 383, 487). 
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    In summary, this case-control study provides evidence that increased intake of flavonoids, 
and particularly flavones, flavonols, flavan-3-ols, and lignans, is associated with reduced risk 
of breast cancer in a population-based sample of post-menopausal women in the U.S.  These 
findings support similar, but more modest reductions observed in Greece and Italy (59, 60).  
Most research to date has not utilized the two recently available USDA databases together, 
with additional sources, to study flavonoids and breast cancer incidence.  Further research 
using these instruments needs to be conducted, particularly among American populations.   
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Tables  
 
Table 3.1.  Distribution of flavonoid intake (mg/d) for cases and controls of the Long 
Island Breast Cancer Study Project 
Pre-menopausal Cases (n = 457) Pre-menopausal Controls (n = 487)  
Variable Mean (mg/d) Mean (mg/d) p-value† p-value* 
Total Flavonoids 211.12 212.19 0.94 0.53 
Flavonols 10.09 10.11 0.96 0.35 
Flavones 0.14 0.14 0.91 0.44 
Flavanones 25.60 27.13 0.44 0.54 
Flavan-3-ols 161.00 161.06 0.99 0.41 
Anthocyanidins 3.16 3.03 0.75 0.64 
Isoflavones 5.50 5.03 0.37 0.38 
Lignans 5.97 5.92 0.85 0.50 
Post-menopausal Cases (n = 977) Post-menopausal Controls (n = 953)  
Variable Mean (mg/d) Mean (mg/d) p-valuea p-valueb 
Total Flavonoids 220.74 242.66 0.02 0.02 
Flavonols 9.68 10.70 0.002 0.0003 
Flavones 0.13 0.15 0.0002 < 0.0001 
Flavanones 34.12 34.17 0.97 0.99 
Flavan-3-ols 163.29 182.68 0.03 0.009 
Anthocyanidins 3.14 3.66 0.17 0.02 
Isoflavones 4.58 4.86 0.46 0.69 
Lignans 6.01 6.62 0.005 0.002 
†P-value for t-test comparing means among pre-menopausal women 
aP-value for t-test comparing means among post-menopausal women 
*Wilcoxon rank sum test comparing medians among pre-menopausal women  
bWilcoxon rank sum test comparing medians among post-menopausal women 
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Table 3.2.  Age and energy-adjusted odds ratios (OR) and 95% confidence intervals (CI) for the 
association between menopausal-specific flavonoid intake in relation to breast cancer incidence  
 Pre-menopausal 
(n = 944) 
 Post-menopausal 
(n = 1930) 
 OR (95% CI)  OR (95% CI) 
Total Flavonoids#  Total Flavonoids#  
0-34.5 1.00 0-51.8 1.00 
34.5-84.5 1.20 (0.79-1.84) 51.8-119.1 0.94 (0.71-1.24) 
84.5-199.5 1.29 (0.84-1.97) 119.1-253.3 0.79 (0.60-1.05) 
199.5-343.0 1.46 (0.96-2.22) 253.3-377.2 0.80 (0.60-1.06) 
343.0+ 1.12 (0.72-1.74) 377.2+ 0.75 (0.56-1.01) 
P for trend* 0.95  0.05 
Total Flavonols#  Total Flavonols#  
0-3.7 1.00 0-4.3 1.00 
3.7-6.0 1.32 (0.86-2.03) 4.3-6.8 0.56 (0.42-0.74) 
6.0-10.2 1.48 (0.97-2.27) 6.8-11.1 0.62 (0.47-0.82) 
10.2-15.1 1.53 (0.99-2.35) 11.1-17.1 0.63 (0.47-0.83) 
15.1+ 1.38 (0.88-2.15) 17.1+ 0.54 (0.40-0.73) 
P for trend* 0.92 P for trend* 0.009 
Total Flavones#  Total Flavones#  
0-0.04 1.00 0-0.04 1.00 
0.05-0.07 0.94 (0.62-1.43) 0.05-0.08 0.90 (0.68-1.19) 
0.08-0.12 1.29 (0.86-1.84) 0.09-0.14 0.95 (0.72-1.26) 
0.13-0.21 1.07 (0.70-1.63) 0.15-0.21 0.70 (0.52-0.94) 
0.22+ 1.07 (0.70-1.65) 0.22+ 0.61 (0.45-0.83) 
P for trend* 0.94 P for trend* 0.0007 
Total Flavanones#  Total Flavanones#  
0-3.1 1.00 0-5.3 1.00 
3.2-10.8 0.69 (0.46-1.04) 5.4-18.8 1.09 (0.82-1.46) 
10.9-24.5 0.69 (0.46-1.04) 18.9-32.1 1.10 (0.83-1.46) 
24.6-40.3 0.85 (0.57-1.26) 32.2-54.2 1.08 (0.81-1.43) 
40.4+ 0.80 (0.53-1.21) 54.3+ 1.00 (0.75-1.34) 
P for trend* 0.34 P for trend* 0.87 
Total Flavan-3-ols# Total Flavan-3-ols# 
0-5.1 1.00 0-7.6 1.00 
5.2-26.4 1.22 (0.80-1.87) 7.7-54.0 0.94 (0.72-1.24) 
26.5-120.8 1.32 (0.87-2.01) 54.1-192.0 0.80 (0.60-1.06) 
120.9-264.1 1.52 (1.00-2.30) 192.1-277.9 0.82 (0.62-1.08) 
264.2+ 1.21 (0.78-1.86) 278.0+ 0.74 (0.55-0.99) 
P for trend* 0.87 P for trend* 0.06 
Total Anthocyanidins# Total Anthocyanidins# 
0-0.04 1.00 0-0.03 1.00 
0.05-0.56 1.15 (0.77-1.72) 0.04-0.56 1.09 (0.83-1.44) 
0.57-1.60 0.77 (0.50-1.17) 0.57-1.84 0.97 (0.73-1.28) 
1.61-4.19 1.07 (0.71-1.61) 1.85-4.84 0.82 (0.62-1.09) 
4.20+ 1.08 (0.71-1.63) 4.85+ 0.85 (0.64-1.14) 
P for trend* 0.81 P for trend* 0.23 
Total Isoflavones#  Total Isoflavones#  
0-0.31 1.00 0-0.27 1.00 
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0.32-1.10 1.03 (0.68-1.56) 0.28-0.62 0.97 (0.72-1.30) 
1.11-3.17 0.98 (0.65-1.47) 0.63-1.94 1.16 (0.87-1.55) 
3.18-7.62 0.88 (0.58-1.33) 1.95-7.63 1.14 (0.85-1.53) 
7.63+ 1.14 (0.76-1.72) 7.64+ 1.02 (0.76-1.38) 
P for trend* 0.56 P for trend* 0.72 
Total Lignans#  Total Lignans#  
0-2.0 1.00 0-2.4 1.00 
2.1-4.0 1.43 (0.95-2.17) 2.5-4.2 1.07 (0.81-1.40) 
4.1-5.4 0.98 (0.63-1.51) 4.3-6.4 0.82 (0.61-1.09) 
5.5-9.3 1.62 (1.07-2.45) 6.5-10.2 0.79 (0.59-1.05) 
9.4+ 1.24 (0.81-1.92) 10.3+ 0.69 (0.51-0.94) 
P for trend* 0.72 P for trend* 0.01 
* P for trend for continuous variable 
# In milligrams per day (mg/d) 
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Table 3.3.  Age and energy-adjusted odds ratios (OR) and 95% confidence intervals (CI) for the 
association between flavonoid intake and breast cancer incidence among post-menopausal 
women, stratified by ER/PR status 
 Controls ER+PR+  ER+PR-, ER-PR+, ER-PR- 
 (n = 953) Cases (n)
(n = 378) 
OR (95% CI) Cases (n)
(n = 274) 
OR (95% CI) 
Total Flavonoids#     
0-51.7 190 89 1.00 72 1.00 
51.8-119.0 192 78 0.90 (0.62-1.31) 62 0.89 (0.59-1.32) 
119.1-253.2 190 72 0.83 (0.57-1.21) 42 0.60 (0.39-0.93) 
253.3-377.1 191 77 0.86 (0.59-1.25) 49 0.68 (0.44-1.04) 
377.2+ 190 62 0.75 (0.50-1.12) 49 0.72 (0.47-1.11) 
P for trend*   0.35  0.09 
Total Flavonols#     
0-4.2 191 113 1.00 93 1.00 
4.3-6.7 190 66 0.59 (0.41-0.86) 47 0.51 (0.34-0.78) 
6.8-11.0 190 67 0.60 (0.41-0.87) 42 0.46 (0.30-0.71) 
11.1-17.0 191 74 0.66 (0.46-0.96) 46 0.49 (0.32-0.75) 
17.1+ 191 58 0.55 (0.37-0.82) 56 0.51 (0.33-0.79) 
P for trend*   0.12  0.03 
Total Flavones#      
0-0.04 191 101 1.00 69 1.00 
0.05-0.08 190 74 0.76 (0.52-1.10) 72 1.05 (0.71-1.56) 
0.09-0.14 191 85 0.89 (0.62-1.29) 55 0.83 (0.54-1.26) 
0.15-0.21 191 61 0.64 (0.43-0.94) 44 0.67 (0.43-1.04) 
0.22+ 190 57 0.59 (0.40-0.89) 34 0.51 (0.32-0.82) 
P for trend*   0.02  0.003 
Total Flavanones#     
0-5.3 190 70 1.00 50 1.00 
5.4-18.8 192 77 1.18 (0.80-1.74) 52 1.05 (0.68-1.63) 
18.9-32.1 189 84 1.21 (0.83-1.78) 61 1.20 (0.78-1.84) 
32.2-54.2 191 80 1.14 (0.77-1.67) 58 1.16 (0.75-1.80) 
54.3+ 191 67 0.95 (0.63-1.42) 53 1.06 (0.68-1.66) 
P for trend*   0.77  0.49 
Total Flavan-3-ols#     
0-7.6 190 93 1.00 71 1.00 
7.7-54.0 192 75 0.81 (0.56-1.18) 62 0.88 (0.59-1.31) 
54.1-192.0 189 65 0.71 (0.49-1.04) 48 0.69 (0.45-1.05) 
192.1-277.9 192 81 0.86 (0.60-1.24) 48 0.66 (0.43-1.02) 
278.0+ 190 64 0.75 (0.51-1.10) 45 0.67 (0.43-1.03) 
P for trend*   0.45  0.13 
Total Anthocyanidins#     
0-0.03 189 77 1.00 58 1.00 
0.04-0.56 192 88 1.19 (0.82-1.73) 70 1.22 (0.81-1.84) 
0.57-1.84 190 88 1.25 (0.86-1.81) 44 0.80 (0.51-1.24) 
1.85-4.84 191 69 0.93 (0.63-1.37) 50 0.90 (0.59-1.39) 
4.85+ 191 56 0.77 (0.51-1.16) 52 0.95 (0.62-1.46) 
P for trend*   0.005  0.63 
Total Isoflavones#     
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0-0.27 190 82 1.00 55 1.00 
0.28-0.62 191 63 0.78 (0.52-1.17) 64 1.19 (0.78-1.83) 
0.63-1.94 191 81 1.09 (0.75-1.60) 50 0.98 (0.62-1.52) 
1.95-7.63 191 88 1.21 (0.83-1.77) 58 1.16 (0.75-1.80) 
7.64+ 190 64 0.92 (0.61-1.37) 47 1.00 (0.63-1.58) 
P for trend*   0.91  0.48 
Total Lignans#      
0-2.4 215 89 1.00 72 1.00 
2.5-4.2 167 81 1.09 (0.76-1.58) 68 1.07 (0.72-1.59) 
4.3-6.4 190 76 0.96 (0.66-1.40) 48 0.74 (0.48-1.14) 
6.5-10.2 191 71 0.89 (0.60-1.30) 43 0.64 (0.41-0.99) 
10.3+ 190 61 0.82 (0.55-1.24) 43 0.67 (0.43-1.05) 
P for trend*   0.35  0.02 
# P for trend for continuous variable 
* In milligrams per day (mg/d) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER IV: DIETARY FLAVONOID INTAKE AND BREAST CANCER 
SURVIVAL AMONG WOMEN IN THE LONG ISLAND BREAST CANCER STUDY 
PROJECT 
 
Abstract 
Background: Laboratory research and a growing number of epidemiologic studies have 
provided evidence for a reduced risk of breast cancer associated with dietary intake of certain 
classes of flavonoids.  However, the effects of flavonoids on survival are not known.  In a 
population-based study, we investigated whether dietary flavonoid intake prior to diagnosis is 
associated with breast cancer survival.  Methods: Women age 25-98 years who were newly 
diagnosed with a first primary invasive breast cancer between August 1, 1996 and July 31, 
1997 and participated in a population-based, case-control study (n = 1,210) were followed for 
vital status through December 31, 2002.  At the case-control interview conducted shortly 
after diagnosis, respondents completed a food frequency questionnaire that assessed dietary 
intake in the previous twelve months.  All-cause mortality (n = 173 deaths) and breast 
cancer-specific mortality (n = 113 deaths) were determined through the National Death 
Index.  Results: Reduced hazard ratios (age-and energy adjusted HR, (and 95% confidence 
intervals (CI))) for all-cause mortality were observed among pre- and post-menopausal 
women for the highest quintile of intake, compared to the lowest, for flavones (0.63, (0.41-
0.96)), isoflavones (0.52, (0.33-0.82)), and anthocyanidins (0.64, (0.42-0.98)).  Effects were 
more pronounced among post-menopausal women for flavones 0.59 (0.35-0.99)) and 
isoflavones (0.44 (0.24-0.81)).  Results were similar when analyses considered breast cancer-
specific mortality only.  Conclusion: This is the first study to provide evidence that mortality 
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is reduced in association with high levels of dietary flavones and isoflavones among breast 
cancer patients, particularly among those who were postmenopausal at diagnosis.   
 
INTRODUCTION 
    Prior laboratory research suggests that flavonoids may inhibit breast cancer development 
by decreasing estrogen production (50-53), inhibiting breast cancer cell proliferation (54, 55, 
488-492), and decreasing reactive oxygen species (ROS) production (56-58).  Several 
population-based studies (59, 60, 493), including analyses from the Long Island Breast 
Cancer Study (LIBCSP) (493) reported inverse associations between dietary flavonoid intake 
and breast cancer risk, but to the best of our knowledge, there are no reports on the 
association between flavonoids and breast cancer survival.  
    Some (30, 32, 33, 305, 494), but not all (306, 361), observational studies have observed a 
reduced risk of all-cause mortality among breast cancer patients in relation to intake of fruit 
and vegetables, which are abundant in flavonoid content (377).  A previous analysis of fruits, 
vegetables, and micronutrients in relation to survival of breast cancer cases who participated 
in the LIBCSP (494) found a reduced risk of mortality with increasing intakes of fruits, fruit 
juices, and vegetables at diagnosis.  However, micronutrients, including vitamin C, vitamin 
E, and alpha- and beta-carotene, were not associated with mortality in this population.   
    The study of flavonoids may help to identify food sources that enhance breast cancer 
survival, and clarify inconsistent results from previous studies assessing fruits and vegetables 
and breast cancer survival.  This study examined whether flavonoid intake reported near the 
time of diagnosis is associated with reduced all-cause and breast cancer-specific mortality in 
a population-based sample of women with incident breast cancer (371).  
 128
 
MATERIALS AND METHODS  
Overview 
    This research draws upon data collected as part of the LIBCSP, which began as a case-
control study (371) and now includes assessment of survival among the breast cancer cases.  
For this analysis, flavonoid intake in the year prior to the baseline case-control study 
interview was used to examine survival among LIBCSP participants diagnosed with invasive 
breast cancer in 1996-1997 (n = 1,273).  Vital status through 2002 was determined using the 
National Death Index (NDI).  Information on dietary intake and potential confounders and 
effect modifiers also was collected at the baseline interview, which took place shortly after 
diagnosis (mean = 96 days) (371).  Treatment information was derived from baseline (1996-
1997) and follow-up (2002-2004) interviews and medical records.   
Study Subjects 
    Eligible cases for the parent LIBCSP case-control study (371) included English-speaking 
women newly diagnosed with a first invasive primary breast cancer between August 1, 1996 
and July 31, 1997 who were residents of Nassau and Suffolk counties, Long Island, New 
York.  Cases were identified through a rapid reporting system that was developed specifically 
for the LIBCSP.  The attending physician was contacted to confirm study eligibility and to 
seek permission to contact each patient.  Of the 1,837 eligible cases with physician consent, 
1,508 (82%) agreed to participate and completed the main questionnaire (n = 1,273 invasive 
cases). 
Exposure Assessment 
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Baseline, Case-Control Interview.  Breast cancer cases and controls were administered a 
standardized questionnaire by trained interviewers that asked about a variety of known and 
suspected breast cancer risk factors.  Participants were also asked to self-complete a modified 
version of the Block food frequency questionnaire (FFQ) (435), which included information 
on frequency and portion size of 100 food items.  The instrument was modified to include 
questions regarding flavonoid-rich foods such as tofu, cherries, soups, fruit drinks, and alfalfa 
sprouts (457). Of the 1,273 invasive cases who completed the case-control questionnaire, 
1,249 completed the FFQ at baseline.  To facilitate comparisons with other studies, 38 
invasive cases with daily energy intakes above or below 3 standard deviations of the log-
transformed mean were excluded from the analysis (48).  Of the remaining cases, 25 had 
unknown menopausal status and were also excluded, resulting in a final sample size of 1,210 
women. 
Dietary Flavonoid Intake Assessment at Baseline.  Details on the food items included in 
each flavonoid class have been described previously (457).  Briefly, food and beverage 
contents of total flavonoids and seven classes of flavonoids (flavonols, flavones, flavan-3-ols, 
flavanones, anthocyanidins, isoflavones, and lignans) were estimated using a database 
created for the LIBCSP (457) that included values from both the USDA Database for the 
Flavonoid Content of Selected Foods (377) and the USDA – Iowa State University Database 
on the Isoflavone Content of Selected Foods (378).  Additional sources (270, 298, 379-382, 
459-461) were utilized to estimate the isoflavone content of products not included on the 
USDA database including selected fruits, vegetables, nuts, and grains that are important 
dietary contributors of flavonoids among American women (392).  These sources also 
provided information for lignans, a class of flavonoids for which laboratory and 
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epidemiologic evidence has demonstrated potential anti-carcinogenic properties (72, 462-
466), that is not included in the USDA databases.  
Fifty items listed on the modified Block FFQ were found to contain at least one flavonoid 
class.  The richest sources of total flavonoids include ‘tea, including herb tea’, which consists 
primarily of flavan-3-ols (111.41 milligrams (mg) per 100 grams (g)); ‘cherries’, which 
consist primarily of anthocyanidins (116.31 mg per 100 g); and ‘grapefruit’, which consists 
primarily of flavanones (54.50 mg per 100 g) (377).   
Treatment Data   
    Treatment information was based on data from respondent reports at the baseline case-
control and follow-up interviews and the medical records collected as part of each study.    
Case-control Interview.  At baseline, medical records were abstracted to obtain information 
on disease stage (in situ versus invasive), initial course of breast cancer treatment, and 
estrogen receptor (ER) and progesterone receptor (PR) status.  Three-fourths of the baseline 
case interviews occurred prior to the initiation of chemotherapy (371).   
Follow-up Interview.  Additional treatment information was obtained from follow-up 
telephone interviews of case participants or proxies in 2002-2004, and from medical records.  
Of the original 1,508 case participants, 1,414 gave permission to re-contacted them.  Of 
these, a total of 1,098 cases (n = 868 invasive cases) were successfully re- interviewed by 
phone.  The remaining cases refused to participate in the follow-up interview, were 
untraceable, or were deceased and had no identifiable proxy.  During the follow-up telephone 
interview, respondents were asked their complete course of treatment for the initial breast 
cancer diagnosis.  Respondents or proxies were asked to sign a Health Insurance Portability 
and Accountability Act (HIPAA)-approved medical record release form.   
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    Follow-up medical records were retrieved and abstracted for 474 invasive cases to 
determine treatments for their first diagnosis of breast cancer.  A high concordance was 
found between treatment reported by the respondent during the follow-up interview and 
information abstracted from the medical records for radiation (Kappa = 0.97), chemotherapy 
(Kappa = 0.96), and hormone therapy (Kappa = 0.92).   
Study Outcome 
    The National Death Index (NDI) was used to ascertain vital status and the cause and date 
of death if deceased.  173 (14.3%) deaths occurred by December 31, 2002 among the 1,210 
women diagnosed with invasive breast cancer in 1996-1997 with adequate dietary intake data 
available for analysis.  Of these, 113 (65.3% of all deaths) were due to breast cancer based on 
ICD codes 174.9 and C-50.9 listed as a primary or secondary code on the death certificate.  
Other causes of death included cardiovascular disease (n = 24), lung cancer (n = 5), other 
cancers (n = 17), and other (n =21).   
Statistical Analysis 
    Kaplan-Meier survival curves (437) were used to compare survival probabilities among 
cases with different levels of flavonoid intake at the baseline case-control interview with 
subsequent vital status.  The effects of flavonoids on survival were also categorized in 
quintiles, deciles, quartiles, tertiles, and dichotomously at the median intake, and results were 
similar.  Quintiles are presented here and were based on the distribution of flavonoid intake 
for pre- and post-menopausal invasive cases combined to facilitate comparisons between the 
two groups.  When menopause-specific cut-points were examined, results were not 
substantially different than those shown.  Total flavonoids and each of the seven flavonoid 
classes of interest were evaluated with log hazard plots to determine whether the proportional 
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hazards assumption was met.  Cox proportional hazards regression (437) was used to 
estimate hazard ratios and 95% confidence intervals (CI) for the association between total 
flavonoids, as well as each of the seven flavonoid classes, with all-cause mortality and breast 
cancer-specific mortality.  All models were adjusted for age at diagnosis (continuous) and 
dietary energy intake (continuous).  Models were re-run with follow-up time limited to 5 
years and the results were nearly identical to those where all follow-up time was included 
(data not shown).   
    Effect modification was examined through use of stratified analysis and by comparing the 
log-likelihood statistic for models that included multiplicative interaction terms to those 
without (437).  Potential modifiers included covariates assessed at the baseline interview: 
menopausal status (pre- or post-menopausal), family history of breast cancer in a first-degree 
relative, physical activity level from menarche to date of diagnosis (hours/day), 
active/passive cigarette smoking, body mass index (BMI) [weight (kg) / height (m)2] at 
diagnosis, average lifetime alcohol intake (grams/day), education, income, hormone 
replacement therapy (HRT), and co-morbidities including history of hypertension, diabetes, 
high cholesterol, myocardial infarction, and stroke.  None of these covariates were found to 
modify the association between flavonoids and survival based on a p-value of 0.20.  
However, because breast cancer survival has been shown to vary with menopausal status in 
some studies (495, 496), results were stratified by menopausal status.   
    We also investigated potential effect modification by the primary treatment for breast 
cancer at diagnosis (obtained as part of the follow-up study), including radiation treatment 
and chemotherapy, and no effects were observed (data not shown).  We examined 
associations between flavonoids and survival according to tumor characteristics, including 
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tumor size and hormone receptor status (ER/PR) obtained from the medical record as part of 
the case-control and follow-up studies.  No effect measure modification was observed, even 
when cases were stratified by each individual hormone receptor type.  Therefore, to 
maximize study power, ER+PR+ cases were considered as one group and the remaining three 
hormone receptor types were combined (ER+PR-, ER-PR+, ER-PR-) into another group.   
    Potential confounders included those considered as effect modifiers.  None of the potential 
confounders altered effect estimates for flavonoid classes by more than 10% (data not 
shown).  Thus, only the age- and energy-adjusted results are shown.     
 
RESULTS 
Invasive cases were pre-dominantly white (94.1%), ever married (96.4%), and post-
menopausal at diagnosis (Table 1).  The proportion of cases with at least some college 
education was approximately equal to the proportion with a high school diploma or less.  
Approximately 30% had a household income of at least $50,000 before taxes.  
As shown in Table 2, flavones (HR = 0.63, 95% CI = 0.41-0.96), isoflavones (HR = 0.52, 
95% CI = 0.33-0.82), and anthocyanidins (HR = 0.64, 95% CI = 0.42-0.98) were inversely 
associated with all-cause mortality when analyses included both pre- and post-menopausal 
women, although dose-response trends were not observed.  When analyses were restricted to 
post-menopausal women only, risk of all-cause mortality was decreased in relation to 
flavones (HR = 0.59, 95% CI: 0.35-0.99) and isoflavones (HR = 0.44, 95% CI = 0.24-0.81), 
comparing the highest quintile of intake to the lowest quintile (Table 2).  Total flavonoids 
(HR = 0.78, 95% CI = 0.49-1.25) and anthocyanidins (HR = 0.66, 95% CI = 0.40-1.08) were 
also associated with a modest reduction in mortality.  Among pre-menopausal women, 
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similar reductions in all-cause mortality were observed for flavones (HR = 0.69, 95% CI = 
0.32-1.47), isoflavones (HR = 0.71, 95% CI = 0.34-1.48), and anthocyanidins (HR = 0.62, 
95% CI = 0.27-1.40), although confidence intervals were wide.  Total flavonoids (HR = 1.77, 
95% CI = 0.91-3.46), flavonols, flavan-3-ols, and lignans were positively associated with 
mortality; however, estimates were imprecise and no clear dose-response trends were 
evident.  
    With results stratified by hormone receptor status, effects were slightly more pronounced 
among those with ER+PR+ tumors, but the confidence intervals were wide (data not shown).  
For example, among post-menopausal women with ER+PR+ tumors, inverse associations 
with all-cause mortality were observed comparing the highest quintile of intake to the lowest 
quintile, for anthocyanidins (HR = 0.57, 95% CI = 0.28-1.17) and flavones (HR = 0.59, 95% 
CI = 0.29-1.21).  More modest reductions in all-cause mortality were found for flavonols 
(HR = 0.77, 95% CI = 0.39-1.52), flavan-3-ols (HR = 0.80, 95% CI = 0.42-1.54), lignans 
(HR = 0.86, 95% CI = 0.45-1.67), and total flavonoids (HR = 0.81, 95% CI = 0.42-1.57).  
For women with all other hormone receptor types (ER+PR-, ER-PR+, and ER+PR+) (n = 
458), no consistent associations were observed.  
    Results for breast cancer-specific mortality were similar to those for all-cause mortality, 
including an inverse association with mortality for flavones among post-menopausal women 
(HR = 0.49, 95% CI: 0.24-0.99) and all women (HR = 0.48, 95% CI = 0.27-0.84), comparing 
the highest quintile of intake to the lowest quintile (Table 3).  Total flavonoids (HR = 0.62, 
95% CI = 0.33-1.16), anthocyanidins (HR = 0.62, 95% CI = 0.33-1.18), and isoflavones (HR 
= 0.79, 95% CI = 0.43-1.44) were also associated with a modest reduction in breast cancer 
mortality among post-menopausal women, although the confidence intervals were wide.   
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Modest reductions in breast cancer mortality were observed among pre-menopausal 
women for flavones (HR = 0.45, 95% CI = 0.17-1.19) and anthocyanidins (HR = 0.81, 95% 
CI = 0.35-1.89), but again the confidence intervals were wide.  Total flavonoids (HR = 1.75, 
95% CI = 0.82-3.72), flavanols, flavan-3-ols, and lignans were positively associated with 
mortality, though no dose-response relationship existed.   
  
DISCUSSION 
To the best of our knowledge, this is the first study to examine the influence of dietary 
flavonoid intake prior to diagnosis on subsequent breast cancer survival.  We found inverse 
associations for intake of flavones and isoflavones with all-cause mortality, that were more 
pronounced among post-menopausal women, although dose-response trends were not 
observed for either association.  Total flavonoids and anthocyanidins also demonstrated 
modest inverse associations with mortality in this group.   
    The observation in our study of a reduced risk of mortality associated with total 
isoflavones in postmenopausal women is inconsistent with one recent study conducted in 
Shanghai, China (497). This Chinese study focused solely on the prognostic effects of soy, 
which is rich in isoflavones and traditionally consumed more frequently by Asian 
populations than in the U.S.  The investigators found that soy intake prior to cancer diagnosis 
was unrelated to disease-free breast cancer survival among pre- and post-menopausal women 
(497).  Reasons for the inconsistent results between the two studies are not clear, although it 
is possible that consumption of soy is uniformly high in this Asian population, which would 
make it more difficult to detect differences in mortality associated with only minor 
differences in intake.  In contrast, prior research conducted in Italy (60), Greece (59), and the 
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U.S. (493) observed a decreased risk of developing breast cancer with increasing levels of 
flavone intake among post-menopausal women.   
    Study power was adequate for our analyses that were conducted among all women and for 
those restricted to post-menopausal women, but was reduced for our analyses that focused on 
pre-menopausal women only.  Thus, any differences we observed by menopausal status 
could be due to the unstable estimates among the younger women. Power would have been 
modestly improved if we were able to consider breast cancer recurrence as an outcome.  
Although women were asked to report this data at the follow-up interview, we were unable to 
confirm these events in the medical records for many women.  Thus, we focused our analyses 
on mortality, which is reliably and consistently reported in the NDI.  
    The Block FFQ has been demonstrated to be a valid and reliable dietary assessment tool 
for estimating usual food intake and ranking individuals into categories of intake of 
micronutrients (375, 383, 487).  However, a potential limitation of this instrument is its lack 
of complete assessment of commonly consumed flavonoid-rich products.  Although the 
Block FFQ was modified for the LIBCSP to include more flavonoid-rich foods, it did not 
include blueberries and raspberries, which are rich sources of anthocyanidins (377).   In the 
future, FFQs and other dietary history assessment tools should incorporate newly developed 
and commonly consumed soy products to enhance coverage of isoflavones.  These products 
include meatless hamburger, chicken, and sausage made from soy protein, as well as soy 
protein found in some fast food hamburgers.  Inclusion of these foods on FFQs used in future 
studies would improve both the estimation of flavonoid intake and thus the ability to detect 
an association with breast cancer survival.   
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    Flavonoid consumption may reflect part of an overall healthy diet and lifestyle (33, 369).  
Furthermore, many lifestyle factors that may potentially confound the relationship between 
flavonoids and breast cancer are highly correlated with high flavonoid intake, making it 
difficult to firmly establish their independent effects (486).  However, in our analyses, age 
and energy-adjusted estimates were very similar to multivariate-adjusted results, indicating 
that confounding by the variables examined was not evident.  However, residual confounding 
by unmeasured or poorly measured confounders could have biased the estimates.  For the 
LIBCSP, stage of breast cancer was defined as in situ or regional invasive types rather than 
the more detailed staging system used by pathologists, ranging from Stage 0 to Stage 4 (498).  
Thus, there may be some confounding by stage in these data, if flavonoid intake is associated 
with stage at diagnosis. 
    Dietary modification following disease diagnosis is an increasingly commonplace 
behavior among survivors (499-501).  Women concerned about breast cancer recurrence 
have been reported to consume more fruits and vegetables compared to those who are not as 
concerned (445-447, 501).  Thus, it is possible that a diagnosis of breast cancer motivated 
dietary behavior change in some of the cases.  Changes in lifestyle might also have affected 
other outcomes (e.g., lung cancer deaths in 2.3% of cases and cardiovascular disease deaths 
in 12.7% of cases).  However, when we restricted our analyses to breast cancer-specific 
deaths only, results were similar to those observed for all-cause mortality.   
    Similarly, case reports of food intake may have been affected by whether or not a woman 
had initiated chemotherapy by the time of the study interview (375).  However, in the 
LIBCSP, most of the case women (> 75%) were interviewed about their dietary history prior 
to any chemotherapy.  In addition, among those that had started treatment, average intake 
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levels of flavonoid-rich fruits and vegetables did not differ from those who had not started 
(48).   
    This study had the advantage of a large sample size and population-based design, reducing 
the likelihood of selection bias and allowing for greater generalizability compared with 
smaller, hospital-based studies.  The LIBCSP population consumed relatively large quantities 
of a wide variety of flavonoid-containing products, such as fruits, vegetables, and tea (457, 
493) and intakes of several flavonoid classes were comparable to those from the populations 
in Italy (60) and Greece (59).  However, our study population consumed, on average, higher 
levels of flavan-3-ols and isoflavones (457, 493). 
    In summary, this follow-up study of breast cancer patients supports a beneficial effect of 
increasing levels of flavones and isoflavones on all-cause mortality, with effects more 
pronounced among post-menopausal, rather than pre-menopausal women.  These results are 
encouraging given that few modifiable lifestyle factors for breast cancer survival have been 
systematically evaluated.  Future studies are needed that include thorough assessments of 
flavonoid-rich food intake at diagnosis and following diagnosis to determine the role of 
flavonoids intake on breast cancer prognosis.    
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Tables 
 
Table 4.1.  Demographic characteristics of invasive cases in the LIBCSP 
Demographic 
Factor 
 Cohort 
(n=1,210) 
Deaths 
(n=173) 
  N % N % 
Age at reference < 44 years 176 14.5 21 12.1 
 45-54 years 293 24.2 33 19.1 
 55-64 years 301 24.9 34 19.7 
 65-74 years 302 25.0 47 27.1 
 75+ years 138 11.4 38 22.0 
 Missing 0  0  
      
Race White 1138 94.1 158 91.3 
 Black 50 4.2 14 8.1 
 Other 21 1.7 1 0.6 
 Missing 1  0  
      
Education < High school 161 13.3 36 20.5 
 High school graduate 439 36.4 75 43.9 
 Some college 283 23.5 34 19.9 
 College graduate 149 12.3 16 9.3 
 Post-college  175 14.5 11 6.4 
 Missing 3  2  
      
Marital Status Never Married 44 3.6 9 5.2 
 Ever Married 1165 96.4 164 94.8 
 Missing 1  0  
      
Religion Catholic 698 57.7 108 62.4 
 Protestant 293 24.2 45 26.0 
 Jewish 196 16.2 16 9.2 
 None 12 1.0 2 1.2 
 Other  11 0.9 2 1.2 
 Missing 0  0  
      
Income Less than $15,000 95 7.9 29 16.8 
 $15,000-$19,999 59 4.9 12 6.9 
 $20,000-$24,999 80 6.6 15 8.7 
 $25,.000-$34,999 212 17.5 40 23.1 
 $35,000-$49,999 198 16.4 26 15.0 
 $50,000-$69,999 183 15.1 19 11.0 
 $70,000-$89,999 152 12.6 14 8.1 
 $90,000 or more 229 19.0 18 10.4 
 Missing 2  0  
      
ER/PR Status ER+ 668 73.4 83 73.4 
 ER- 242 26.6 54 26.6 
 Missing 300  36  
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 PR+ 582 64.2 64 35.8 
 PR- 324 35.8 73 64.2 
 Missing 304  36  
Tumor Size (cm)b 0-1.9  370 78.2 21 70.0 
 2.0-5.0 84 19.9 8 26.7 
 > 5.0 9 1.9 1 3.3 
 Missing 737  737  
aIncludes values for missing income, which were imputed using age, race, and education. 
bCentimeters. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.2.  Age and energy-adjusted hazard ratios (HR) and 95% confidence intervals (CI) 
stratified by menopausal status for the association between flavonoid intake in relation to all-
cause mortality among breast cancer cases diagnosed in 1996-1997. 
Variable 
(mg/day)  
Deaths/
Cohort 
# deaths/ 
376 
Pre-
menopausal 
HR  
(95% CI) 
Deaths/
Cohort 
# deaths/
834 
Post-
menopausal 
HR (95% CI) 
Deaths/ 
Cohort 
# deaths/ 
1,210 
Pre and Post 
HR  
(95% CI) 
Total 
Flavonoids* 
      
0-42.4 3/82 1.00 25/161 1.00 28/243 1.00 
42.5-95.0 15/72 2.49  
(1.32-4.69) 
23/171 0.81  
(0.52-1.28) 
38/243 1.10  
(0.77-1.57) 
95.1-216.2 6/79 0.58  
(0.24-1.36) 
28/162 1.09  
(0.71-1.65) 
34/241 0.95  
(0.66-1.39) 
216.3-340.4 6/75 0.61  
(0.26-1.46) 
32/168 1.24  
(0.83-1.86) 
38/243 1.11  
(0.77-1.59) 
340.5+ 13/68 1.77  
(0.91-3.46) 
22/172 0.78  
(0.49-1.25) 
35/240 0.96  
(0.66-1.40) 
Total 
Flavonols* 
      
0-3.4 4/58 1.00 31/185 1.00 35/243 1.00 
3.5-5.9 12/81 1.65  
(0.84-3.26) 
23/162 0.89  
(0.57-1.40) 
35/243 1.03  
(0.71-1.49) 
6.0-10.1 8/83 0.78  
(0.36-1.68) 
25/159 0.99  
(0.64-1.54) 
33/242 0.94  
(0.64-1.37) 
10.2-14.4 5/76 0.47  
(0.19-1.19) 
26/164 1.02  
(0.66-1.57) 
31/240 0.86  
(0.58-1.27) 
14.5+ 14/78 1.64  
(0.84-3.17) 
25/164 0.98  
(0.62-1.53) 
39/242 1.12  
(0.78-1.62) 
Total 
Flavones* 
      
0-0.03 7/61 1.00 32/180 1.00 39/241 1.00 
0.04-0.07 9/80 1.07  
(0.51-2.25) 
29/163 1.24  
(0.82-1.88) 
38/243 1.20 (0.83-
1.72) 
0.08-0.12 11/75 1.36  
(0.69-2.70) 
27/167 1.13  
(0.74-1.73) 
38/242 1.17  
(0.82-1.68) 
0.13-0.19 7/70 0.87  
(0.39-1.95) 
25/172 0.92  
(0.59-1.44) 
32/242 0.88  
(0.60-1.29) 
0.20+ 9/90 0.69  
(0.32-1.47) 
17/152 0.59  
(0.35-0.99) 
26/242 0.63  
(0.41-0.96) 
Total 
Flavanones* 
      
0-4.0 12/97 1.00 21/143 1.00 33/240 1.00 
4.1-16.3 8/84 0.80  
(0.37-1.73) 
28/156 1.49  
(0.97-2.29) 
36/240 1.25  
(0.86-1.81) 
16.4-29.9 6/67 0.75  
(0.32-1.78) 
19/176 0.60  
(0.37-0.98) 
25/243 0.64  
(0.42-0.97) 
30.0-48.5 9/74 1.04  
(0.50-2.17) 
30/172 1.13  
(0.75-1.71) 
39/246 1.10  
(0.77-1.57) 
48.6+ 8/54 1.08  32/187 0.99  40/241 1.03  
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(0.48-2.43) (0.66-1.49) (0.72-1.48) 
Total Flavan-3-ols*      
0-5.0 3/66 1.00 29/178 1.00 32/244 1.00 
5.1-34.4 8/84 0.80  
(0.37-1.74) 
22/158 0.88  
(0.56-1.39) 
30/242 0.83  
(0.56-1.23) 
34.5-140.0 12/78 1.42  
(0.73-2.77) 
26/164 1.01  
(0.66-1.56) 
38/242 1.12  
(0.78-1.61) 
140.1-263.7 7/79 0.72  
(0.32-1.63) 
29/162 1.21  
(0.80-1.83) 
36/241 1.10  
(0.76-1.59) 
263.8+ 13/69 1.76  
(0.91-3.42) 
24/172 0.84  
(0.53-1.32) 
37/241 1.01  
(0.70-1.46) 
Total Anthocyanidins*      
0-0.03 6/60 1.00 39/181 1.00 45/241 1.00 
0.04-0.40 16/86 2.12  
(1.14-3.93) 
28/158 1.18  
(0.77-1.79) 
44/244 1.42 (1.01-
2.00) 
0.41-1.60 10/70 1.33  
(0.66-2.71) 
25/178 0.92  
(0.59-1.42) 
35/248 1.00 (0.69-
1.45) 
1.61-4.23 4/81 0.36  
(0.13-1.01) 
20/157 0.74  
(0.46-1.19) 
24/238 0.62  
(0.40-0.95) 
4.24+ 7/79 0.62  
(0.27-1.40) 
18/160 0.66  
(0.40-1.08) 
25/239 0.64  
(0.42-0.98) 
Total 
Isoflavones* 
      
0-0.29 8/70 1.00 19/172 1.00 27/242 1.00 
0.30-0.78 7/58 1.10  
(0.49-2.48) 
43/185 1.58  
(1.09-2.30) 
50/243 1.49  
(1.07-2.08) 
0.79-2.34 9/69 1.23  
(0.59-2.56) 
25/175 0.89  
(0.58-1.38) 
34/244 0.96  
(0.66-1.39) 
2.35-7.47 10/88 0.93  
(0.46-1.90) 
31/152 1.59  
(1.06-2.38) 
41/240 1.36  
(0.96-1.94) 
7.48+ 9/91 0.71  
(0.34-1.48) 
12/150 0.44  
(0.24-0.81) 
21/241 0.52  
(0.33-0.82) 
Total 
Lignans* 
      
0-2.2 7/72 1.00 26/171 1.00 33/243 1.00 
2.3-3.9 5/72 0.60  
(0.24-1.53) 
28/170 1.09  
(0.72-1.65) 
33/242 0.96  
(0.65-1.40) 
4.0-5.9 14/82 1.69  
(0.89-3.21) 
25/162 0.98  
(0.63-1.51) 
39/244 1.14  
(0.80-1.63) 
6.0-8.9 6/77 0.61  
(0.26-1.45) 
26/163 0.96  
(0.62-1.48) 
32/240 0.88  
(0.60-1.30) 
9.0+ 11/73 1.27  
(0.63-2.54) 
25/168 0.98  
(0.63-1.54) 
36/241 1.03  
(0.71-1.49) 
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Table 4.3.  Age and energy-adjusted hazard ratios (HR) and 95% confidence intervals (CI) 
stratified by menopausal status for the association between flavonoid intake in relation to 
breast cancer-specific mortality.  
Variable 
(mg/day) 
Deaths/
Cohort 
# deaths/ 
367 
Pre-
menopausal 
HR  
(95% CI) 
Deaths/
Cohort 
# deaths/
781 
Post-
menopausal 
HR  
(95% CI) 
Deaths/ 
Cohort 
# deaths/ 
1,148 
Pre and Post 
HR  
(95% CI) 
Total 
Flavonoids* 
      
0-42.4 2/81 1.00 16/152 1.00 18/233 1.00 
42.5-95.0 13/70 2.88  
(1.44-5.78) 
16/164 0.97  
(0.56-1.68) 
29/234 1.37  
(0.90-2.10) 
95.1-216.2 5/78 0.61  
(0.24-1.58) 
14/148 0.90  
(0.51-1.61) 
19/226 0.81  
(0.49-1.32) 
216.3-340.4 4/73 0.50  
(0.18-1.42) 
21/156 1.40  
(0.84-2.33) 
25/229 1.10  
(0.70-1.73) 
340.5+ 10/65 1.75  
(0.82-3.72) 
12/161 0.62  
(0.33-1.16) 
22/226 0.88  
(0.55-1.42) 
Total 
Flavonols* 
      
0-3.4 4/58 1.00 17/171 1.00 21/229 1.00 
3.5-5.9 10/79 1.80  
(0.85-3.80) 
16/155 1.04  
(0.60-1.81) 
26/234 1.22  
(0.78-1.89) 
6.0-10.1 6/81 0.73  
(0.30-1.77) 
14/148 0.92  
(0.52-1.65) 
20/229 0.86  
(0.53-1.39) 
10.2-14.4 3/74 0.34  
(0.10-1.12) 
15/152 0.87  
(0.49-1.55) 
18/226 0.69  
(0.41-1.16) 
14.5+ 11/75 1.64  
(0.78-3.46) 
17/155 1.02  
(0.59-1.79) 
28/230 1.20  
(0.77-1.87) 
Total 
Flavones* 
      
0-0.03 4/58 1.00 16/163 1.00 20/221 1.00 
0.04-0.07 9/80 1.46  
(0.67-3.15) 
17/151 1.24  
(0.72-2.13) 
26/231 1.30  
(0.83-2.01) 
0.08-0.12 10/74 1.62  
(0.77-3.39) 
19/158 1.20  
(0.71-2.03) 
29/232 1.32  
(0.86-2.02) 
0.13-0.19 6/69 0.94  
(0.39-2.27) 
18/165 1.06  
(0.62-1.80) 
24/234 1.01  
(0.64-1.59) 
0.20+ 5/86 0.45  
(0.17-1.19) 
9/144 0.49  
(0.24-0.99) 
14/230 0.48  
(0.27-0.84) 
Total 
Flavanones* 
      
0-4.0 10/95 1.00 12/133 1.00 22/228 1.00 
4.1-16.3 7/83 0.89  
(0.39-2.05) 
19/146 1.52  
(0.89-2.61) 
26/229 1.27  
(0.81-1.99) 
16.4-29.9 6/67 0.97  
(0.40-2.35) 
9/166 0.47  
(0.23-0.94) 
15/233 0.60  
(0.35-1.03) 
30.0-48.5 7/72 1.03  
(0.45-2.38) 
19/161 1.21  
(0.72-2.03) 
26/233 1.15  
(0.74-1.78) 
48.6+ 4/50 0.61  20/175 1.09  24/225 0.98  
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(0.21-1.81) (0.65-1.82) (0.62-1.56) 
Total Flavan-3-ols*      
0-5.0 2/65 1.00 19/168 1.00 21/233 1.00 
5.1-34.4 6/82 0.76  
(0.31-1.85) 
13/149 0.83  
(0.46-1.50) 
19/231 0.78  
(0.48-1.28) 
34.5-140.0 11/77 1.75  
(0.85-3.60) 
14/152 0.90  
(0.50-1.60) 
25/229 1.14  
(0.73-1.78) 
140.1-263.7 5/77 0.63  
(0.24-1.63) 
21/153 1.46  
(0.88-2.43) 
26/230 1.19  
(0.76-1.86) 
263.8+ 10/66 1.75  
(0.83-3.69) 
12/159 0.63  
(0.34-1.18) 
22/225 0.89  
(0.55-1.43) 
Total Anthocyanidins*      
0-0.03 4/58 1.00 21/163 1.00 25/221 1.00 
0.04-0.40 11/81 1.80  
(0.88-3.69) 
15/145 1.05  
(0.60-1.85) 
26/226 1.28  
(0.82-1.98) 
0.41-1.60 8/68 1.33  
(0.60-2.95) 
21/173 1.27  
(0.76-2.12) 
29/241 1.30  
(0.85-1.99) 
1.61-4.23 4/81 0.46  
(0.16-1.31) 
11/148 0.65  
(0.35-1.24) 
15/229 0.58  
(0.34-1.00) 
4.24+ 7/79 0.81  
(0.35-1.89) 
11/152 0.62  
(0.33-1.18) 
18/231 0.68  
(0.41-1.13) 
Total 
Isoflavones* 
      
0-0.15 7/76 1.00 11/150 1.00 18/226 1.00 
0.16-0.26 5/71 0.96  
(0.40-2.35) 
21/165 1.02  
(0.59-1.78) 
26/236 0.99  
(0.62-1.59) 
0.27-0.37 8/67 1.69  
(0.79-3.62) 
15/159 0.99  
(0.57-1.72) 
23/226 1.17  
(0.75-1.83) 
0.38-0.59 8/71 0.48  
(0.17-1.36) 
24/158 1.08  
(0.63-1.84) 
32/229 0.86  
(0.54-1.39) 
0.60+ 6/82 1.03  
(0.46-2.28) 
8/149 0.79  
(0.43-1.44) 
14/231 0.87  
(0.54-1.41) 
Total 
Lignans* 
      
0-2.2 6/71 1.00 15/160 1.00 21/231 1.00 
2.3-3.9 4/71 0.60  
(0.21-1.71) 
18/160 1.17  
(0.69-1.98) 
22/231 0.99  
(0.62-1.57) 
4.0-5.9 12/80 1.92  
(0.95-3.89) 
16/153 1.04  
(0.60-1.80) 
28/233 1.28  
(0.84-1.97) 
6.0-8.9 4/75 0.50  
(0.18-1.42) 
15/151 0.88  
(0.49-1.57) 
19/226 0.76  
(0.46-1.26) 
9.0+ 8/70 1.16  
(0.52-2.58) 
15/157 0.87  
(0.49-1.55) 
23/227 0.95  
(0.60-1.51) 
 
 
 
 
Chapter V: DISCUSSION 
 
Summary 
    In the population-based case-control study of women in Nassau and Suffolk counties, New 
York, total flavonoid intake, including intake of flavonols, flavones, flavan-3-ols, and 
lignans, were associated with a reduced risk of developing breast cancer in post-menopausal 
women.  Among post-menopausal women with ER+PR+ tumors, similar risk reductions were 
observed.  Intake of flavanones and isoflavones were associated with a modest reduction in 
risk in pre-menopausal women. 
    In the follow-up study, among the post-menopausal breast cancer cases, intake of flavones 
and isoflavones at or just prior to diagnosis was associated with a subsequent reduced risk of 
all-cause mortality, and intake of flavones was associated with a reduced risk of breast cancer 
mortality.  Similar, but more modest reductions in mortality were observed for these 
flavonoid classes among pre-menopausal women.   
Study Strengths 
Biologic Plausibility of the Hypothesis 
   A biologic mechanism by which flavonoids may affect breast cancer development and 
progression is through an estrogenic pathway.  Endogenous hormones, particularly estrogens, 
are believed to play a significant role in the development of breast cancer, and serum levels 
differ substantially between pre- and post-menopausal women (169).  Flavonoids have 
demonstrated the ability to lower endogenous hormone levels in pre- (49, 502) and post-
menopausal women (503), inhibit transcriptional factors involved in cancer metastasis (504, 
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505), including vascular endothelial growth factor (VEGF), which is strongly associated with 
tumor angiogenesis (506).  Thus, it is biologically plausible that dietary intake of these 
compounds may affect breast cancer risk and survival. 
    In this study of dietary flavonoid intake on breast cancer risk and survival, beneficial 
effects of flavonoids were more pronounced among post-menopausal women.  The reasons 
for this heterogeneity by menopausal status are not entirely clear, but may due in part to their 
differences in the underlying levels of endogenous estrogen levels in part to their differences 
in the underlying levels of endogenous estrogen levels (or to other possible methodologically 
related considerations, which are discussed below).   
    Pre-menopausal women, for whom endogenous estrogen levels are very high, derive 
endogenous hormones primarily from ovarian hormone production and secondarily from 
conversion of androgens (testosterone and androstenedione) in adipose tissue.  With the 
cessation of ovarian function, post-menopausal women produce much less estrogen, and thus 
have much lower levels of endogenous estrogens compared to pre-menopausal women.  The 
lower levels of endogenous estrogens in post-menopausal women may be a reason why we 
observed a more dramatic reduction in breast cancer risk with increasing levels of flavonoid 
intake.  In post-menopausal women, flavonoids have less estrogen to compete with for 
binding to estrogen receptors and therefore have a greater ability to decrease breast cell 
proliferation and the risk of DNA mutation, both of which are necessary precursors for 
preventing breast cancer (112, 507).  The anti-estrogenic effects of flavonoids may be 
insufficient to influence the higher endogenous estrogen levels in pre-menopausal women, 
resulting in no evidence of an inverse association between flavonoids and breast cancer risk 
among this younger subgroup. 
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   Although flavones were the smallest contributor to total flavonoid intake in our study, they 
have the strongest inverse association with breast cancer risk and a strong inverse association 
with mortality among post-menopausal women.  With a mean intake of approximately 0.10 
mg per day, it is uncertain if this amount is sufficient to exert anti-carcinogenic effects.  
However, flavones are potent inhibitors of enzymes involved in estrogen metabolism, 
aromatase and 17 β-hydroxysteroid oxidoreductase (53, 508), and inhibitors of enzymes 
involved in carcinogenesis, including cyclooxygenase (509, 510).  The biological properties 
of this class of flavonoids, in addition to the consistency of our results with those reported in 
Greece (59) and Italy (60), provide evidence that flavone intake may be inversely related to 
breast cancer risk and mortality.          
Novelty of the Hypothesis 
    To date, very few studies (59, 60, 511) have addressed the impact of dietary flavonoid 
intake on risk of breast cancer.  Two of the studies (59, 60) focused solely on populations in 
Mediterranean countries.  One very recently published investigation was conducted in an in 
an American population (511), but only one class of flavonoids,  flavonols, were examined.  
Furthermore, prior to this dissertation, no published research had examined the association 
between flavonoid intake and breast cancer survival.  However, a very recent investigation 
conducted among women in Shanghai, China, examined the influence of only a single 
flavonoid class, isoflavones (497).   
Flavonoid Database        
    To estimate the flavonoid content of consumed food items, the two previous case-control 
studies, conducted in Greece (59) and Italy (60), relied on two sources: the USDA Database 
for the Flavonoid Content of Selected Foods and the USDA – Iowa State University 
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Database on the Isoflavone Content of Selected Foods.  For this dissertation, flavonoid 
content of food consumed by women on Long Island was estimated using these same 
databases that were further augmented to provide more comprehensive coverage of 
flavonoid-containing foods and beverages.  In particular, these enhancements included 
assessment of total flavonoids and lignans, neither of which were analyzed in the two 
previously conducted case-control studies.   
Sample Size and Source of Population 
    This study also had the advantage of a sufficiently large sample size (n = 2,874) with 
adequate power to detect an association between flavonoids and breast cancer risk and 
survival.  This sample size is slightly greater than that of the hospital-based Greek study (n = 
2,368), but smaller than the hospital-based Italian study (n = 5,157).  The population-based 
design of the LIBCSP, however, reduces selection bias and allows for greater generalizability 
of the results compared with the results from these two previously conducted hospital-based 
studies.   
Interview and Dietary Data 
    The comprehensive interview data for the LIBCSP case-control study provided an efficient 
opportunity to examine an important, yet unresolved question in breast cancer research.  The 
Block FFQ utilized in the LIBCSP is a validated, reliable dietary assessment tool for 
estimating usual food group intake and ranking individuals into categories of intake (375, 
383, 487).  The data from this dietary instrument indicated that the study population 
consumed a wide variety and significant amounts of flavonoid-containing products, including 
fruits, vegetables, and tea, enabling the specific aims of the dissertation to be addressed 
(457).   
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Measurement of All-Cause and Breast Cancer-Specific Mortality 
All-Cause Mortality 
    All-cause mortality reflects the number of women who died during the follow-up period, 
regardless of cause of death.  The reduced risk of all-cause mortality observed among post-
menopausal women consuming high levels of flavones and isoflavones is of public health 
importance; it indicates the potential for fruit, vegetable, and soy consumption to reduce 
mortality, regardless of cause of death, following breast cancer diagnosis.   
    This reduced risk raises the issue that flavonoids may be reducing the risk of mortality due 
to diseases other than breast cancer, including heart disease.  Thus, the hypothesized biologic 
effects of flavonoids may be more strongly related to other chronic diseases.  Of the 173 
deaths during the follow-up, 113 (65.3%) were due to breast cancer, and, the study results 
were similar for both all-cause mortality and breast cancer-specific mortality.  Thus, the 
reduced risk of all-cause mortality likely must reflect, in part, a reduction in breast cancer 
mortality.    
Breast Cancer-Specific Mortality 
    The assessment of breast cancer-specific mortality is of particular importance for the 
clinician and for researchers.  Clinicians are concerned with diagnosis and treatment of breast 
cancer as well as prognosis.  Identification of exposures which may affect the risk of 
mortality from breast cancer is important for advising breast cancer patients who are in the 
process of rehabilitation and recovery.  For the researcher, the findings for breast cancer-
specific mortality are important to advancing our scientific understanding of how these 
compounds may affect breast cancer progression, by elucidating the underlying biologic 
pathways.  For example, high levels of flavone intake among post-menopausal women were 
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associated with a reduced risk of breast cancer-specific mortality.  It is possible that flavones 
are interacting with endogenous estrogens and reducing their ability to stimulate breast cell 
proliferation and DNA mutation.  However, further research of flavones and post-
menopausal women needs to be conducted. 
 
Study Limitations 
Exposure Misclassification 
Dietary Recall in the Case-Control Study 
    One limitation of the case-control analysis was that breast cancer cases and controls could 
have differentially reported dietary intake because of the differences in their health status.  
For example, cases could have potentially attributed their breast cancer diagnosis to a poor 
diet.  In this instance, they could have overestimated their intake of seemingly unhealthy 
foods and beverages, resulting in relatively low estimates of flavonoid intake compared to 
estimates for controls.  This could have potentially caused large disparities in reported intake 
by cases as compared with the controls, and potentially overemphasized the benefits of 
flavonoids. 
    Alternatively, controls may have over-reported consumption of flavonoid-rich foods, such 
as fruits and vegetables, in an attempt to appear socially correct.  If this had occurred, it 
would have been expected that over-reporting would occur among all control women, 
regardless of menopausal status.  Post-menopausal controls tended to consume greater levels 
of total flavonoids and all flavonoid classes per day than did pre-menopausal controls.  
Possible explanations for this finding include the following, older women may have better 
diet recall ability than younger women, and, as the women in the study population grew 
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older, they became more health-conscious and their intake of flavonoid-rich foods steadily 
increased.  Furthermore, it would be expected that with increasing age, there is a greater 
likelihood that women will obtain routine medical examinations and screening tests, such as 
mammography.  It is plausible that post-menopausal women would therefore receive more 
health care and more advice, including dietary recommendations, than pre-menopausal 
women.  
    The food frequency questionnaire was self-completed by the respondent as part of the in-
home interview at the time of the case-control interview.  Both breast cancer cases and 
controls may have been influenced by the presence of the trained interviewer, resulting in the 
over-reporting of healthier diets.  This would have made the breast cancer cases and controls 
appear more homogeneous with respect to dietary intake and inhibited the ability to detect 
associations between flavonoids and breast cancer.  However, inverse associations were 
found for increasing intake of total flavonoids and most flavonoid classes and breast cancer 
risk among post-menopausal women.  However, the physical presence of the interviewer in 
the home at the time the FFQ was being completed by the respondent is likely to have 
improved the accuracy of reporting by both cases and controls, because any difficulties in 
completing the instrument could have been addressed immediately by the trained interviewer.   
Dietary Recall Error 
    Any study attempting to obtain dietary information from participants about events in the 
past may be subject to error.  Both breast cancer cases and controls were asked to recall their 
usual dietary intake in the previous 12 months.  However, it is difficult to remember exactly 
what one consumes over such a long period of time, resulting in an estimate, at best, of what 
products and how often those products were truly consumed.  Since this error in recalling diet 
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was likely present among all study subjects, the potential to misclassify both cases and 
controls within quintiles of flavonoid intake was equally probable.  In this case, non-
differential recall had an unpredictable effect on our results. 
Time Period of Dietary Assessment for the Case-Control Study 
    At the time of the baseline, case-control interview, which was conducted shortly after the 
initial breast cancer diagnosis, dietary intake was assessed for the year prior to interview.  
This baseline assessment was used for both the case-control and follow-up analyses reported 
here.  However, it is hypothesized that breast cancer is a result of an accumulation of 
exposures and changes within the body, which can take many years to develop before a 
diagnosis is made.  A person’s eating habits can change throughout life as certain products 
are added or deleted from the diet, or are increased or decreased in consumption.  Thus, 
assessing the 12-month period prior to breast cancer diagnosis may not be as relevant with 
regard to breast cancer development as assessing average lifetime consumption of flavonoids.  
However, the difficulty in recalling lifetime consumption is a problem that affects all 
epidemiologic research.  It is unknown how levels of flavonoid intake increased or decreased 
throughout each participant’s life.  Thus, it is uncertain if the estimated odds ratios and 
hazard ratios would be further from or closer to the null if this detailed consumption were 
estimated.   Further, the dietary assessment tools, such as the Block FFQ, are currently 
considered among the best available for these types of studies. 
Time Period of Dietary Assessment for the Follow-Up Study 
The diagnosis of breast cancer has been reported to influence subsequent dietary behavior, 
including increased fruit and vegetable intake (445-447).  In the analysis reported here, pre-
diagnosis flavonoid intake showed modest reductions for risk of mortality in the follow-up 
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study.  However, a more marked reduction may have been obscured if consumers of a low-
flavonoid diet prior to diagnosis had since increased their flavonoid intake and subsequently 
improved their prognosis. 
Alternatively, there has been concern expressed by some clinicians that use of 
multivitamins and supplements during treatment may inhibit treatment effectiveness.  Thus, 
if women with high intake of flavonoids at baseline continue this practice, it is possible that 
any beneficial effects for flavonoid use at non-treatment could have been attenuated.  Future 
studies would benefit from more careful assessment of post-diagnosis diet before, during, and 
after chemotherapy. 
Omission of Flavonoid-Rich Foods and Beverages on the Block FFQ 
    Though the Block FFQ was modified to include products such as tofu for the LIBCSP, 
other flavonoid-rich sources were omitted.  The omission of blueberries and raspberries, both 
rich in anthocyanidins (377), may have resulted in underestimation of anthocyanidin intake 
in these analyses.  Isoflavone intake may also have been underestimated as numerous soy 
products, including soy milk and meatless soy products, were not included on the FFQ.  
Although, the instrument was specifically modified to increase the number of food items 
containing isoflavones, these may not be the flavonoid-rich foods that are most commonly 
consumed by American women.   
Other Nutrients  
    Since flavonoids are present in fruits and vegetables, any association found between 
flavonoids and breast cancer may be due to other well-studied components in these products.  
In other words, the flavonoid and breast cancer association results may have been 
confounded by nutrients that are derived from common food sources.  However, assessments 
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of micronutrients including vitamin C, vitamin E, alpha and beta-carotene, lutein, and 
lycopene in the LIBCSP (48, 512) found no reduced risk of breast incidence or mortality.   
    Fiber, which is rich in fruits and vegetables, has been hypothesized to decrease breast 
cancer risk by inhibiting intestinal re-absorption of estrogens, resulting in lower circulating 
estrogen levels (112).  However, when the flavonoid and breast cancer incidence analysis 
was adjusted by fiber intake, the inverse associations remained (Table A.23).  Further, 
adjustment for fiber intake did not affect the association between flavonoid intake and breast 
cancer survival (Table A.24). 
    Though not a well-established risk or prognostic factor, inadequate folate intake may result 
in abnormal DNA synthesis and repair, potentially increasing the risk for breast cancer (112, 
513).  However, in unadjusted analyses of folate, no associations with breast cancer 
incidence and survival in the LIBCSP were observed. 
Serum Flavonoid Levels 
    Bioavailability of flavonoids varies widely among dietary sources (514). The polyphenols 
that are most well absorbed in the gut by humans are isoflavones, followed by flavan-3-ols, 
flavanones, and flavonols (514). The least well-absorbed flavonoids are the anthocyanidins 
(514).  Flavonoids are measured in the blood as well as urine (72).  Having serum or urinary 
biomarkers of flavonoid intake may have been useful to compare with estimates from the 
FFQ.  However, serum and urinary levels reflect short-term intake of flavonoids, usually 24 
hours to 1 week (515), whereas the FFQ  asks about intake in the 12 months prior to the 
interview.  Given that the biomarkers and the FFQ do not correspond to the same time frame, 
low correlations among the measures would be expected.  In addition, it is unknown whether 
the diagnosis of breast cancer, or the treatment for the disease, would alter the biomarker 
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levels of these compounds.  Thus, for estimating usual dietary intake of flavonoids in the 
prior year or more, the FFQ remains the most practical assessment tool. 
Classification of Flavonoids 
    For this analysis, all flavonoids were combined together to obtain a measure of total 
flavonoid intake.  However, it is possible that the different flavonoid classes may have 
different biological effects and thus, if true, it would be erroneous to combine them.  Little 
research, however, has focused on the flavonoid classes other than isoflavones.  Even among 
the isoflavones, there could be dual effects, both anti-estrogenic and endocrine disruptive.  
Until further research is done, usefulness of the total flavonoid intake measure is unclear. 
Covariate Misclassification 
Treatment Information 
    We attempted to obtain detailed information on the primary course of treatment, which 
was collected as part of the LIBCSP case-control and follow-up interviews, and was obtained 
as part of the medical record retrieval.  Most of the data was collapsed into dichotomous 
‘yes/no’ variables to enhance study power.  Therefore, the level of detail was not as fine as 
the data that is collected in a clinical trial, although it was comparable to what is often 
reported to the SEER registries.  However, the treatment data available did not prove to be an 
important confounder or effect modifier in these data.   
    In the follow-up study, case subjects were asked to recall treatment modalities undergone 
for the initial breast cancer diagnosis.  For cases that had died or were too ill to be 
interviewed, proxies were interviewed.  The recall of treatment by proxy respondents, 
however, may be less accurate than the recall of the cases themselves.  For respondents and 
their proxies who had provided written permission, medical records were retrieved and 
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abstracted.  A high concordance was found between treatment reported by respondents (cases 
and proxies) during the follow-up interview and the information abstracted from the medical 
record (radiation (98.5%), chemotherapy (98.3%), hormone therapy (96.4%)).  
Co-morbidities 
    Post-menopausal patients frequently have one or more pre-existing co-morbidities at the 
time of diagnosis (e.g. diabetes, hypertension, and heart disease) (516).  Prior research has 
found that co-morbidity is an independent predictor of survival among breast cancer patients 
(517-520).  More African-American breast cancer patients die from co-morbidities, including 
diabetes and hypertension, than Caucasian patients (520).  In our survival analysis, however, 
94% of the study population was Caucasian and only 4% was African-American.  Thus, we 
were unable to examine differences by race.  The main, case-control questionnaire had 
extensive assessment of medical history, which included history of hypertension and 
diabetes, as well as high cholesterol, myocardial infarction, and stroke.  When these factors 
were controlled for, the results from the survival analyses were not substantially altered 
(Table A.25). 
Lifestyle Factors 
    Many lifestyle factors that may confound the relationship between flavonoids and breast 
cancer are highly correlated with the exposure of interest (48, 484, 485), inhibiting the ability 
to firmly establish independent effects of flavonoids on breast cancer risk (486).  The main, 
case-control questionnaire had extensive assessment of exposures over the life course 
including recreational physical activity from menarche to age at diagnosis, lifetime active 
and passive smoking exposure, and lifetime alcohol consumption (48).  When these factors 
were controlled for mutually or individually, the results were not substantially altered.  
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Although, given that many of the lifestyle variables are difficult to measure in an 
epidemiologic study, and thus misclassification of these exposures is of concern, it is likely 
that there is some residual confounding present in the results shown.   
Social Support and Health Care Factors 
    Social support, quality of life, and other psychosocial factors have been demonstrated to 
impact survival (521).  The absence of this type of information in this study is another 
potential source of residual confounding.  Factors of concern include social support 
mechanisms, stress, complimentary and alternative medicine (CAM), and health care 
coverage.  It is believed that social support from family and friends, low stress, and adequate 
health care coverage improve quality of life and prolong survival (344, 521, 522).  Therefore, 
these factors may have played a role in reducing the risk of mortality among the post-
menopausal women of the LIBCSP, for whom high intakes of flavones and isoflavones 
appeared to be beneficial.   
    It is also possible that these support and health care factors motivated cases to improve the 
quality of their diet.  This may have led to an increase in flavonoid intake. Therefore, the 
intake assessed at the baseline, case-control interview may be an underestimate and the 
inverse associations observed among post-menopausal cases may be stronger than what are 
presented.  Furthermore, studies of social support and stress have reported weak, 
inconclusive results regarding survival (523-526).  Overall, social support appears to improve 
quality of life rather than quantity of life (523, 525, 526).  Thus, since these various social 
and health care factors do not appear to be strongly related to breast cancer survival, it is 
unlikely they confounded the association between dietary flavonoid intake and breast cancer 
survival.     
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Outcome Misclassification 
    The analysis on flavonoids and breast cancer survival may have had outcome 
misclassification if any deaths were not ascertained by the National Death Index (NDI).  
However, studies testing the effectiveness of the NDI (388-391) found the service to 
correctly identify the vital status of nearly 100% of all participants, distinguishing it as the 
“gold standard” of mortality ascertainment.   
Sample Size Considerations 
    Study power was adequate for both the case-control and case-only analyses that were 
conducted among all women and for those restricted to post-menopausal women.  However, 
power was reduced for our analyses that focused on pre-menopausal women only.  Thus, any 
differences we observed by menopausal status could be due to the imprecise and unstable 
estimates among the younger women.  Power would have been modestly improved if we 
were able to consider breast cancer recurrence as an outcome.   
Future Directions 
    The present study contributed to the understanding of an important modifiable lifestyle 
factor, dietary flavonoid intake, on breast cancer incidence and survival.  Flavonoid intake 
near the time of breast cancer diagnosis had never been evaluated among a large sample of 
American women.  Given the paucity of the evidence with regard to dietary flavonoid intake 
and breast cancer incidence and survival, more research is warranted to better understand 
these relationships. 
    To improve our understanding of the relationship between dietary flavonoid intake and 
breast cancer incidence and survival, future investigations should include sufficiently large 
sample sizes and comprehensive dietary assessment instruments.  In particular, food 
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frequency questionnaires and diet histories need to inquire about intake of as many 
flavonoid-containing foods and beverages as possible.  Items that are currently absent from 
some instruments which should be included are, berries (e.g., blueberries, raspberries, 
blackberries, and elderberries); soy foods and beverages, including meatless soy products, 
and non-traditional sources of soy (e.g., fast food hamburgers). 
    More relevant to breast cancer survival, it would be beneficial to improve measurement of 
co-morbidities, complimentary and alternative medicine, family and social support 
mechanisms, health insurance coverage, and stress.  Sufficiently long follow-up periods 
would also allow for both pre- and post-diagnosis dietary information to be collected.  It is 
unknown how dietary flavonoid intake changes over time among survivors and it is not 
established that increased intake improves prognosis.  Evaluating dietary patterns throughout 
a woman’s life (pre- and post-diagnosis) may help us better understand if there is a critical 
period for dietary flavonoid intake with regard to survival.   
    Most research to date addressing diet and breast cancer incidence has focused on fruits, 
vegetables, micronutrients, and fat.  While fruits and vegetables have been reported to 
decrease breast cancer risk, it remains unclear what components in these products are driving 
this effect.  If flavonoids are involved, then intake of products other than fruits and 
vegetables may also be beneficial in reducing risk, such as grains (i.e., bread and rice), nuts, 
soy, red wine, tea, coffee, and chocolate.  Fortification, already a common practice with 
many vitamins and minerals, may also be a method for adding flavonoid content to products 
available in the marketplace.   
    Further advancement into this area of research may help physicians and other health 
professionals recommend dietary behaviors that will provide more options to women for 
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reducing their risk of breast cancer and potentially improving the prognosis for those who 
already have been diagnosed with breast cancer.  Gaining a more precise knowledge of the 
role of dietary flavonoid intake on breast cancer incidence and survival may also help 
researchers better understand the mechanisms associated with breast cancer etiology and 
prognosis.     
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Table A.1.  Primary cause of death for invasive cases according to NDI records. 
  Number of Invasive Cases 1273 
Number of Deaths (%) 188 (14.8%) 
Cause of Death  
Breast Cancer 121 (64.4%) 
Other Causes  
     Lung Cancer 5 
     Other Cancer 17 
     Cardiovascular Disease 24 
     Other Causes 21 
     Total from Non-breast cancer causes 67 (35.6%) 
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Table A.2.  Distribution of flavonoid intake (mg/d) for cases and controls of the Long 
Island Breast Cancer Study Project 
Pre-menopausal Cases (n = 457) Pre-menopausal Controls (n = 487)  
Variable Mean (mg/d) Mean (mg/d) p-value† p-value* 
Total Flavonoids 211.12 212.19 0.94 0.53 
Flavonols 10.09 10.11 0.96 0.35 
Flavones 0.14 0.14 0.91 0.44 
Flavanones 25.60 27.13 0.44 0.54 
Flavan-3-ols 161.00 161.06 0.99 0.41 
Anthocyanidins 3.16 3.03 0.75 0.64 
Isoflavones 5.50 5.03 0.37 0.38 
Lignans 5.97 5.92 0.85 0.50 
Post-menopausal Cases (n = 977) Post-menopausal Controls (n = 953)  
Variable Mean (mg/d) Mean (mg/d) p-valuea p-valueb 
Total Flavonoids 220.74 242.66 0.02 0.02 
Flavonols 9.68 10.70 0.002 0.0003 
Flavones 0.13 0.15 0.0002 < 0.0001 
Flavanones 34.12 34.17 0.97 0.99 
Flavan-3-ols 163.29 182.68 0.03 0.009 
Anthocyanidins 3.14 3.66 0.17 0.02 
Isoflavones 4.58 4.86 0.46 0.69 
Lignans 6.01 6.62 0.005 0.002 
†P-value for t-test comparing means among pre-menopausal women 
aP-value for t-test comparing means among post-menopausal women 
*Wilcoxon rank sum test comparing medians among pre-menopausal women  
bWilcoxon rank sum test comparing medians among post-menopausal women 
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Table A.3.  Distribution of geometric means of flavonoid intake for cases and controls of 
the LIBCSP  
Pre-menopausal Cases (n = 457) Pre-menopausal Controls (n = 487)  
Variable Geometric 
Mean 
(mg/d) 
 Geometric 
Mean 
(mg/d) 
   p-value†
Total Flavonoids 121.51  113.55    0.39 
Flavonols 7.91  7.56    0.37 
Flavones 0.10  0.10    0.45 
Flavanones 16.29  16.68    0.78 
Flavan-3-ols 49.54  43.67    0.34 
Anthocyanidins 0.91  1.03    0.34 
Isoflavones 1.78  1.65    0.48 
Lignans 4.28  4.14    0.60 
Post-menopausal Cases (n = 977) Post-menopausal Controls (n = 953)  
Variable Geometric 
Mean 
(mg/d) 
 Geometric 
Mean 
(mg/d) 
   p-value*
Total Flavonoids 126.87  143.27    0.02 
Flavonols 7.08  8.16    0.001 
Flavones 0.09  0.10    0.003 
Flavanones 22.85  22.54    0.81 
Flavan-3-ols 42.81  55.46    0.007 
Anthocyanidins 0.90  1.03    0.16 
Isoflavones 1.29  1.35    0.56 
Lignans 4.31  4.77    0.02 
†P-value for t-test comparing geometric means among cases 
*P-value for t-test comparing geometric means among controls 
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Table A.4.  Foods and beverages included in each flavonoid class, listed according to flavonoid 
content (highest to lowest) 
Total 
Flavonols 
Total 
Flavones 
Total 
Flavanones 
Total 
Flavan- 
3-ols 
Total 
Antho-
cyanidins 
Total 
Isoflavones 
Total 
Lignans 
Mustard 
greens, turnip 
greens, 
collards, kale 
Spinach (raw) Grapefruit Tea, 
including 
herb tea  
(hot or iced) 
Cherries 
(fresh in 
season) 
Tofu Tea, 
including 
herb tea (hot 
or iced) 
Spinach (raw) Red or green 
peppers 
Oranges Chocolate 
candy 
Wine Low-fat, 
frozen tofu 
Strawberries 
(fresh in 
season) 
Broccoli Tomatoes, 
tomato juice, 
V-8 juice 
Orange 
Juice or 
Grapefruit 
Juice 
Cherries 
(fresh in 
season) 
 Green peas Whole-
wheat or 
other whole 
grain bread 
Tea, 
including 
herb tea (hot 
or iced) 
Cauliflower or 
brussel sprouts 
 Chocolate 
cake, 
brownies, 
cookies 
 Other beans 
(baked, pinto, 
kidney, lima, 
blackeyed, 
chili w/beans) 
Coffee, 
regular or 
decaf 
Hamburgers, 
Cheeseburger
s, meat loaf, 
tacos 
Green salad  Apples, 
applesauce, 
pears 
 Peanuts, 
peanut butter 
Broccoli 
Apples, 
applesauce, 
pears 
Hamburgers, 
cheeseburgers 
meat loaf, 
tacos 
 Wine  White bread, 
rye, 
pumpernickel 
bread, 
sandwiches, 
bagels 
Peanuts, 
peanut 
butter 
Green salad Cole slaw, 
cabbage, 
sauerkraut 
 Peaches, 
apricots 
(canned, 
frozen, or 
dried) 
 Whole-wheat 
or other whole 
grain bread 
Winter 
squash, 
baked 
squash 
String beans, 
green beans 
  Strawberries 
(fresh in 
season) 
 Cole slaw, 
cabbage, 
sauerkraut 
Carrots, or 
mixed 
vegetables 
containing 
carrots 
Strawberries 
(fresh in 
season) 
  Other beans 
(baked, 
pinto, 
kidney, 
lima, 
blackeyed, 
chili 
w/beans) 
 Other potatoes 
(boiled, baked, 
mashed, potato 
salad) 
Orange 
Juice or 
Grapefruit 
Juice 
Tomatoes, 
tomato juice, 
V-8 juice 
 
 Peaches, 
apricots 
(canned, 
frozen, or 
dried) 
 Brown Rice Brown Rice 
Cherries     White rice Sweet 
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(fresh in 
season) 
potatoes, 
yams 
Pizza      Grapefruit 
Spaghetti, 
lasagna, other 
pasta with 
tomato sauce 
     Hamburgers, 
Cheeseburge
rs, meat 
loaf, tacos 
Grapefruit      Red or green 
peppers 
Peaches, 
apricots 
(canned, 
frozen, or 
dried) 
     Cantaloupe 
Wine      Wine 
Cauliflower 
or brussel 
sprouts 
     Spaghetti, 
lasagna, 
other pasta 
with tomato 
sauce 
Red or green 
peppers 
     Pizza 
Tomato and 
vegetable 
soups 
     High fiber, 
bran or 
granola 
cereals 
Cole slaw, 
cabbage, 
sauerkraut 
     Green salad 
Green peas      Cauliflower 
or brussel 
sprouts 
Beer      String 
beans, green 
beans 
Other 
potatoes 
(boiled, 
baked, 
mashed, 
potato salad) 
     White bread, 
rye, 
pumpernick
el bread, 
sandwiches, 
bagels 
Orange Juice 
or Grapefruit 
Juice 
     Oranges 
Carrots, or 
mixed 
vegetables 
containing 
carrots 
     Bananas 
      Corn bread, 
corn 
muffins, 
corn tortillas 
      Tomatoes, 
tomato 
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juice, V-8 
juice 
      Other beans 
(baked, 
pinto, 
kidney, 
lima, 
blackeyed, 
chili 
w/beans) 
      Apples, 
applesauce, 
pears 
      Cole slaw, 
cabbage, 
sauerkraut 
      Corn, 
including 
corn on the 
cob 
      Alfalfa 
Sprouts 
      Other 
potatoes 
(boiled, 
baked, 
mashed, 
potato salad) 
      Green peas 
      White rice 
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Table A.5. Cases total flavonoid intake and class intake per day (in mg) by ER/PR 
status.  
 
Variable N Mean 
(mg/d) 
Median 
(mg/d) 
Minimum Maximum 
ER+PR+      
Total 
Flavonoids 
258 208.98 143.01 5.16 870.24 
Flavonols 258 9.37 7.67 0.41 33.01 
Flavones 258 0.14 0.10 0.00 0.74 
Flavanones 258 33.66 23.06 0.00 216.03 
Flavan-3-ols 258 150.52 106.33 0.14 652.10 
Anthocyanidins 258 3.78 0.87 0.00 69.79 
Isoflavones 258 1.06 0.31 0.00 53.76 
Lignans 258 5.68 4.66 0.10 19.81 
ER+PR-      
Total 
Flavonoids 
68  216.98 154.87 8.09 732.67 
Flavonols 68 10.30 9.85 0.83 29.01 
Flavones 68 0.13 0.10 0.01 0.58 
Flavanones 68 26.41 24.09 0.00 149.33 
Flavan-3-ols 68 164.52 115.57 0.12 646.87 
Anthocyanidins 68 4.74 0.74 0.00 93.13 
Isoflavones 68 0.71 0.32 0.03 7.25 
Lignans 68 4.84 6.38 0.33 19.45 
ER-PR+      
Total 
Flavonoids 
22 266.61 231.59 26.24 709.25 
Flavonols 22 11.59 10.20 1.96 27.05 
Flavones 22 0.14 0.13 0.01 0.37 
Flavanones 22 32.47 32.59 0.00 95.94 
Flavan-3-ols 22 205.97 193.42 3.07 645.49 
Anthocyanidins 22 3.51 2.20 0.00 11.17 
Isoflavones 22 0.85 0.35 0.03 7.30 
Lignans 22 6.86 6.23 0.34 19.16 
ER-PR-      
Total 
Flavonoids 
94 200.89 114.55 10.38 733.17 
Flavonols 94 8.95 6.47 0.67 28.93 
Flavones 94 0.12 0.10 0.00 0.57 
Flavanones 94 30.08 25.82 0.00 132.08 
Flavan-3-ols 94 149.29 52.81 0.00 654.60 
Anthocyanidins 94 3.55 0.90 0.00 93.59 
Isoflavones 94 0.78 0.31 0.03 14.69 
Lignans 94 5.56 4.19 0.17 17.27 
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Table A.6. Controls total flavonoid intake and class intake per day (in mg) by ER/PR 
status.  
Variable N Mean 
(mg/d) 
Median 
(mg/d) 
Minimum Maximum 
ER+PR+      
Total 
Flavonoids 
274 222.12 151.28 4.65 809.24 
Flavonols 274 10.21 9.26 0.79 33.02 
Flavones 274 0.16 0.13 0.00 1.03 
Flavanones 274 36.58 28.24 0.00 196.25 
Flavan-3-ols 274 161.26 111.54 0.19 664.33 
Anthocyanidins 274 3.16 0.75 0.00 52.92 
Isoflavones 274 0.73 0.30 0.03 25.81 
Lignans 274 5.98 4.83 0.10 17.08 
ER+PR-      
Total 
Flavonoids 
62 221.40 132.78 5.60 801.15 
Flavonols 62 10.17 7.91 0.70 37.74 
Flavones 62 0.15 0.13 0.00 0.62 
Flavanones 62 26.56 22.44 0.00 116.29 
Flavan-3-ols 62 170.53 69.99 0.35 654.20 
Anthocyanidins 62 3.48 0.70 0.00 78.80 
Isoflavones 62 0.91 0.36 0.02 23.44 
Lignans 62 6.31 4.90 0.08 20.30 
ER-PR+      
Total 
Flavonoids 
26 294.50 209.34 7.55 756.72 
Flavonols 26 12.72 8.63 1.80 35.12 
Flavones 26 0.14 0.11 0.01 0.34 
Flavanones 26 29.20 16.03 0.00 123.40 
Flavan-3-ols 26 236.38 116.47 2.17 650.91 
Anthocyanidins 26 3.67 0.80 0.00 22.11 
Isoflavones 26 0.81 0.38 0.10 7.02 
Lignans 26 7.99 5.55 0.61 18.58 
ER-PR-      
Total 
Flavonoids 
102 223.84 139.00 0.83 714.67 
Flavonols 102 10.55 7.50 0.39 27.00 
Flavones 102 0.15 0.13 0.00 0.86 
Flavanones 102 32.44 23.12 0.00 172.52 
Flavan-3-ols 102 165.62 59.55 0.09 644.73 
Anthocyanidins 102 4.02 0.73 0.00 69.82 
Isoflavones 102 0.76 0.31 0.01 11.63 
Lignans 102 6.31 4.74 0.04 18.49 
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Table A.7.  Case and control distribution for each quintiled flavonoid exposure stratified by 
menopausal status.* 
 Pre-menopausal 
(n=944) 
Post-menopausal 
(n=1,930) 
Total Flavonoids# Cases Controls Cases Controls 
0-44.6 99 124 197 160 
44.6-101.2 90 94 211 191 
101.2-230.2 101 91 192 198 
230.2-364.7 91 89 196 202 
364.7+ 76 89 181 202 
Total 457 487 977 953 
Total Flavonols#     
0-4.0 82 116 260 170 
4.0-6.4 101 99 168 187 
6.4-10.7 92 90 189 197 
10.7-16.2 98 91 196 197 
16.2+ 84 91 164 202 
Total 457 487 977 953 
Total Flavones#     
0-0.05 85 101 238 187 
0.05-0.09 94 107 204 182 
0.09-0.14 106 101 208 186 
0.14-0.22 84 84 182 204 
0.22+ 88 94 145 194 
Total 457 487 977 953 
Total Flavanones#     
0-4.5 123 107 176 177 
4.5-15.2 97 125 167 163 
15.2-30.0 80 95 209 191 
30.0-50.3 94 81 211 206 
50.3+ 63 79 214 216 
Total 457 487 977 953 
Total Flavan-3-ols#    
0-6.5 81 108 222 177 
6.5-39.5 99 108 185 177 
39.5-189.8 100 87 197 201 
189.8-267.9 97 96 204 195 
267.9+ 80 88 169 203 
Total 457 487 977 953 
Total Anthocyanidins#    
0-0.04 84 91 221 200 
0.04-0.56 109 103 216 179 
0.56-1.75 88 109 189 179 
1.75-4.57 86 97 172 194 
4.57+ 90 87 179 201 
Total 457 487 977 953 
Total Isoflavones#     
0-0.17 101 100 202 185 
0.17-0.26 80 95 184 198 
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0.26-0.38 93 99 211 185 
0.38-0.61 85 84 203 206 
0.61+ 98 109 177 179 
Total 457 487 977 953 
Total Lignans#     
0-2.3 88 118 213 173 
2.3-4.2 109 94 235 195 
4.2-6.2 86 103 171 175 
6.2-9.8 97 83 194 206 
9.8+ 77 89 164 204 
Total 457 487 977 953 
# In milligrams per day (mg/d). 
*29 cases and 60 controls missing data for menopausal status. 
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Table A.8. A summary of the preliminary evaluation of confounding and effect 
modification of flavonoids and breast cancer incidence by selected covariates.  
FLAVONOID EXPOSURES  Covariate Relationship 
between 
Covariate and 
Outcome 
(Incidence)? 
OR (95% CI) 
Relationship 
between 
covariate and 
Total 
Flavonoids? 
OR (95% CI) 
Evidence of 
Effect 
Measure 
Modification? 
p-value from 
Likelihood 
Ratio Test 
Does the OR 
for Total 
Flavonoids 
change by 
more than 
10% when 
Covariate is 
added to 
model? 
Menopausal Status Borderline YES YES No 
Age YES YES YES No 
Alcohol No No No No 
Smoking No No No No 
Family History  YES No No No 
BBD YES No No No 
Physical Activity Borderline YES No No 
BMI No No No No 
Income Borderline Borderline No No 
Education Borderline Borderline No No 
Parity YES Borderline No No 
Mammography YES Borderline No No 
OC Use No No No No 
Fruits Borderline YES No No 
Vegetables Borderline YES No No 
Antioxidants No YES No No 
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Table A.9.  Age and energy-adjusted ORs and 95% CIs for the association between 
menopausal-specific flavonoid intake in relation to breast cancer incidence  
 Pre-menopausal 
(n = 944) 
 Post-menopausal 
(n = 1930) 
 OR (95% CI)  OR (95% CI) 
Total Flavonoids#  Total Flavonoids#  
0-34.5 1.00 0-51.8 1.00 
34.5-84.5 1.20 (0.79-1.84) 51.8-119.1 0.94 (0.71-1.24) 
84.5-199.5 1.29 (0.84-1.97) 119.1-253.3 0.79 (0.60-1.05) 
199.5-343.0 1.46 (0.96-2.22) 253.3-377.2 0.80 (0.60-1.06) 
343.0+ 1.12 (0.72-1.74) 377.2+ 0.75 (0.56-1.01) 
P for trend* 0.95 P for trend* 0.05 
Total Flavonols#  Total Flavonols#  
0-3.7 1.00 0-4.3 1.00 
3.7-6.0 1.32 (0.86-2.03) 4.3-6.8 0.56 (0.42-0.74) 
6.0-10.2 1.48 (0.97-2.27) 6.8-11.1 0.62 (0.47-0.82) 
10.2-15.1 1.53 (0.99-2.35) 11.1-17.1 0.63 (0.47-0.83) 
15.1+ 1.38 (0.88-2.15) 17.1+ 0.54 (0.40-0.73) 
P for trend* 0.92 P for trend* 0.009 
Total Flavones#  Total Flavones#  
0-0.04 1.00 0-0.04 1.00 
0.05-0.07 0.94 (0.62-1.43) 0.05-0.08 0.90 (0.68-1.19) 
0.08-0.12 1.29 (0.86-1.84) 0.09-0.14 0.95 (0.72-1.26) 
0.13-0.21 1.07 (0.70-1.63) 0.15-0.21 0.70 (0.52-0.94) 
0.22+ 1.07 (0.70-1.65) 0.22+ 0.61 (0.45-0.83) 
P for trend* 0.94 P for trend* 0.0007 
Total Flavanones#  Total Flavanones#  
0-3.1 1.00 0-5.3 1.00 
3.2-10.8 0.69 (0.46-1.04) 5.4-18.8 1.09 (0.82-1.46) 
10.9-24.5 0.69 (0.46-1.04) 18.9-32.1 1.10 (0.83-1.46) 
24.6-40.3 0.85 (0.57-1.26) 32.2-54.2 1.08 (0.81-1.43) 
40.4+ 0.80 (0.53-1.21) 54.3+ 1.00 (0.75-1.34) 
P for trend* 0.34 P for trend* 0.87 
Total Flavan-3-ols# Total Flavan-3-ols# 
0-5.1 1.00 0-7.6 1.00 
5.2-26.4 1.22 (0.80-1.87) 7.7-54.0 0.94 (0.72-1.24) 
26.5-120.8 1.32 (0.87-2.01) 54.1-192.0 0.80 (0.60-1.06) 
120.9-264.1 1.52 (1.00-2.30) 192.1-277.9 0.82 (0.62-1.08) 
264.2+ 1.21 (0.78-1.86) 278.0+ 0.74 (0.55-0.99) 
P for trend* 0.87 P for trend* 0.06 
Total Anthocyanidins# Total Anthocyanidins# 
0-0.04 1.00 0-0.03 1.00 
0.05-0.56 1.15 (0.77-1.72) 0.04-0.56 1.09 (0.83-1.44) 
0.57-1.60 0.77 (0.50-1.17) 0.57-1.84 0.97 (0.73-1.28) 
1.61-4.19 1.07 (0.71-1.61) 1.85-4.84 0.82 (0.62-1.09) 
4.20+ 1.08 (0.71-1.63) 4.85+ 0.85 (0.64-1.14) 
P for trend* 0.81 P for trend* 0.23 
Total Isoflavones#  Total Isoflavones#  
0-0.31 1.00 0-0.27 1.00 
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0.32-1.10 1.03 (0.68-1.56) 0.28-0.62 0.97 (0.72-1.30) 
1.11-3.17 0.98 (0.65-1.47) 0.63-1.94 1.16 (0.87-1.55) 
3.18-7.62 0.88 (0.58-1.33) 1.95-7.63 1.14 (0.85-1.53) 
7.63+ 1.14 (0.76-1.72) 7.64+ 1.02 (0.76-1.38) 
P for trend* 0.56 P for trend* 0.72 
Total Lignans#  Total Lignans#  
0-2.0 1.00 0-2.4 1.00 
2.1-4.0 1.43 (0.95-2.17) 2.5-4.2 1.07 (0.81-1.40) 
4.1-5.4 0.98 (0.63-1.51) 4.3-6.4 0.82 (0.61-1.09) 
5.5-9.3 1.62 (1.07-2.45) 6.5-10.2 0.79 (0.59-1.05) 
9.4+ 1.24 (0.81-1.92) 10.3+ 0.69 (0.51-0.94) 
P for trend* 0.72 P for trend* 0.01 
* P for trend for continuous variable. 
# In milligrams per day (mg/d). 
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Table A.10.  Age and energy-adjusted ORs and 95% CI for the association between flavonoid 
intake and breast cancer incidence among post-menopausal women, stratified by ER/PR status 
 Controls ER+PR+  ER+PR-, ER-PR+, ER-PR- 
 (n = 953) Cases (n)
(n = 378) 
OR (95% CI) Cases (n)
(n = 274) 
OR (95% CI) 
Total Flavonoids#     
0-51.7 190 89 1.00 72 1.00 
51.8-119.0 192 78 0.90 (0.62-1.31) 62 0.89 (0.59-1.32) 
119.1-253.2 190 72 0.83 (0.57-1.21) 42 0.60 (0.39-0.93) 
253.3-377.1 191 77 0.86 (0.59-1.25) 49 0.68 (0.44-1.04) 
377.2+ 190 62 0.75 (0.50-1.12) 49 0.72 (0.47-1.11) 
P for trend*   0.35  0.09 
Total Flavonols#     
0-4.2 191 113 1.00 93 1.00 
4.3-6.7 190 66 0.59 (0.41-0.86) 47 0.51 (0.34-0.78) 
6.8-11.0 190 67 0.60 (0.41-0.87) 42 0.46 (0.30-0.71) 
11.1-17.0 191 74 0.66 (0.46-0.96) 46 0.49 (0.32-0.75) 
17.1+ 191 58 0.55 (0.37-0.82) 56 0.51 (0.33-0.79) 
P for trend*   0.12  0.03 
Total Flavones#      
0-0.04 191 101 1.00 69 1.00 
0.05-0.08 190 74 0.76 (0.52-1.10) 72 1.05 (0.71-1.56) 
0.09-0.14 191 85 0.89 (0.62-1.29) 55 0.83 (0.54-1.26) 
0.15-0.21 191 61 0.64 (0.43-0.94) 44 0.67 (0.43-1.04) 
0.22+ 190 57 0.59 (0.40-0.89) 34 0.51 (0.32-0.82) 
P for trend*   0.02  0.003 
Total Flavanones#     
0-5.3 190 70 1.00 50 1.00 
5.4-18.8 192 77 1.18 (0.80-1.74) 52 1.05 (0.68-1.63) 
18.9-32.1 189 84 1.21 (0.83-1.78) 61 1.20 (0.78-1.84) 
32.2-54.2 191 80 1.14 (0.77-1.67) 58 1.16 (0.75-1.80) 
54.3+ 191 67 0.95 (0.63-1.42) 53 1.06 (0.68-1.66) 
P for trend*   0.77  0.49 
Total Flavan-3-ols#     
0-7.6 190 93 1.00 71 1.00 
7.7-54.0 192 75 0.81 (0.56-1.18) 62 0.88 (0.59-1.31) 
54.1-192.0 189 65 0.71 (0.49-1.04) 48 0.69 (0.45-1.05) 
192.1-277.9 192 81 0.86 (0.60-1.24) 48 0.66 (0.43-1.02) 
278.0+ 190 64 0.75 (0.51-1.10) 45 0.67 (0.43-1.03) 
P for trend*   0.45  0.13 
Total Anthocyanidins#     
0-0.03 189 77 1.00 58 1.00 
0.04-0.56 192 88 1.19 (0.82-1.73) 70 1.22 (0.81-1.84) 
0.57-1.84 190 88 1.25 (0.86-1.81) 44 0.80 (0.51-1.24) 
1.85-4.84 191 69 0.93 (0.63-1.37) 50 0.90 (0.59-1.39) 
4.85+ 191 56 0.77 (0.51-1.16) 52 0.95 (0.62-1.46) 
P for trend*   0.005  0.63 
Total Isoflavones#     
0-0.27 190 82 1.00 55 1.00 
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0.28-0.62 191 63 0.78 (0.52-1.17) 64 1.19 (0.78-1.83) 
0.63-1.94 191 81 1.09 (0.75-1.60) 50 0.98 (0.62-1.52) 
1.95-7.63 191 88 1.21 (0.83-1.77) 58 1.16 (0.75-1.80) 
7.64+ 190 64 0.92 (0.61-1.37) 47 1.00 (0.63-1.58) 
P for trend*   0.91  0.48 
Total Lignans#      
0-2.4 215 89 1.00 72 1.00 
2.5-4.2 167 81 1.09 (0.76-1.58) 68 1.07 (0.72-1.59) 
4.3-6.4 190 76 0.96 (0.66-1.40) 48 0.74 (0.48-1.14) 
6.5-10.2 191 71 0.89 (0.60-1.30) 43 0.64 (0.41-0.99) 
10.3+ 190 61 0.82 (0.55-1.24) 43 0.67 (0.43-1.05) 
P for trend*   0.35  0.02 
*P for trend for continuous variable. 
# In milligrams per day (mg/d). 
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Table A.11.  Age, fruit, fruit juice, vegetable, antioxidant, and energy-adjusted odds ratios (OR) 
and 95% confidence intervals (CI) stratified by menopausal status for the association between 
flavonoid intake in relation to breast cancer incidence.  
 Pre-menopausal Post-menopausal Pre- and Post-menopausal 
 OR (95% CI) OR (95% CI) OR (95% CI) 
Total Flavonoids#    
0-44.6 1.00 1.00 1.00 
44.6-101.2 1.24 (0.81-1.89) 0.92 (0.68-1.25) 1.04 (0.82-1.33) 
101.2-230.2 1.38 (0.90-2.10) 0.80 (0.59-1.09) 1.02 (0.80-1.30) 
230.2-364.7 1.34 (0.88-2.04) 0.80 (0.59-1.08) 0.99 (0.78-1.25) 
364.7+ 1.10 (0.71-1.72) 0.77 (0.56-1.05) 0.91 (0.71-1.17) 
P for trend* 0.91 0.06 0.17 
Total Flavonols#    
0-4.0 1.00 1.00 1.00 
4.0-6.4 1.43 (0.94-2.19) 0.63 (0.47-0.84) 0.83 (0.66-1.05) 
6.4-10.7 1.39 (0.89-2.16) 0.70 (0.52-0.94) 0.88 (0.69-1.12) 
10.7-16.2 1.51 (0.97-2.36) 0.71 (0.53-0.96) 0.93 (0.73-1.18) 
16.2+ 1.30 (0.82-2.05) 0.58 (0.43-0.80) 0.79 (0.61-1.01) 
P for trend* 0.66 0.06 0.13 
Total Flavones#    
0-0.05 1.00 1.00 1.00 
0.05-0.09 0.92 (0.61-1.40) 0.94 (0.70-1.25) 0.94 (0.75-1.19) 
0.09-0.14 0.98 (0.63-1.52) 1.00 (0.73-1.36) 1.00 (0.78-1.29) 
0.14-0.22 0.78 (0.47-1.29) 0.84 (0.59-1.19) 0.84 (0.64-1.12) 
0.22+ 0.60 (0.33-1.08) 0.74 (0.49-1.12) 0.74 (0.53-1.03) 
P for trend* 0.04 0.19 0.06 
Total Flavanones#    
0-4.5 1.00 1.00 1.00 
4.5-15.2 0.66 (0.44-0.97) 1.05 (0.77-1.44) 0.90 (0.71-1.14) 
15.2-30.0 0.74 (0.44-1.23) 1.09 (0.77-1.54) 0.96 (0.73-1.27) 
30.0-50.3 1.00 (0.54-1.83) 1.06 (0.71-1.58) 1.07 (0.77-1.48) 
50.3+ 0.72 (0.34-1.54) 1.06 (0.66-1.69) 1.01 (0.68-1.49) 
P for trend* 0.53 0.66 0.75 
Total Flavan-3-ols#   
0-6.5 1.00 1.00 1.00 
6.5-39.5 1.18 (0.78-1.78) 0.86 (0.65-1.16) 0.97 (0.77-1.22) 
39.5-189.8 1.51 (0.99-2.30) 0.79 (0.60-1.05) 1.00 (0.79-1.25) 
189.8-267.9 1.33 (0.88-2.02) 0.84 (0.63-1.11) 1.01 (0.80-1.27) 
267.9+ 1.22 (0.79-1.89) 0.70 (0.52-0.94) 0.86 (0.68-1.09) 
P for trend* 0.97 0.06 0.17 
Total Anthocyanidins#   
0-0.04 1.00 1.00 1.00 
0.04-0.56 1.12 (0.74-1.69) 1.10 (0.83-1.46) 1.09 (0.87-1.37) 
0.56-1.75 0.80 (0.52-1.21) 1.02 (0.76-1.35) 0.96 (0.76-1.20) 
1.75-4.57 0.88 (0.57-1.35) 0.86 (0.65-1.15) 0.88 (0.70-1.12) 
4.57+ 0.95 (0.61-1.48) 0.89 (0.67-1.19) 0.93 (0.74-1.18) 
P for trend* 0.84 0.47 0.43 
Total Isoflavones#    
0-0.17 1.00 1.00 1.00 
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0.17-0.26 0.79 (0.51-1.20) 0.93 (0.69-1.24) 0.88 (0.69-1.11) 
0.26-0.38 0.87 (0.57-1.32) 1.13 (0.84-1.53) 1.01 (0.80-1.28) 
0.38-0.61 0.91 (0.59-1.43) 1.02 (0.75-1.39) 0.98 (0.77-1.26) 
0.61+ 0.79 (0.51-1.22) 1.10 (0.79-1.53) 1.00 (0.78-1.30) 
P for trend* 0.62 0.56 0.19 
Total Lignans#    
0-2.3 1.00 1.00 1.00 
2.3-4.2 1.52 (1.02-2.26) 0.98 (0.74-1.30) 1.14 (0.91-1.43) 
4.2-6.2 1.09 (0.72-1.65) 0.80 (0.59-1.08) 0.87 (0.69-1.10) 
6.2-9.8 1.57 (1.03-2.39) 0.77 (0.57-1.03) 0.99 (0.79-1.25) 
9.8+ 1.16 (0.76-1.78) 0.67 (0.49-0.91) 0.82 (0.65-1.05) 
P for trend* 0.92 0.01 0.07 
# In milligrams per day (mg/d). 
* P for trend for continuous variable. 
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Table A.12. Age and energy-adjusted odds ratios (OR) and 95% confidence intervals (CI) stratified by 
ER/PR status for the association between flavonoid intake and breast cancer incidence among post-
menopausal women. 
Variable Controls ER+ 
PR+ 
 ER+ 
PR- 
 ER-
PR+ 
 ER- 
PR- 
 
 (n = 953) Cases 
(n) 
(n=378) 
OR 
(95%
CI) 
Cases 
(n) 
(n=117) 
OR  
(95%
CI) 
Cases 
(n) 
(n=29) 
OR 
(95% 
CI) 
Cases 
(n) 
(n=128) 
OR  
(95%  
CI) 
Total Flavonoids*         
0 - 230.2 549 228 1.00 75 1.00 16 1.00 82 1.00 
230.2+ 404 150 0.91 
(0.71-
1.17) 
42 0.74 
(0.49-
1.11) 
13 1.02 
(0.48-
2.18) 
46 0.82  
(0.56- 
1.22) 
P for 
trend# 
  0.32  0.18  0.58  0.08 
Total 
Flavonol
s* 
         
0 - 10.7 554 240 1.00 77 1.00 15 1.00 85 1.00 
10.7+ 399 138 0.84 
(0.65-
1.08) 
40 0.70 
(0.46-
1.07) 
14 1.16 
(0.54-
2.50) 
43 0.77  
(0.51- 
1.15) 
P for 
trend# 
  0.11  0.03  0.39  0.04 
Total 
Flavones
* 
         
0 - 0.14 555 252 1.00 79 1.00 16 1.00 95 1.00 
0.14+ 398 126 0.72 
(0.56-
0.94) 
38 0.68 
(0.45-
1.04) 
13 1.02 
(0.48-
2.17) 
33 0.52 (0.34-
0.80) 
P for 
trend# 
  0.02  0.006  0.52  0.01 
Total Flavanones*         
0 – 30.0 531 218 1.00 60 1.00 16 1.00 77 1.00 
30.0+ 422 160 0.89 
(0.69-
1.14) 
57 1.12 
(0.75-
1.66) 
13 0.99 
(0.46-
2.13) 
51 0.88  
(0.60- 
1.31) 
P for 
trend# 
  0.75  0.55  0.27  0.22 
Total Flavan-3-ols*         
0 – 189.8 555 228 1.00 76 1.00 16 1.00 81 1.00 
189.8+ 398 150 0.94 
(0.73-
1.21) 
41 0.72 
(0.48-
2.10) 
13 1.06 
(0.50-
2.25) 
47 0.87 
(0.59- 
1.29) 
P for 
trend# 
  0.41  0.14  0.47  0.16 
Total 
Anthocyanidins* 
        
0 – 1.75 558 248 1.00 75 1.00 15 1.00 82 1.00 
1.75+ 395 130 0.75 
(0.58-
0.96) 
42 0.81 
(0.54-
1.22) 
14 1.28 
(0.61-
2.68) 
46 0.83  
(0.56- 
1.22) 
P for   0.005  0.36  0.55  0.11 
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trend# 
Total Isoflavones*         
0 – 0.38 568 235 1.00 71 1.00 14 1.00 81 1.00 
0.38+ 385 143 0.96 
(0.73-
1.25) 
46 0.98 
(0.64-
1.51) 
15 1.37 
(0.62-
3.04) 
47 0.98  
(0.65- 
1.48) 
P for 
trend# 
  1.00  0.74  0.06  0.58 
Total 
Lignans* 
         
0 – 6.2 543 235 1.00 79 1.00 16 1.00 85 1.00 
6.2+ 410 143 0.83 
(0.65-
1.07) 
38 0.62 
(0.41-
0.94) 
13 0.99 
(0.46-
2.10) 
43 0.72  
(0.48- 
1.07) 
P for 
trend# 
  0.32  0.05  0.55  0.02 
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Table A.13. Age and energy-adjusted odds ratios (OR) and 95% confidence intervals (CI) for 
the association between flavonoid intake and breast cancer incidence among post-menopausal 
women, stratified by ER/PR. 
 Controls ER+PR+, ER+PR-, ER-PR+ ER-PR-  
 (n = 953) Cases (n)
(n = 524) 
OR (95% CI) Cases (n)
(n = 128) 
OR (95% CI) 
Total Flavonoids#     
0-44.6 160 107 1.00 32 1.00 
44.6-101.2 191 111 1.09 (0.83-1.42) 29 1.18 (0.76-1.85) 
101.2-230.2 198 101 0.89 (0.68-1.16) 21 0.75 (0.46-1.23) 
230.2-364.7 202 104 0.89 (0.68-1.16) 27 1.03 (0.65-1.63) 
364.7+ 202 101 0.95 (0.72-1.25) 19 0.70 (0.42-1.19) 
P for trend*   0.28  0.09 
Total Flavonols#     
0-4.0 170 144 1.00 39 1.00 
4.0-6.4 187 97 0.92 (0.70-1.21) 21 0.79 (0.48-1.30) 
6.4-10.7 197 91 0.82 (0.62-1.08) 25 0.96 (0.60-1.54) 
10.7-16.2 197 101 0.90 (0.69-1.18) 24 0.95 (0.59-1.53) 
16.2+ 202 91 0.84 (0.63-1.12) 19 0.70 (0.42-1.19) 
P for trend*   0.07  0.05 
Total Flavones#      
0-0.05 187 137 1.00 33 1.00 
0.05-0.09 182 110 1.13 (0.86-1.47) 30 1.28 (0.82-1.99) 
0.09-0.14 186 100 0.99 (0.76-1.30) 32 1.39 (0.90-2.15) 
0.14-0.22 204 96 0.85 (0.65-1.12) 22 0.81 (0.50-1.33) 
0.22+ 194 81 0.72 (0.54-0.97) 11 0.40 (0.21-0.76) 
P for trend*   0.01  0.01 
Total Flavanones#     
0-4.5 177 89 1.00 24 1.00 
4.5-15.2 163 87 1.04 (0.78-1.39) 25 1.16 (0.72-1.87) 
15.2-30.0 191 118 1.14 (0.88-1.48) 28 1.11 (0.71-1.74) 
30.0-50.3 206 117 1.02 (0.79-1.32) 25 0.90 (0.57-1.44) 
50.3+ 216 113 0.91 (0.70-1.18) 26 0.93 (0.58-1.49) 
P for trend*   0.86  0.23 
Total Flavan-3-ols#     
0-6.5 177 133 1.00 28 1.00 
6.5-39.5 177 87 0.87 (0.65-1.15) 30 1.34 (0.86-2.08) 
39.5-189.8 201 100 0.87 (0.67-1.14) 23 0.81 (0.50-1.31) 
189.8-267.9 195 110 1.00 (0.76-1.30) 28 1.12 (0.71-1.76) 
267.9+ 203 94 0.86 (0.65-1.14) 19 0.70 (0.41-1.17) 
P for trend*   0.34  0.16 
Total Anthocyanidins#     
0-0.04 200 108 1.00 33 1.00 
0.04-0.56 179 121 1.28 (0.98-1.67) 31 1.37 (0.88-2.13) 
0.56-1.75 179 109 1.18 (0.90-1.54) 18 0.71 (0.42-1.20) 
1.75-4.57 194 99 0.92 (0.70-1.21) 22 0.82 (0.50-1.33) 
4.57+ 201 87 0.75 (0.57-0.99) 24 0.92 (0.57-1.49) 
P for trend*   0.09  0.10 
Total Isoflavones#     
 182
0-0.17 185 105 1.00 26 1.00 
0.17-0.26 198 108 0.99 (0.76-1.30) 20 0.70 (0.42-1.16) 
0.26-0.38 185 107 1.03 (0.79-1.35) 35 1.60 (1.05-2.45) 
0.38-0.61 206 109 0.96 (0.73-1.26) 28 1.10 (0.70-1.74) 
0.61+ 179 95 1.03 (0.77-1.37) 19 0.86 (0.50-1.47) 
P for trend*   0.53  0.56 
Total Lignans#      
0-2.3 173 110 1.00 33 1.00 
2.3-4.2 195 124 1.17 (0.90-1.51) 31 1.20 (0.77-1.86) 
4.2-6.2 175 96 1.02 (0.77-1.35) 21 0.92 (0.56-1.52) 
6.2-9.8 206 99 0.83 (0.63-1.09) 27 1.00 (0.63-1.58) 
9.8+ 204 95 0.87 (0.66-1.15) 16 0.57 (0.32-0.99) 
P for trend*   0.19  0.03 
* P for trend for continuous variable. 
# In milligrams per day (mg/d). 
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Table A.14.  Number and percentage of eligible invasive breast cancer cases for each categorical 
characteristic included in the LIBCSP follow-up study. 
Characteristic N (%) 
(n = 1,273) 
Characteristic N (%) 
Race  Alcohol Use  
White 1191 (93.8%)  Never 498 (39.1%) 
Black 57 (4.5%) Ever 775 (60.9%) 
Other 22 (1.7%)   
Missing 3 Family History of BC 255 (20.7%) 
  Missing 39 
Estrogen Receptor Status    
Negative 255 (26.8%) Education  
Positive 695 (73.2%) Less than High School 171 (13.5%) 
Missing 323 High School Graduate 456 (36.0%) 
  Some College 302 (23.8%) 
Progesterone Receptor Status  College Graduate 157 (12.4%) 
Negative 341 (36.0%) Post-college Education 182 (14.3%) 
Positive 605 (64.0%) Missing 5 
Missing 327   
  Household Income/yr.  
Age at Diagnosis (years)  Less than $15,000 103 (9.4%) 
< 35 36 (2.8%) $15,000-$19,999 59 (5.4%) 
35-39 38 (3.0%) $20,000-$24,999 68 (6.2%) 
40-44 109 (8.6%) $25,.000-$34,999 161 (14.7%) 
45-50 192 (15.1%) $35,000-$49,999 169 (15.4%) 
≥ 51 898 (70.5%) $50,000-$69,999 158 (14.4%) 
  $70,000-$89,999 140 (12.8%) 
Menopausal Status  $90,000 or more 237 (21.7%) 
Pre-menopausal 387 (31.0%) Missing 178 
Post-menopausal 861 (69.0%)   
Missing 25 Any Chemotherapy 
Prior to Interview 
418 (48.7%) 
  Missing 415 
Nulliparous 165 (13.0%)   
  Any Radiation 
Therapy Prior to 
Interview 
563 (65.4%) 
Ever Breastfed 388 (31.4%) Missing 412 
    
Age at menarche: < 12 years 338 (26.6%) Ever Married 1222 (96.1%) 
    
Ever Used Oral Contraceptives 541 (42.6%)   
    
Ever Smoker    
Never 568 (44.6%)   
Past/Former 453 (35.6%)   
Current 252 (19.8%)   
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Table A.15.  Number and percentage of invasive breast cancer cases for each categorical 
characteristic included in the LIBCSP follow-up study. 
Characteristic N (%) 
(n = 1,210) 
Characteristic N (%) 
Race  Alcohol Use  
White 1138 (94.1%)  Never 466 (38.5%) 
Black 50 (4.2%) Ever 744 (61.5%) 
Other 21 (1.7%)   
Missing 1 Family History of BC 239 (20.4%) 
  Missing 37 
Estrogen Receptor Status    
Negative 242 (26.6%) Education  
Positive 668 (73.4%) Less than High School 161 (13.3%) 
Missing 300 High School Graduate 439 (36.4%) 
  Some College 283 (23.5%) 
Progesterone Receptor Status  College Graduate 159 (12.3%) 
Negative 324 (35.8%) Post-college Education 175 (14.5%) 
Positive 582 (64.2%) Missing 3 
Missing 304   
  Household Income/yr.  
Age at Diagnosis (years)  Less than $15,000 95 (9.1%) 
< 35 35 (2.9%) $15,000-$19,999 56 (5.4%) 
35-39 36 (3.0%) $20,000-$24,999 64 (6.1%) 
40-44 143 (11.8%) $25,.000-$34,999 154 (14.8%) 
45-50 141 (11.7%) $35,000-$49,999 160 (15.3%) 
≥ 51 855 (70.6%) $50,000-$69,999 155 (14.9%) 
  $70,000-$89,999 135 (13.0%) 
Menopausal Status  $90,000 or more 223 (21.4%) 
Pre-menopausal 376 (31.1%) Missing 168 
Post-menopausal 834 (68.9%)   
  Any Chemotherapy 
Prior to Interview 
424 (51.5%) 
Nulliparous 154 (12.7%) Missing 387 
    
Ever Breastfed 381 (31.5%) Any Radiation 
Therapy Prior to 
Interview 
539 (65.3%) 
  Missing 384 
Age at menarche: < 12 years 310 (25.6%)   
  Ever Married 1165 (96.4%) 
Ever Used Oral Contraceptives 515 (42.6%)   
Missing 2 
  
  
Ever Smoker    
Never 541 (44.7%)   
Past/Former 435 (36.0%)   
Current 234 (19.3%)   
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Table A.16.  Invasive case distribution for each quintile of flavonoid exposure stratified by 
menopausal status.  
Variable Pre-menopausal 
(n=376) 
Post-menopausal 
(n=834) 
Pre- and Post-menopausal 
(n=1,210) 
 Cases Cases Cases 
Total Flavonoids*    
0-42.5 82 161 243 
42.5-95.1 72 171 243 
95.1-216.3 79 162 241 
216.3-340.5 75 168 243 
340.5+ 68 172 240 
Total 376 834 1210 
Total Flavonols*    
0-3.5 58 185 243 
3.5-6.0 81 162 243 
6.0-10.2 83 159 242 
10.2-14.5 76 164 240 
14.5+ 78 164 242 
Total 376 834 1210 
Total Flavones*    
0-0.04 61 180 241 
0.04-0.08 80 163 243 
0.08-0.13 75 167 242 
0.13-0.20 70 172 242 
0.20+ 90 152 242 
Total 376 834 1210 
Total Flavanones*    
0-4.1 97 143 240 
4.1-16.4 84 156 240 
16.4-30.0 67 176 243 
30.0-48.6 74 172 246 
48.6+ 54 187 241 
Total 376 834 1210 
Total Flavan-3-ols*   
0-5.1 66 178 244 
5.1-34.5 84 158 242 
34.5-140.1 78 164 242 
140.1-263.8 79 162 241 
263.8+ 69 172 241 
Total 376 834 1210 
Total Anthocyanidins*   
0-0.04 60 181 241 
0.04-0.41 86 158 244 
0.41-1.61 70 178 248 
1.61-4.24 81 157 238 
4.24+ 79 160 239 
Total 376 834 1210 
Total Isoflavones*    
0-0.16 78 160 238 
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0.16-0.27 71 172 243 
0.27-0.38 70 175 245 
0.38-0.60 72 172 244 
0.60+ 85 155 240 
Total 376 834 1210 
Total Lignans*    
0-2.3 72 171 243 
2.3-4.0 72 170 242 
4.0-6.0 82 162 244 
6.0-9.0 77 163 240 
9.0+ 83 168 241 
Total 376 834 1210 
* In milligrams per day (mg/d). 
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Table A.17.  Age and energy-adjusted hazard ratios (HR) and 95% confidence intervals (CI) 
stratified by menopausal status for the association between flavonoid intake in relation to all-
cause mortality among breast cancer cases diagnosed in 1996-1997. 
Variable 
(mg/day)  
Deaths/ 
Cohort 
# deaths/ 
376 
Pre-
menopausal 
HR 
(95% CI) 
Deaths/ 
Cohort 
# deaths/ 
834 
Post-
menopausal 
HR  
(95% CI) 
Deaths/ 
Cohort 
# deaths/ 
1,210 
Pre and 
Post 
HR  
(95% CI) 
Total Flavonoids*       
0-42.4 3/82 1.00 25/161 1.00 28/243 1.00 
42.5-95.0 15/72 2.49 
(1.32-4.69) 
23/171 0.81 
(0.52-1.28) 
38/243 1.10  
(0.77-1.57) 
95.1-216.2 6/79 0.58  
(0.24-1.36) 
28/162 1.09  
(0.71-1.65) 
34/241 0.95  
(0.66-1.39) 
216.3-340.4 6/75 0.61  
(0.26-1.46) 
32/168 1.24  
(0.83-1.86) 
38/243 1.11 
(0.77-1.59) 
340.5+ 13/68 1.77  
(0.91-3.46) 
22/172 0.78  
(0.49-1.25) 
35/240 0.96  
(0.66-1.40) 
Total Flavonols*       
0-3.4 4/58 1.00 31/185 1.00 35/243 1.00 
3.5-5.9 12/81 1.65  
(0.84-3.26) 
23/162 0.89  
(0.57-1.40) 
35/243 1.03  
(0.71-1.49) 
6.0-10.1 8/83 0.78 
(0.36-1.68) 
25/159 0.99 
(0.64-1.54) 
33/242 0.94  
(0.64-1.37) 
10.2-14.4 5/76 0.47  
(0.19-1.19) 
26/164 1.02  
(0.66-1.57) 
31/240 0.86  
(0.58-1.27) 
14.5+ 14/78 1.64 
(0.84-3.17) 
25/164 0.98 
(0.62-1.53) 
39/242 1.12  
(0.78-1.62) 
Total Flavones*       
0-0.03 7/61 1.00 32/180 1.00 39/241 1.00 
0.04-0.07 9/80 1.07  
(0.51-2.25) 
29/163 1.24  
(0.82-1.88) 
38/243 1.20  
(0.83-1.72) 
0.08-0.12 11/75 1.36 
(0.69-2.70) 
27/167 1.13 
 (0.74-1.73) 
38/242 1.17  
(0.82-1.68) 
0.13-0.19 7/70 0.87  
(0.39-1.95) 
25/172 0.92 
 (0.59-1.44) 
32/242 0.88  
(0.60-1.29) 
0.20+ 9/90 0.69  
(0.32-1.47) 
17/152 0.59  
(0.35-0.99) 
26/242 0.63  
(0.41-0.96) 
Total Flavanones*       
0-4.0 12/97 1.00 21/143 1.00 33/240 1.00 
4.1-16.3 8/84 0.80  
(0.37-1.73) 
28/156 1.49  
(0.97-2.29) 
36/240 1.25 
(0.86-1.81) 
16.4-29.9 6/67 0.75 
(0.32-1.78) 
19/176 0.60 
(0.37-0.98) 
25/243 0.64  
(0.42-0.97) 
30.0-48.5 9/74 1.04  
(0.50-2.17) 
30/172 1.13  
(0.75-1.71) 
39/246 1.10  
(0.77-1.57) 
48.6+ 8/54 1.08 
(0.48-2.43) 
32/187 0.99  
(0.66-1.49) 
40/241 1.03  
(0.72-1.48) 
Total Flavan-3-ols*      
0-5.0 3/66 1.00 29/178 1.00 32/244 1.00 
5.1-34.4 8/84 0.80  
(0.37-1.74) 
22/158 0.88  
(0.56-1.39) 
30/242 0.83 
(0.56-1.23) 
34.5-140.0 12/78 1.42  
(0.73-2.77) 
26/164 1.01  
(0.66-1.56) 
38/242 1.12  
(0.78-1.61) 
140.1-263.7 7/79 0.72 
(0.32-1.63) 
29/162 1.21  
(0.80-1.83) 
36/241 1.10  
(0.76-1.59) 
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263.8+ 13/69 1.76  
(0.91-3.42) 
24/172 0.84 
(0.53-1.32) 
37/241 1.01 
(0.70-1.46) 
Total Anthocyanidins*      
0-0.03 6/60 1.00 39/181 1.00 45/241 1.00 
0.04-0.40 16/86 2.12  
(1.14-3.93) 
28/158 1.18  
(0.77-1.79) 
44/244 1.42  
(1.01-2.00) 
0.41-1.60 10/70 1.33 
(0.66-2.71) 
25/178 0.92  
(0.59-1.42) 
35/248 1.00  
(0.69-1.45) 
1.61-4.23 4/81 0.36  
(0.13-1.01) 
20/157 0.74  
(0.46-1.19) 
24/238 0.62  
(0.40-0.95) 
4.24+ 7/79 0.62  
(0.27-1.40) 
18/160 0.66  
(0.40-1.08) 
25/239 0.64 
(0.42-0.98) 
Total Isoflavones*       
0-0.29 8/70 1.00 19/172 1.00 27/242 1.00 
0.30-0.78 7/58 1.10 
(0.49-2.48) 
43/185 1.58 
(1.09-2.30) 
50/243 1.49  
(1.07-2.08) 
0.79-2.34 9/69 1.23  
(0.59-2.56) 
25/175 0.89  
(0.58-1.38) 
34/244 0.96  
(0.66-1.39) 
2.35-7.47 10/88 0.93  
(0.46-1.90) 
31/152 1.59 
(1.06-2.38) 
41/240 1.36  
(0.96-1.94) 
7.48+ 9/91 0.71  
(0.34-1.48) 
12/150 0.44 
(0.24-0.81) 
21/241 0.52  
(0.33-0.82) 
Total Lignans*       
0-2.2 7/72 1.00 26/171 1.00 33/243 1.00 
2.3-3.9 5/72 0.60  
(0.24-1.53) 
28/170 1.09  
(0.72-1.65) 
33/242 0.96  
(0.65-1.40) 
4.0-5.9 14/82 1.69 
(0.89-3.21) 
25/162 0.98  
(0.63-1.51) 
39/244 1.14  
(0.80-1.63) 
6.0-8.9 6/77 0.61  
(0.26-1.45) 
26/163 0.96  
(0.62-1.48) 
32/240 0.88  
(0.60-1.30) 
9.0+ 11/73 1.27  
(0.63-2.54) 
25/168 0.98  
(0.63-1.54) 
36/241 1.03  
(0.71-1.49) 
* In milligrams per day (mg/d).
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Table A.18.  Age and energy-adjusted hazard ratios (HR) and 95% confidence intervals (CI) 
stratified by menopausal status for the association between flavonoid intake in relation to 
breast cancer-specific mortality.  
Variable 
(mg/day) 
Deaths/ 
Cohort 
# deaths/ 
367 
Pre-
menopausal 
HR  
(95% CI) 
Deaths/ 
Cohort 
# deaths/ 
781 
Post-
menopausal 
HR  
(95% CI) 
Deaths/ 
Cohort 
# deaths/ 
1,148 
Pre and Post 
HR (95% CI) 
Total Flavonoids*       
0-42.4 2/81 1.00 16/152 1.00 18/233 1.00 
42.5-95.0 13/70 2.88  
(1.44-5.78) 
16/164 0.97  
(0.56-1.68) 
29/234 1.37  
(0.90-2.10) 
95.1-216.2 5/78 0.61  
(0.24-1.58) 
14/148 0.90  
(0.51-1.61) 
19/226 0.81  
(0.49-1.32) 
216.3-340.4 4/73 0.50 
(0.18-1.42) 
21/156 1.40  
(0.84-2.33) 
25/229 1.10  
(0.70-1.73) 
340.5+ 10/65 1.75  
(0.82-3.72) 
12/161 0.62  
(0.33-1.16) 
22/226 0.88  
(0.55-1.42) 
Total Flavonols*       
0-3.4 4/58 1.00 17/171 1.00 21/229 1.00 
3.5-5.9 10/79 1.80 
(0.85-3.80) 
16/155 1.04  
(0.60-1.81) 
26/234 1.22  
(0.78-1.89) 
6.0-10.1 6/81 0.73  
(0.30-1.77) 
14/148 0.92  
(0.52-1.65) 
20/229 0.86  
(0.53-1.39) 
10.2-14.4 3/74 0.34  
(0.10-1.12) 
15/152 0.87  
(0.49-1.55) 
18/226 0.69  
(0.41-1.16) 
14.5+ 11/75 1.64 
(0.78-3.46) 
17/155 1.02  
(0.59-1.79) 
28/230 1.20  
(0.77-1.87) 
Total Flavones*       
0-0.03 4/58 1.00 16/163 1.00 20/221 1.00 
0.04-0.07 9/80 1.46  
(0.67-3.15) 
17/151 1.24 
(0.72-2.13) 
26/231 1.30  
(0.83-2.01) 
0.08-0.12 10/74 1.62  
(0.77-3.39) 
19/158 1.20  
(0.71-2.03) 
29/232 1.32  
(0.86-2.02) 
0.13-0.19 6/69 0.94  
(0.39-2.27) 
18/165 1.06  
(0.62-1.80) 
24/234 1.01  
(0.64-1.59) 
0.20+ 5/86 0.45  
(0.17-1.19) 
9/144 0.49  
(0.24-0.99) 
14/230 0.48  
(0.27-0.84) 
Total Flavanones*       
0-4.0 10/95 1.00 12/133 1.00 22/228 1.00 
4.1-16.3 7/83 0.89  
(0.39-2.05) 
19/146 1.52  
(0.89-2.61) 
26/229 1.27  
(0.81-1.99) 
16.4-29.9 6/67 0.97  
(0.40-2.35) 
9/166 0.47  
(0.23-0.94) 
15/233 0.60  
(0.35-1.03) 
30.0-48.5 7/72 1.03  
(0.45-2.38) 
19/161 1.21  
(0.72-2.03) 
26/233 1.15 
(0.74-1.78) 
48.6+ 4/50 0.61  
(0.21-1.81) 
20/175 1.09  
(0.65-1.82) 
24/225 0.98  
(0.62-1.56) 
Total Flavan-3-ols*      
0-5.0 2/65 1.00 19/168 1.00 21/233 1.00 
5.1-34.4 6/82 0.76  
(0.31-1.85) 
13/149 0.83  
(0.46-1.50) 
19/231 0.78  
(0.48-1.28) 
34.5-140.0 11/77 1.75 
(0.85-3.60) 
14/152 0.90  
(0.50-1.60) 
25/229 1.14  
(0.73-1.78) 
140.1-263.7 5/77 0.63  
(0.24-1.63) 
21/153 1.46  
(0.88-2.43) 
26/230 1.19  
(0.76-1.86) 
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263.8+ 10/66 1.75 
(0.83-3.69) 
12/159 0.63  
(0.34-1.18) 
22/225 0.89  
(0.55-1.43) 
Total Anthocyanidins*      
0-0.03 4/58 1.00 21/163 1.00 25/221 1.00 
0.04-0.40 11/81 1.80  
(0.88-3.69) 
15/145 1.05  
(0.60-1.85) 
26/226 1.28  
(0.82-1.98) 
0.41-1.60 8/68 1.33 
(0.60-2.95) 
21/173 1.27 
(0.76-2.12) 
29/241 1.30 
(0.85-1.99) 
1.61-4.23 4/81 0.46  
(0.16-1.31) 
11/148 0.65  
(0.35-1.24) 
15/229 0.58  
(0.34-1.00) 
4.24+ 7/79 0.81 
(0.35-1.89) 
11/152 0.62  
(0.33-1.18) 
18/231 0.68  
(0.41-1.13) 
Total Isoflavones*       
0-0.15 7/76 1.00 11/150 1.00 18/226 1.00 
0.16-0.26 5/71 0.96  
(0.40-2.35) 
21/165 1.02  
(0.59-1.78) 
26/236 0.99  
(0.62-1.59) 
0.27-0.37 8/67 1.69  
(0.79-3.62) 
15/159 0.99  
(0.57-1.72) 
23/226 1.17  
(0.75-1.83) 
0.38-0.59 8/71 0.48 
(0.17-1.36) 
24/158 1.08  
(0.63-1.84) 
32/229 0.86  
(0.54-1.39) 
0.60+ 6/82 1.03  
(0.46-2.28) 
8/149 0.79  
(0.43-1.44) 
14/231 0.87  
(0.54-1.41) 
Total Lignans*       
0-2.2 6/71 1.00 15/160 1.00 21/231 1.00 
2.3-3.9 4/71 0.60 
(0.21-1.71) 
18/160 1.17  
(0.69-1.98) 
22/231 0.99  
(0.62-1.57) 
4.0-5.9 12/80 1.92  
(0.95-3.89) 
16/153 1.04  
(0.60-1.80) 
28/233 1.28  
(0.84-1.97) 
6.0-8.9 4/75 0.50  
(0.18-1.42) 
15/151 0.88  
(0.49-1.57) 
19/226 0.76  
(0.46-1.26) 
9.0+ 8/70 1.16  
(0.52-2.58) 
15/157 0.87 
(0.49-1.55) 
23/227 0.95 
(0.60-1.51) 
* In milligrams per day (mg/d).
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Table A.19. A summary of the preliminary evaluation of confounding and effect 
modification of flavonoids and breast cancer survival by selected covariates.  
 
FLAVONOID EXPOSURES  Covariate Relationship 
between 
Covariate and 
Outcome 
(Mortality)? 
HR (95% CI) 
Relationship 
between 
covariate and 
Total 
Flavonoids? 
HR (95% CI) 
Evidence of 
Effect Measure 
Modification? 
p-value from 
Likelihood 
Ratio Test 
Does the HR 
for Total 
Flavonoids 
change by 
more than 
10% when 
Covariate is 
added to 
model? 
Menopausal Status YES Borderline YES No 
Age YES YES YES No 
Alcohol No No No No 
Smoking No No No No 
Family History  No No No No 
Physical Activity No No No No 
BMI No No No No 
Income No No No No 
Education No No No No 
Parity No No No No 
OC Use No No No No 
ER Status Borderline Borderline No No 
PR Status Borderline Borderline No No 
Chemotherapy No No No No 
Radiation Therapy No No No No 
Fruits No No No No 
Hypertension No No No No 
Diabetes No No No No 
High Cholesterol No No No No 
Myocardial 
Infarction 
No No No No 
Stroke No No No No 
Vegetables No Borderline No No 
Antioxidants No Borderline No No 
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Table A.20.  Age, fruit, fruit juice, vegetable,  antioxidant, and energy-adjusted hazard ratios 
(HR) and 95% confidence intervals (CI) stratified by menopausal status for the association 
between flavonoid intake in relation to all-cause mortality.  
Variable Pre-menopausal 
(n=376) 
Post-menopausal 
(n=834) 
Pre- and Post-menopausal 
(n=1,210) 
 HR (95% CI) HR (95% CI) HR (95% CI) 
Total Flavonoids*    
0-42.5 1.00 1.00 1.00 
42.5-95.1 2.50 (1.32-4.76) 0.84 (0.53-1.33) 1.08 (0.75-1.56) 
95.1-216.3 0.52 (0.22-1.26) 1.08 (0.71-1.66) 0.94 (0.65-1.38) 
216.3-340.5 0.61 (0.26-1.48) 1.23 (0.82-1.84) 1.08 (0.75-1.55) 
340.5+ 1.72 (0.88-3.39) 0.81 (0.50-1.30) 1.02 (0.70-1.48) 
P for trend# 0.09 0.82 0.49 
Total Flavonols*    
0-3.5 1.00 1.00 1.00 
3.5-6.0 1.64 (0.81-3.31) 0.94 (0.59-1.48) 1.03 (0.71-1.50) 
6.0-10.2 0.77 (0.36-1.68) 0.99 (0.64-1.53) 0.93 (0.64-1.37) 
10.2-14.5 0.47 (0.18-1.22) 1.05 (0.68-1.62) 0.86 (0.58-1.26) 
14.5+ 1.64 (0.83-3.23) 1.07 (0.67-1.69) 1.26 (0.87-1.82) 
P for trend# 0.21 0.80 0.67 
Total Flavones*    
0-0.04 1.00 1.00 1.00 
0.04-0.08 1.31 (0.58-2.97) 1.14 (0.74-1.74) 1.10 (0.76-1.60) 
0.08-0.13 1.41 (0.70-2.86) 1.14 (0.74-1.74) 1.18 (0.82-1.68) 
0.13-0.20 0.70 (0.31-1.62) 1.03 (0.65-1.62) 0.92 (0.62-1.37) 
0.20+ 0.61 (0.25-1.51) 0.70 (0.39-1.27) 0.71 (0.43-1.15) 
P for trend# 0.18 0.78 0.66 
Total Flavanones*    
0-4.1 1.00 1.00 1.00 
4.1-16.4 0.90 (0.39-2.08) 1.59 (0.99-2.56) 1.23 (0.82-1.84) 
16.4-30.0 0.79 (0.33-1.90) 0.61 (0.37-0.99) 0.66 (0.44-1.01) 
30.0-48.6 1.01 (0.45-2.24) 1.21 (0.79-1.85) 1.11 (0.77-1.62) 
48.6+ 0.79 (0.31-2.03) 1.04 (0.61-1.78) 1.07 (0.67-1.69) 
P for trend# 0.52 0.54 0.43 
Total Flavan-3-ols*   
0-5.1 1.00 1.00 1.00 
5.1-34.5 0.78 (0.35-1.76) 0.90 (0.57-1.42) 0.81 (0.55-1.20) 
34.5-140.1 1.43 (0.72-2.84) 1.01 (0.65-1.55) 1.11 (0.77-1.58) 
140.1-263.8 0.72 (0.31-1.64) 1.22 (0.80-1.84) 1.07 (0.74-1.54) 
263.8+ 1.82 (0.93-3.57) 0.84 (0.54-1.33) 1.07 (0.74-1.53) 
P for trend# 0.06 0.85 0.45 
Total Anthocyanidins*   
0-0.04 1.00 1.00 1.00 
0.04-0.41 2.25 (1.20-4.22) 1.14 (0.74-1.74) 1.48 (1.06-2.08) 
0.41-1.61 1.36 (0.66-2.79) 0.91 (0.59-1.42) 1.01 (0.70-1.46) 
1.61-4.24 0.33 (0.12-0.93) 0.76 (0.47-1.23) 0.63 (0.41-0.97) 
4.24+ 0.60 (0.26-1.37) 0.69 (0.42-1.15) 0.63 (0.41-0.96) 
P for trend# 0.06 0.60 0.13 
Total Isoflavones*    
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0-0.16 1.00 1.00 1.00 
0.16-0.27 0.72 (0.30-1.76) 0.83 (0.53-1.31) 0.78 (0.52-1.17) 
0.27-0.38 1.70 (0.85-3.37) 1.15 (0.77-1.72) 1.29 (0.91-1.81) 
0.38-0.60 0.41 (0.16-1.08) 1.26 (0.84-1.91) 1.00 (0.69-1.45) 
0.60+ 1.11 (0.52-2.36) 0.74 (0.44-1.23) 0.87 (0.58-1.30) 
P for trend# 0.72 0.21 0.19 
Total Lignans*    
0-2.3 1.00 1.00 1.00 
2.3-4.0 0.61 (0.24-1.55) 1.08 (0.71-1.64) 0.94 (0.64-1.37) 
4.0-6.0 1.52 (0.79-2.94) 0.99 (0.64-1.53) 1.12 (0.78-1.61) 
6.0-9.0 0.62 (0.26-1.51) 0.94 (0.61-1.46) 0.88 (0.60-1.29) 
9.0+ 1.31 (0.65-2.63) 1.01 (0.65-1.59) 1.06 (0.73-1.54) 
P for trend# 0.08 0.74 0.69 
* In milligrams per day (mg/d). 
# P for trend for continuous variable. 
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Table A.21. Age and energy-adjusted hazard ratios (HR) and 95% confidence intervals (CI) stratified by 
ER/PR status for the association between flavonoid intake in relation to all-cause mortality.  
Variable ER+PR+  ER+PR-  ER-
PR+ 
 ER-PR-  
 Cases (n) 
Deaths 
(n) 
HR 
(95% 
CI) 
Cases (n) 
Deaths 
(n) 
HR 
(95% 
CI) 
Cases 
(n) 
Deaths 
(n) 
HR (95% 
CI) 
Cases 
(n) 
Deaths 
(n) 
HR 
(95% 
CI) 
Total Flavonoids*        
0-216.3 329 
32 
1.00 87 
18 
1.00 30 
4 
1.00 128 
25 
1.00 
216.3+ 215 
25 
1.08 
(0.63-
1.84) 
45 
9 
0.94 
(0.41-
2.15) 
18 
3 
1.16 
(0.25-
5.49) 
69 
22 
1.48 
(0.82-
2.68) 
P for trend#  0.19  0.36  0.89  0.47 
Total 
Flavonols* 
        
0-10.2 336 
36 
1.00 87 
18 
1.00 27 
4 
1.00 126 
28 
1.00 
10.2+ 208 
21 
0.88 
(0.50-
1.55) 
45 
9 
0.94 
(0.41-
2.15) 
21 
3 
0.82 
(0.16-
4.18) 
71 
19 
1.17 
(0.63-
2.16) 
P for trend#  0.35  0.36  0.70  0.69 
Total 
Flavones* 
        
0-0.13 357 
41 
1.00 86 
18 
1.00 28 
6 
1.00 134 
35 
1.00 
0.13+ 187 
16 
0.63 
(0.35-
1.14) 
46 
9 
0.85 
(0.37-
1.96) 
20 
1 
0.18 
(0.02-
1.59) 
63 
12 
0.77 
(0.39-
1.51) 
P for trend#  0.60  0.86  0.19  0.43 
Total Flavanones*        
0-30.0 343 
30 
1.00 71 
17 
1.00 29 
3 
1.00 118 
26 
1.00 
30.0+ 201 
27 
1.24 
(0.72-
2.14) 
61 
10 
0.63 
(0.29-
1.37) 
19 
4 
2.52 
(0.49-
13.06) 
79 
21 
1.04 
(0.56-
1.90) 
P for trend#  0.23  0.16  0.75  0.45 
Total Flavan-3-ols*        
0-140.1 328 
33 
1.00 87 
18 
1.00 29 
4 
1.00 125 
23 
1.00 
140.1+ 216 
24 
1.03 
(0.61-
1.76) 
45 
9 
0.97 
(0.43-
2.19) 
19 
3 
1.03 
(0.21-
4.96) 
72 
24 
1.70 
(0.95-
3.05) 
P for trend#  0.24  0.51  0.98  0.47 
Total Anthocyanidins*        
0-1.61 342 
42 
1.00 88 
22 
1.00 32 
6 
1.00 124 
35 
1.00 
1.61+ 202 
15 
0.53 
(0.29-
0.96) 
44 
5 
0.41 
(0.16-
1.08) 
16 
1 
0.30 
(0.04-
2.54) 
73 
12 
0.54 
(0.28-
1.06) 
P for trend#  0.04  0.52  0.39  0.11 
Total Isoflavones*        
0-0.38 332 1.00 78 1.00 26 1.00 122 1.00 
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30 13 4 34 
0.38+ 212 
27 
1.26 
(0.71-
2.23) 
54 
14 
1.69 
(0.73-
3.92) 
22 
3 
0.77 
(0.16-
3.78) 
75 
13 
0.53 
(0.27-
1.03) 
P for trend*  0.39  0.47  0.41  0.25 
Total 
Lignans* 
        
0-6.0 331 
33 
1.00 89 
20 
1.00 30 
4 
1.00 126 
28 
1.00 
6.0+ 213 
24 
1.08 
(0.63-
1.85) 
43 
7 
0.67 
(0.28-
1.62) 
18 
3 
1.15 
(0.23-
5.71) 
71 
19 
1.11 
(0.61-
2.03) 
P for trend#  0.28  0.53  0.97  0.77 
* In milligrams per day (mg/d). 
# P for trend for continuous variable. 
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Table A.22. Age and energy-adjusted hazard ratios (HR) and 95% confidence intervals (CI) stratified by 
ER/PR status for the association between flavonoid intake in relation to breast cancer-specific mortality.  
Variable ER+PR+  ER+PR-  ER-
PR+ 
 ER-PR-  
 Cases (n) 
Deaths 
(n) 
HR 
(95% 
CI) 
Cases (n) 
Deaths 
(n) 
HR 
(95% 
CI) 
Cases 
(n) 
Deaths 
(n) 
HR (95% 
CI) 
Cases 
(n) 
Deaths 
(n) 
HR 
(95% 
CI) 
Total Flavonoids*        
0-216.3 315 
18 
1.00 81 
12 
1.00 30 
4 
1.00 121 
18 
1.00 
216.3+ 205 
16 
1.18 
(0.59-
2.34) 
41 
5 
0.76 
(0.26-
2.20) 
17 
2 
0.74 
(0.13-
4.21) 
63 
16 
1.62 
(0.81-
3.24) 
P for trend#  0.30  0.24  0.79  0.37 
Total 
Flavonols* 
        
0-10.2 320 
20 
1.00 81 
12 
1.00 27 
4 
1.00 118 
20 
1.00 
10.2+ 200 
14 
0.93 
(0.46-
1.91) 
41 
5 
0.70 
(0.24-
2.03) 
20 
2 
0.49 
(0.08-
3.02) 
66 
14 
1.27 
(0.61-
2.63) 
P for trend#  0.46  0.24  0.64  0.63 
Total 
Flavones* 
        
0-0.13 338 
23 
1.00 78 
10 
1.00 27 
5 
1.00 125 
26 
1.00 
0.13+ 182 
11 
0.70 
(0.33-
1.47) 
44 
7 
1.08 
(0.39-
3.01) 
20 
1 
0.22 
(0.02-
1.95) 
59 
8 
0.63 
(0.28-
1.42) 
P for trend#  0.95  0.95  0.26  0.30 
Total Flavanones*        
0-30.0 330 
18 
1.00 64 
10 
1.00 28 
2 
1.00 111 
19 
1.00 
30.0+ 190 
16 
1.22 
(0.60-
2.47) 
58 
7 
0.74 
(0.28-
1.94) 
19 
4 
3.96 
(0.59-
26.56) 
73 
15 
1.07 
(0.53-
2.17) 
P for trend#  0.58  0.44  1.00  0.31 
Total Flavan-3-ols*        
0-140.1 314 
19 
1.00 81 
12 
1.00 29 
4 
1.00 118 
16 
1.00 
140.1+ 206 
15 
1.06 
(0.54-
2.12) 
41 
5 
0.77 
(0.27-
2.21) 
18 
2 
0.64 
(0.11-
3.68) 
66 
18 
1.98 
(1.00-
3.92) 
P for trend#  0.30  0.27  0.84  0.39 
Total Anthocyanidins*        
0-1.61 325 
25 
1.00 79 
13 
1.00 31 
5 
1.00 115 
26 
1.00 
1.61+ 195 
9 
0.49 
(0.22-
1.05) 
43 
4 
0.51 
(0.17-
1.58) 
16 
1 
0.35 
(0.04-
2.12) 
69 
8 
0.47 
(0.21-
1.05) 
P for trend#  0.14  0.25  0.49  0.09 
Total Isoflavones*        
0-0.38 318 1.00 74 1.00 26 1.00 111 1.00 
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16 9 4 23 
0.38+ 202 
18 
1.39 
(0.66-
1.93) 
48 
8 
1.18 
(0.42-
3.35) 
21 
2 
0.48 
(0.08-
2.92) 
73 
11 
0.62 
(0.29-
1.31) 
P for trend*  0.42  0.50  0.43  0.34 
Total 
Lignans* 
        
0-6.0 316 
18 
1.00 82 
13 
1.00 30 
4 
1.00 119 
21 
1.00 
6.0+ 204 
16 
1.23 
(0.62-
2.44) 
40 
4 
0.52 
(0.17-
1.64) 
17 
2 
0.71 
(0.12-
4.23) 
65 
13 
1.10 
(0.54-
2.22) 
P for trend#  0.47  0.32  0.85  0.56 
* In milligrams per day (mg/d). 
# P for trend for continuous variable. 
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Table A.23.  Age, fiber, and energy-adjusted ORs and 95% CIs for the association between 
menopausal-specific flavonoid intake in relation to breast cancer incidence  
 Pre-menopausal 
(n = 944) 
 Post-menopausal 
(n = 1930) 
 OR (95% CI)  OR (95% CI) 
Total Flavonoids#  Total Flavonoids#  
0-34.5 1.00 0-51.8 1.00 
34.5-84.5 1.19 (0.79-1.78) 51.8-119.1 0.93 (0.69-1.24) 
84.5-199.5 1.42 (0.95-2.13) 119.1-253.3 0.81 (0.61-1.10) 
199.5-343.0 1.36 (0.90-2.04) 253.3-377.2 0.80 (0.60-1.07) 
343.0+ 1.13 (0.74-1.72) 377.2+ 0.78 (0.57-1.05) 
P for trend* 0.87 P for trend* 0.07 
Total Flavonols#  Total Flavonols#  
0-3.7 1.00 0-4.3 1.00 
3.7-6.0 1.56 (1.04-2.35) 4.3-6.8 0.60 (0.45-0.80) 
6.0-10.2 1.60 (1.04-2.45) 6.8-11.1 0.65 (0.49-0.87) 
10.2-15.1 1.78 (1.15-2.74) 11.1-17.1 0.66 (0.49-0.89) 
15.1+ 1.56 (0.99-2.43) 17.1+ 0.55 (0.41-0.75) 
P for trend* 0.67 P for trend* 0.02 
Total Flavones#  Total Flavones#  
0-0.04 1.00 0-0.04 1.00 
0.05-0.07 1.01 (0.67-1.52) 0.05-0.08 0.89 (0.67-1.18) 
0.08-0.12 1.30 (0.86-1.96) 0.09-0.14 0.90 (0.68-1.20) 
0.13-0.21 1.22 (0.79-1.90) 0.15-0.21 0.72 (0.54-0.97) 
0.22+ 1.27 (0.78-2.07) 0.22+ 0.60 (0.43-0.84) 
P for trend* 0.47 P for trend* 0.005 
Total Flavanones#  Total Flavanones#  
0-3.1 1.00 0-5.3 1.00 
3.2-10.8 0.68 (0.47-0.99) 5.4-18.8 1.06 (0.79-1.44) 
10.9-24.5 0.73 (0.49-1.09) 18.9-32.1 1.11 (0.83-1.49) 
24.6-40.3 1.00 (0.66-1.51) 32.2-54.2 1.05 (0.79-1.41) 
40.4+ 0.73 (0.45-1.16) 54.3+ 1.07 (0.79-1.45) 
P for trend* 0.63 P for trend* 0.50 
Total Flavan-3-ols# Total Flavan-3-ols# 
0-5.1 1.00 0-7.6 1.00 
5.2-26.4 1.24 (0.83-1.86) 7.7-54.0 0.86 (0.64-1.15) 
26.5-120.8 1.59 (1.05-2.41) 54.1-192.0 0.80 (0.60-1.05) 
120.9-264.1 1.42 (0.94-2.14) 192.1-277.9 0.84 (0.63-1.11) 
264.2+ 1.28 (0.83-1.98) 278.0+ 0.70 (0.52-0.93) 
P for trend* 0.86 P for trend* 0.06 
Total Anthocyanidins# Total Anthocyanidins# 
0-0.04 1.00 0-0.03 1.00 
0.05-0.56 1.13 (0.75-1.69) 0.04-0.56 1.08 (0.81-1.42) 
0.57-1.60 0.87 (0.58-1.32) 0.57-1.84 0.98 (0.74-1.31) 
1.61-4.19 0.96 (0.63-1.46) 1.85-4.84 0.82 (0.62-1.09) 
4.20+ 1.11 (0.72-1.72) 4.85+ 0.85 (0.64-1.12) 
P for trend* 0.65 P for trend* 0.36 
Total Isoflavones#  Total Isoflavones#  
0-0.31 1.00 0-0.27 1.00 
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0.32-1.10 1.14 (0.73-1.80) 0.28-0.62 0.96 (0.72-1.28) 
1.11-3.17 1.06 (0.69-1.62) 0.63-1.94 1.28 (0.96-1.71) 
3.18-7.62 1.09 (0.72-1.65) 1.95-7.63 1.18 (0.88-1.60) 
7.63+ 1.33 (0.86-2.08) 7.64+ 1.12 (0.82-1.52) 
P for trend* 0.36 P for trend* 0.94 
Total Lignans#  Total Lignans#  
0-2.0 1.00 0-2.4 1.00 
2.1-4.0 1.55 (1.04-2.30) 2.5-4.2 0.97 (0.74-1.29) 
4.1-5.4 1.15 (0.76-1.72) 4.3-6.4 0.81 (0.60-1.09) 
5.5-9.3 1.69 (1.12-2.57) 6.5-10.2 0.77 (0.57-1.02) 
9.4+ 1.21 (0.79-1.85) 10.3+ 0.67 (0.50-0.91) 
P for trend* 0.70 P for trend* 0.01 
* P for trend for continuous variable. 
# In milligrams per day (mg/d). 
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Table A.24.  Age, fiber, and energy-adjusted hazard ratios (HR) and 95% confidence intervals 
(CI) stratified by menopausal status for the association between flavonoid intake in relation to 
all-cause mortality among breast cancer cases diagnosed in 1996-1997. 
Variable 
(mg/day)  
Deaths/
Cohort 
# deaths/ 
376 
Pre-
menopausal 
HR  
(95% CI) 
Deaths/
Cohort 
# deaths/
834 
Post-
menopausal 
HR  
(95% CI) 
Deaths/ 
Cohort 
# deaths/ 
1,210 
Pre and Post 
HR  
(95% CI) 
Total 
Flavonoids* 
      
0-42.4 3/82 1.00 25/161 1.00 28/243 1.00 
42.5-95.0 15/72 2.58  
(1.36-4.90) 
23/171 0.80  
(0.51-1.25) 
38/243 1.08  
(0.75-1.56) 
95.1-216.2 6/79 0.55  
(0.23-1.32) 
28/162 1.11  
(0.73-1.70) 
34/241 0.97  
(0.66-1.42) 
216.3-340.4 6/75 0.61  
(0.26-1.46) 
32/168 1.24  
(0.83-1.85) 
38/243 1.11  
(0.77-1.58) 
340.5+ 13/68 1.77  
(0.90-3.45) 
22/172 0.80  
(0.50-1.29) 
35/240 0.98  
(0.67-1.44) 
Total 
Flavonols* 
      
0-3.4 4/58 1.00 31/185 1.00 35/243 1.00 
3.5-5.9 12/81 1.69  
(0.85-3.36) 
23/162 0.87  
(0.55-1.36) 
35/243 1.01  
(0.70-1.47) 
6.0-10.1 8/83 0.78  
(0.36-1.68) 
25/159 1.01  
(0.65-1.56) 
33/242 0.94  
(0.65-1.38) 
10.2-14.4 5/76 0.46  
(0.18-1.18) 
26/164 1.03  
(0.67-1.59) 
31/240 0.87  
(0.59-1.28) 
14.5+ 14/78 1.62  
(0.83-3.17) 
25/164 1.03  
(0.65-1.63) 
39/242 1.17  
(0.80-1.69) 
Total 
Flavones* 
      
0-0.03 7/61 1.00 32/180 1.00 39/241 1.00 
0.04-0.07 9/80 1.12  
(0.52-2.41) 
29/163 1.21  
(0.79-1.83) 
38/243 1.17  
(0.81-1.69) 
0.08-0.12 11/75 1.39  
(0.69-2.77) 
27/167 1.12  
(0.73-1.72) 
38/242 1.16  
(0.81-1.67) 
0.13-0.19 7/70 0.87  
(0.39-1.95) 
25/172 0.92  
(0.59-1.44) 
32/242 0.88  
(0.60-1.29) 
0.20+ 9/90 0.58  
(0.25-1.35) 
17/152 0.61  
(0.35-1.06) 
26/242 0.62  
(0.39-0.98) 
Total 
Flavanones* 
      
0-4.0 12/97 1.00 21/143 1.00 33/240 1.00 
4.1-16.3 8/84 0.81  
(0.37-1.74) 
28/156 1.46  
(0.95-2.24) 
36/240 1.23  
(0.84-1.79) 
16.4-29.9 6/67 0.76  
(0.32-1.80) 
19/176 0.59  
(0.36-0.96) 
25/243 0.63  
(0.41-0.96) 
30.0-48.5 9/74 1.03  
(0.49-2.16) 
30/172 1.13  
(0.75-1.70) 
39/246 1.10  
(0.77-1.58) 
48.6+ 8/54 1.03  32/187 1.08  40/241 1.09  
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(0.44-2.42) (0.70-1.66) (0.74-1.60) 
Total Flavan-3-ols*      
0-5.0 3/66 1.00 29/178 1.00 32/244 1.00 
5.1-34.4 8/84 0.81  
(0.37-1.77) 
22/158 0.89  
(0.56-1.41) 
30/242 0.83  
(0.56-1.23) 
34.5-140.0 12/78 1.40  
(0.71-2.78) 
26/164 1.02  
(0.66-1.56) 
38/242 1.13  
(0.79-1.62) 
140.1-263.7 7/79 0.73  
(0.32-1.65) 
29/162 1.20  
(0.80-1.82) 
36/241 1.10  
(0.76-1.59) 
263.8+ 13/69 1.76  
(0.91-3.41) 
24/172 0.85  
(0.54-1.34) 
37/241 1.02  
(0.71-1.48) 
Total Anthocyanidins*      
0-0.03 6/60 1.00 39/181 1.00 45/241 1.00 
0.04-0.40 16/86 2.15  
(1.16-4.01) 
28/158 1.14  
(0.75-1.75) 
44/244 1.40  
(0.99-1.98) 
0.41-1.60 10/70 1.33  
(0.65-2.70) 
25/178 0.90  
(0.58-1.40) 
35/248 1.00  
(0.69-1.45) 
1.61-4.23 4/81 0.36  
(0.13-1.01) 
20/157 0.74  
(0.46-1.19) 
24/238 0.62  
(0.40-0.95) 
4.24+ 7/79 0.60  
(0.26-1.37) 
18/160 0.68  
(0.41-1.12) 
25/239 0.65  
(0.42-1.00) 
Total 
Isoflavones* 
      
0-0.29 8/70 1.00 19/172 1.00 27/242 1.00 
0.30-0.78 7/58 1.13  
(0.50-2.57) 
43/185 1.55  
(1.06-2.26) 
50/243 1.47  
(1.05-2.06) 
0.79-2.34 9/69 1.23  
(0.59-2.57) 
25/175 0.91  
(0.59-1.42) 
34/244 0.97  
(0.66-1.41) 
2.35-7.47 10/88 0.94  
(0.46-1.91) 
31/152 1.63  
(1.08-2.45) 
41/240 1.37  
(0.96-1.96) 
7.48+ 9/91 0.65  
(0.29-1.42) 
12/150 0.45  
(0.25-0.83) 
21/241 0.52  
(0.33-0.84) 
Total 
Lignans* 
      
0-2.2 7/72 1.00 26/171 1.00 33/243 1.00 
2.3-3.9 5/72 0.60  
(0.23-1.53) 
28/170 1.10  
(0.72-1.66) 
33/242 0.96  
(0.66-1.40) 
4.0-5.9 14/82 1.71  
(0.90-3.24) 
25/162 0.98  
(0.63-1.52) 
39/244 1.14  
(0.80-1.63) 
6.0-8.9 6/77 0.58  
(0.24-1.41) 
26/163 0.95  
(0.62-1.47) 
32/240 0.89  
(0.60-1.30) 
9.0+ 11/73 1.30  
(0.64-2.62) 
25/168 1.00  
(0.64-1.57) 
36/241 1.03  
(0.71-1.50) 
* In milligrams per day (mg/d). 
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Table A.25.  Age, co-morbidity^, and energy-adjusted hazard ratios (HR) and 95% confidence 
intervals (CI) stratified by menopausal status for the association between flavonoid intake in 
relation to all-cause mortality among breast cancer cases diagnosed in 1996-1997. 
Variable Pre-menopausal 
(n=376) 
Post-menopausal 
(n=834) 
 HR (95% CI) HR (95% CI) 
Total Flavonoids*   
0-42.4 1.00 1.00 
42.5-95.0 2.89 (1.50-5.55) 0.90 (0.57-1.41) 
95.1-216.2 0.60 (0.25-1.43) 1.05 (0.69-1.60) 
216.3-340.4 0.64 (0.27-1.52) 1.24 (0.83-1.86) 
340.5+ 1.55 (0.78-3.09) 0.80 (0.50-1.29) 
Total Flavonols*   
0-3.4 1.00 1.00 
3.5-5.9 1.67 (0.84-3.30) 0.91 (0.58-1.42) 
6.0-10.1 0.83 (0.38-1.80) 0.95 (0.62-1.48) 
10.2-14.4 0.51 (0.20-1.30) 1.04 (0.68-1.60) 
14.5+ 1.46 (0.74-2.90) 1.00 (0.64-1.58) 
Total Flavones*   
0-0.03 1.00 1.00 
0.04-0.07 1.08 (0.51-2.28) 1.29 (0.85-1.96) 
0.08-0.12 1.36 (0.68-2.71) 1.07 (0.70-1.64) 
0.13-0.19 0.92 (0.41-2.09) 0.89 (0.57-1.39) 
0.20+ 0.66 (0.31-1.41) 0.63 (0.37-1.06) 
Total Flavanones*   
0-4.0 1.00 1.00 
4.1-16.3 0.87 (0.40-1.89) 1.60 (1.03-2.48) 
16.4-29.9 0.81 (0.34-1.93) 0.62 (0.38-1.01) 
30.0-48.5 1.14 (0.54-2.40) 1.05 (0.69-1.58) 
48.6+ 0.99 (0.43-2.29) 1.03 (0.68-1.55) 
Total Flavan-3-ols*  
0-5.0 1.00 1.00 
5.1-34.4 0.92 (0.42-2.03) 0.96 (0.60-1.53) 
34.5-140.0 1.49 (0.76-2.91) 0.99 (0.65-1.52) 
140.1-263.7 0.72 (0.32-1.64) 1.14 (0.75-1.72) 
263.8+ 1.59 (0.80-3.14) 0.90 (0.57-1.42) 
Total Anthocyanidins*  
0-0.03 1.00 1.00 
0.04-0.40 1.89 (1.00-3.57) 1.27 (0.83-1.93) 
0.41-1.60 1.35 (0.66-2.75) 0.89 (0.57-1.38) 
1.61-4.23 0.38 (0.14-1.08) 0.70 (0.43-1.13) 
4.24+ 0.67 (0.30-1.52) 0.70 (0.42-1.16) 
Total Isoflavones*   
0-0.29 1.00 1.00 
0.30-0.78 1.27 (0.56-2.88) 1.37 (0.94-2.02) 
0.79-2.34 1.29 (0.62-2.72) 0.93 (0.60-1.45) 
2.35-7.47 0.99 (0.48-2.02) 1.53 (1.01-2.31) 
7.48+ 0.66 (0.31-1.42) 0.49 (0.27-0.89) 
Total Lignans*   
 203
0-2.2 1.00 1.00 
2.3-3.9 0.56 (0.22-1.43) 1.06 (0.70-1.61) 
4.0-5.9 1.99 (1.04-3.84) 1.00 (0.65-1.56) 
6.0-8.9 0.64 (0.27-1.52) 0.95 (0.62-1.46) 
9.0+ 1.12 (0.54-2.30) 1.02 (0.65-1.60) 
* In milligrams per day (mg/d). 
^Co-morbidities adjusted for included hypertension, diabetes, high cholesterol, myocardial infarction, 
and stroke. 
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Figure A.1. Flavonoids ability to reduce breast cancer through the estrogen pathway. 
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Figure A.2. Flavonoids ability to reduce breast cancer through the oxidative stress 
pathway. 
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ABSTRACT 
Background:  Flavonoids have been hypothesized to reduce the risk of cancer.  However, 
their quantification in epidemiologic research has been limited because there are no 
standardized food intake methods.  Previous studies of cancer risk have not included all 
flavonoid classes, thereby overlooking flavonoids that constitute a large proportion of intake 
in the U.S.   
Objective:  We developed a database to quantify flavonoid content for the modified Block 
food frequency questionnaire (FFQ).   
Methods:  Using available literature and USDA databases, we estimated content for seven 
flavonoid classes, including 30 individual flavonoids, for 50 of 100 food group items in the 
LIBCSP FFQ.  We estimated individual daily flavonoid intake for the 1,500 population-
based control women without breast cancer.   
Results:  Total flavonoid content of food items ranged from 0 to129 milligrams (mg) / 100 
grams (g), with flavan-3-ols the largest contributor.  Individual intake estimates, from highest 
to lowest, were flavan-3-ols (median 101 mg/day), flavanones, flavonols, lignans, 
isoflavones, anthocyanidins, and flavones.  
Conclusion:  Flavonoid intake exhibits a wide range of levels and classes in the population-
based sample of women.  Highest intake was found for flavan-3-ols and moderate intake for 
lignans, a class previously excluded in flavonoid intake estimates. This database will be 
useful to quantify flavonoid intake for other studies using the Block FFQ.   
 
 
INTRODUCTION 
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Flavonoids are a group of more than 4,000 polyphenolic compounds that occur 
naturally in foods of plant origin (49).  Evidence from laboratory studies and epidemiological 
investigations implicate flavonoids in cancer prevention (49, 51-58, 269-271, 273-277).  
Many mechanisms of action have been identified, including carcinogen activation, anti-
proliferation, cell cycle arrest, induction of apoptosis and cell differentiation, inhibition of 
angiogenesis, and antioxidation (49).   
Most human studies have only been able to quantitate intake of a small portion of 
flavonoids or intake of a small portion of foods containing flavonoids, because of the lack of 
a flavonoid food composition database.  Due to their to potential health benefits, growing 
interest in flavonoids has led to the improvement of flavonoid intake assessment and to the 
creation of the USDA – Iowa State University Database on the Isoflavone Content of 
Selected Foods in 1999 and the USDA Database for the Flavonoid Content of Selected Foods 
in 2003.   
While these are useful tools to estimate flavonoid intake, coverage of foods and 
beverages containing these flavonoids remains incomplete.  Unless these databases are 
supplemented with additional information available in the literature, underestimation of 
intake is likely.  For example, isoflavone coverage in the USDA Isoflavone Database 
includes primarily soybeans and soy-based products, as well as legumes such as beans and 
peas.  However, isoflavones also occur in foods more frequently consumed by American 
populations (392), including fruits, vegetables, nuts, and cereals, although in relatively 
smaller amounts.  Without accounting for the isoflavone content in these commonly-
consumed products, results among an American population could be underestimates of 
flavonoid intake. 
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Isoflavones have demonstrated the ability to suppress luteinizing hormone (LH) and 
follicular stimulating hormone (FSH), increasing the length of the follicular phase and thus 
delaying menstruation (289, 290).  A change in menstrual cycle length alters the duration of 
mammary epithelial cells in the luteal phase of the cycle where breast cells are more 
proliferative (40, 287).  Reducing the number of menstrual cycles in a woman’s lifetime may 
reduce her breasts’ exposure to estrogen (40, 287).  Additionally, isoflavones have been 
shown to increase serum levels of sex hormone-binding globulin (SHBG), which decreases 
the amount of bioavailable estrogen by decreasing levels of free estradiol (39, 42, 279-282).   
Another class of flavonoids, lignans, have shown inverse associations with breast 
cancer risk in case-control studies in Finland, China, and Australia (72, 462, 466).  Inverse 
associations have also been found with ovarian cancer (465), endometrial cancer (463), and 
thyroid cancer (464).  Recent studies of flavonoids and breast cancer conducted in Greece 
and Italy (59, 60) exclude lignans, but include the following six classes, flavonols, flavones, 
flavanones, flavan-3-ols, anthocyanidins, and isoflavones.  Lignans are found in fruits, 
vegetables, nuts, grains, tea, and coffee (382).   However, lignans are not included in a 
USDA database.  
Lignans, have demonstrated the ability to reduce circulating hormone levels in the 
body through aromatase inhibition (41, 51-53, 278).  This research has led to the hypothesis 
that flavonoids, such as lignans and isoflavones, compete with estradiol for binding to 
estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) and thus inhibit cell 
proliferation and tumorigenesis via gene transcription (269).    
In order to study dietary flavonoid intake, particularly in American populations, we 
created an enhanced flavonoid database.  To improve the comprehensiveness of flavonoid 
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coverage in foods and beverages, additional sources of literature were reviewed and 
incorporated into the USDA databases. 
METHODS 
The aim of this report was to develop an expanded flavonoid database to estimate the 
mean intake of flavonoids among participants of the Long Island Breast Cancer Study Project 
(LIBCSP).  The LIBCSP was a population-based study of women of Nassau and Suffolk 
counties in Long Island, New York (371).  We report here values for control participants 
only.  Controls were identified using random digit dialing for women under the age of 65 
years and Health Care Finance Administration rosters for women 65 years or older, and were 
frequency-matched to the expected distribution of case women by 5-year age group (371).  
Because the original study was focused on breast cancer, a disease frequently diagnosed in 
post-menopausal women (112), the age range of our controls was 20-95 years and the mean 
age (57 years) was older than that of the underlying general population of women in the 
United States (mean = 40-44 years) (527).   
The LIBCSP collected information on dietary intake in the year prior to the case-
control interview utilizing a modified version of the 100-item Block food frequency 
questionnaire (FFQ) (435).  Important flavonoid-containing foods included in this version 
were beef stew, soups, cherries, fruit drinks, alfalfa sprouts, corn, and tofu. 
Databases and Literature Used 
USDA Database for the Flavonoid Content of Selected Foods 
The database is the product of a two-stage project undertaken by the Nutrient Data 
Laboratory (NDL) and the Food Composition Laboratory (FCL) of the Beltsville Human 
Nutrition Research Center (BHNRC) of the Agricultural Research Service (ARS) and U.S. 
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Department of Agriculture (USDA), in collaboration with epidemiology and nutrition groups 
from universities, institutes, and corporations (377).  The first phase consisted of an extensive 
survey of the literature for articles containing data on the flavonoid content of foods.  Only 
data from analytical studies which used acceptable procedures defined as those which lead to 
good separation of flavonoid compounds, such as column chromatography or high-
performance liquid chromatography (HPLC), were used (377).  The second phase of this 
government-sponsored analysis, currently underway, includes approximately sixty fruits, 
vegetables, and nuts at the FCL (377). 
The USDA Database for the Flavonoid Content of Selected Foods contains values for 
five classes of flavonoids: flavanols, flavones, flavanones, flavan-3-ols, and anthocyanidins 
(Table 1).  Twenty-six individual flavonoids comprise these classes and they are measured in 
225 foods and beverages.  Values are reported as milligrams per 100 grams (mg/100g) of 
fresh weight of edible portion of food and values of beverages were adjusted by their specific 
gravities and reported as served.  This database provided the flavonoid content for these five 
classes in the foods and beverages included in the LIBCSP FFQ. 
USDA - Iowa State University Database on the Isoflavone Content of Selected Foods 
The USDA - Iowa State University Database on the Isoflavone Content of Selected 
Foods was a collaborative effort between the FCL and NDL of the ARS/USDA and the 
Department of Food Science and Human Nutrition of the Iowa State University (378).  Data 
on the isoflavone content of foods were collected from scientific articles published in 
refereed journals and by extensive sampling of soy-containing foods and subsequent analyses 
at the Iowa State University (378).  The data was then compiled for daidzein, genistein, and 
glycitein and their glucosides.   
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Additional Literature 
 Additional sources of literature were used to broaden the coverage of flavonoid 
content provided by the two USDA databases.  De Kleijn et al. (382) estimated the mean 
intake of dietary isoflavones, coumestans, and lignans in healthy, Western, pre-menopausal 
women.  To do this, they first conducted a literature search to locate published laboratory 
data on flavonoid content of food and beverage items (382).  The isoflavones, daidzein and 
genistein, as well as two lignan precursors, matairesinol and secoisolariciresinol, were 
included to form a database.   
 In 2000 and 2002, Liggins et al. (379-381) published papers on the daidzein and 
genistein content of fruits, nuts and vegetables, and cereals.  Of all the foods analyzed, 36 
fruits and nuts, 66 vegetables, and 57 cereals contained measurable quantities of daidzein and 
genistein.  When multiple references reported different values for a specific food or 
beverage, the mean of the published values was used.    
 Additional databases (528) provided isoflavone and lignan content of selected foods 
and beverages assessed in previous studies.  The initial values were derived from Pillow et al. 
(298) and were updated and refined using extensive literature searches and published 
laboratory data.  These databases improved the comprehensiveness of coverage of lignan 
content of the foods and beverages inquired about on the FFQ because they included data on 
secoisolariciresinol and matairesinol, precursors of the lignans enterodiol and enterolactone, 
respectively.   
Database Construction 
The traditional construction of a database for analysis in association studies involves 
the linking of FFQ food data, specifically frequency and portion size, with existing databases 
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for the dietary components being studied.  For our present purposes, the modified Block FFQ 
food data was linked to the flavonoid content data in the two USDA databases and additional 
literature sources.   
A total of 50 items from the 100-item modified Block FFQ were found to contain at 
least one class of flavonoids (Table 2).  Quantifiable flavonoid contents for flavones, 
flavanones, flavonols, flavan-3-ols, and anthocyanidins from the USDA Database for the 
Flavonoid Content of Selected Foods were found for 31 of the 50 (62.0%) FFQ items.  
Isoflavone content was retrieved from the literature and utilized for 19 of the 50 (38.0%) 
FFQ food group items (378, 382).  The USDA – Iowa State University Database on the 
Isoflavone Content of Selected Foods was utilized to obtain isoflavone content of the 
following foods from the FFQ: tofu, frozen tofu, green peas, and other beans (baked, pinto, 
kidney, lima, black-eyed, chili with beans).  Isoflavone content of apples, cauliflower, 
cabbage, tea, carrots, and peanut butter, strawberry, cantaloupe, broccoli, other potatoes 
(boiled, baked, mashed, potato salad), whole-wheat or other whole grain bread, white bread, 
tomatoes, brown rice, and white rice were obtained from separate databases (379-382).  
Lignan content for 39 of the 50 (78.0%) FFQ items was obtained from two databases (382, 
528).   
Derivation of Weights for Foods and Beverages 
Weights were assigned to the flavonoid content of the foods and beverages from the 
USDA databases and literature which most accurately represented the LIBCSP FFQ item.  
This was necessary because some items listed in the modified Block FFQ include multiple 
foods or beverages rather than single foods (e.g., ‘Cauliflower or brussel sprouts’).  Weights 
(percentages) were assigned to the respective database items (e.g., give equal weight to both 
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foods by assigning 0.50 to ‘Cauliflower, raw’ and 0.50 to ‘Brussel sprouts, raw’ from the 
USDA Database for the Flavonoid Content of Selected Foods) to provide their flavonoid 
contribution when a subject reports its consumption.   
The Foods Commonly Eaten in the United States: Quantities Consumed Per Eating 
Occasion and in a Day, 1994-1996 was utilized to aid in the assignment of weights to these 
multiple food items (392).  This publication contains estimates of food intakes by individuals 
residing in households in the entire United States (392).  The estimates were based on 
information from 14,262 non-breast fed individuals ages 2 and above for whom 2 days of 
dietary intake information was obtained in the 1994-1996 USDA Continuing Survey of Food 
Intakes by Individuals (CSFII 1994-96) (392).  Since the LIBCSP participants consisted of 
females ages 20 and older, only intake estimates pertaining to females in the following age 
categories listed within the CSFII were reviewed: Age 20-39, Age 40-59, and Age 60 and 
older.  The average of these categories was calculated and used to assign weights.  
RESULTS 
Table 2 presents content of total flavonoids and of the 7 classes of flavonoids for each 
of the 50 FFQ items and the 100 foods and beverages they represent.  Food items in the 
database with a 0.00 value indicate that any flavonoid content was below the limit of 
detection in laboratory analysis (377).  Cherries have the greatest total flavonoid content per 
100 g (129.13 mg), followed by tea (118.06 mg), grapefruit (55.62 mg), and tofu (28.61 mg).  
Total isoflavone content was highest in tofu, frozen tofu (16.87 mg), and green peas (2.42 
mg).  Lignan content was highest in tea (2.72 mg), strawberries (1.58 mg), and coffee (0.72 
mg) but, similar to isoflavones, small amounts are present in many other items. 
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 Among the controls in the LIBCSP, the distribution of flavonoid intake is presented 
in Table 3.  The controls consumed a mean of 230.43 mg of total flavonoids per day.  Flavan-
3-ols (173.82 mg/day, 75.4%) and flavanones (31.43 mg/day, 31.6%) were the classes of 
flavonoids consumed the most by this population.  Isoflavones and lignans contributed 2.1% 
and 2.8%, respectively, to the mean intake of total flavonoids.  Individual foods and 
beverages (see Appendix 1) are listed from the richest source of flavonoids to the smallest 
source (top to bottom) for each flavonoid class.  The richest sources of total flavonoids in this 
database include ‘tea, including herb tea’, which contains 111.41 mg of flavan-3-ols per 100 
g; ‘cherries’, which contains 116.31 mg of anthocyanidins per 100 g; and ‘grapefruit’, which 
contains 54.50 mg of flavanones per 100 g.  For total flavonoids, intakes ranged from 0.8 to 
44.3 mg/day for the lowest 20% of consumers and from 364.5 to 902.0 mg/day for the 
highest 20% of consumers (data not shown).    
 For purposes of summarizing and reporting flavonoid consumption patterns in the 
LIBCSP, the items on the modified Block FFQ were aggregated on the basis of the classes of 
flavonoids which they contained.  Table 4 lists the major food and beverage contributors of 
the specific flavonoids in the diets of the control women in the LIBCSP.  Tea, including herb 
tea was the greatest contributor of lignans, flavonols, and flavan-3-ols.   
DISCUSSION 
Flavonoid intake in our American population was comparable to the levels of intake 
observed in Greece (59) and Italy (26).  The median intake of flavan-3-ols for the Greek 
study was 23.5 mg/day, and for the Italian study it was 44.1 mg/day.  Similar to the LIBCSP, 
flavan-3-ols were the greatest source of flavonoid intake in the Italian study (26).  The 
LIBCSP controls consumed a median of 100.77 mg/day of flavan-3-ols, strongly influenced 
 217
by tea consumption.  Median isoflavone intake in our study (1.49 mg/day) was greater than 
both of the aforementioned studies, with frozen tofu and tofu serving as the largest 
contributors. 
Soy products are the richest source of isoflavones (298) and there is increasing 
prevalence of soy in non-traditional sources (470), such as soy flour in doughnuts and soy 
protein in fast food hamburgers.  To elucidate whether isoflavone intake is associated with 
various diseases such as cancer, future research should include assessing intake of as many of 
these products as possible.  Future databases will also need to be developed to include the 
estimated flavonoid content of these products. 
 Two recently published studies of flavonoids and breast cancer risk (59, 60) have 
used both the USDA Database for the Flavonoid Content of Selected Foods and the USDA - 
Iowa State University Database on the Isoflavone Content of Selected Foods 
to estimate flavonoid intake, with the Italian study (60) supplementing the databases with 
additional sources of data (379-381).  The database described here used these sources along 
with additional sources to increase the coverage of isoflavones and include a category of 
flavonoids not measured by the previous studies (59, 60).  Although they represented a small 
proportion of intake overall, lignans (41, 51-53, 278) and isoflavones (39, 40, 42, 279, 280, 
282, 289-291) are known to have strong biologic activity and both were consumed at some 
level by all LIBCSP control participants.  The expanded coverage of our database may 
enhance the ability to address etiologic questions with regard to breast cancer and other 
maladies. 
 While this database is more comprehensive than those used in previous studies, it 
may not reflect true intake for several reasons.  Flavonoid content in foods is variable, in part 
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being influenced by environmental conditions (472).  Particularly, in fruits and vegetables, 
flavonoid distributions vary due to the different cultivars, cultural practices, climatic 
conditions and geographic location, degree of ripeness, storage conditions, and industrial 
processing (292, 473-476).      
The FFQ does not include all flavonoid-containing foods.  Although we modified the 
Block FFQ for the LIBCSP to include some flavonoid-containing foods, it did not include 
blueberries and raspberries, both rich sources of anthocyanidins (377).  Omission of these 
berries from the modified Block FFQ may have contributed to the lower anthocyanidin 
intake reported in our study population compared to those in Greece (59) and Italy (60).   
The reported properties of flavonoids suggest that increased consumption of 
flavonoid-containing foods and beverages may decrease the risk of many diseases, including 
cancer and heart disease (298).  This database will facilitate research on the associations 
between flavonoids and disease in observational studies.   
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Table 1.  Flavonoid database values for total flavonoids and total flavonoid classes (in 
mg per 100 g). 
Block  
FFQ Item 
Total 
Flavo-
noids 
Total 
Flavo-
nols 
Total 
Flav-
ones 
Total 
Flavan-
ones 
Total 
Flavan- 
3-ols 
Total 
Antho-
cyanidins 
Total 
Isoflav-
ones 
Total 
Lig-
nans 
Apples, 
applesauce, 
pears 9.78 2.52 0.00 0.00 7.20 0.00 0.01 0.05 
Bananas 0.07 0.00 0.00 0.00 0.00 0.00 0.00 0.07 
Peaches, 
apricots, 
nectarines 
(fresh in 
season) 6.21 0.85 0.00 0.00 5.36 0.00 0.00 0.00 
Strawberries 
(fresh in 
season) 7.54 1.44 0.00 0.00 4.47 0.00 0.05 1.58 
Cherries 
(fresh in 
season) 129.13 1.24 0.00 0.00 11.58 116.31 0.00 0.00 
Peaches, 
apricots 
(canned, 
frozen, or 
dried) 1.87 0.00 0.00 0.00 1.87 0.00 0.00 0.00 
Oranges 22.02 0.00 0.00 21.94 0.00 0.00 0.00 0.08 
Grapefruit 55.62 0.90 0.00 54.50 0.00 0.00 0.00 0.22 
Orange Juice 
or Grapefruit 
Juice 19.68 0.05 0.00 19.33 0.00 0.00 0.00 0.30 
Other beans 
(baked, pinto, 
kidney, lima, 
blackeyed, 
chili w/beans) 3.67 0.00 0.00 0.00 2.01 0.00 1.60 0.06 
String beans, 
green beans 2.02 1.93 0.00 0.00 0.00 0.00 0.00 0.10 
Green peas 2.53 0.10 0.00 0.00 0.00 0.00 2.42 0.01 
Corn, 
including 
corn on the 
cob 0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.04 
Tomatoes, 
tomato juice, 
V-8 juice 1.57 1.26 0.21 0.00 0.00 0.00 0.05 0.06 
Broccoli 4.64 4.17 0.00 0.00 0.00 0.00 0.03 0.44 
Cauliflower 
or brussel 
sprouts 1.09 0.77 0.21 0.00 0.00 0.00 0.02 0.10 
Spinach (raw) 5.99 4.88 1.11 0.00 0.00 0.00 0.00 0.00 
Mustard 
greens, turnip 
greens, 
collards, kale 12.33 12.33 0.00 0.00 0.00 0.00 0.00 0.00 
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Cole slaw, 
cabbage, 
sauerkraut 0.24 0.13 0.03 0.00 0.00 0.00 0.05 0.04 
Carrots, or 
mixed 
vegetables 
containing 
carrots 0.38 0.04 0.00 0.00 0.00 0.00 0.00 0.35 
Red or green 
peppers 1.18 0.33 0.66 0.00 0.00 0.00 0.00 0.20 
Green salad 2.22 1.97 0.15 0.00 0.00 0.00 0.00 0.10 
Other 
potatoes 
(boiled, 
baked, 
mashed, 
potato salad) 0.11 0.06 0.00 0.00 0.00 0.00 0.04 0.01 
Tofu 28.61 0.00 0.00 0.00 0.00 0.00 28.61 0.00 
Hamburgers, 
cheeseburgers 
meat loaf, 
tacos 3.01 2.74 0.07 0.00 0.00 0.07 0.00 0.21 
Spaghetti, 
lasagna, other 
pasta with 
tomato sauce 1.32 1.17 0.00 0.00 0.00 0.00 0.00 0.15 
Pizza 1.36 1.21 0.00 0.00 0.00 0.00 0.00 0.15 
Tomato and 
vegetable 
soups 0.14 0.14 0.00 0.00 0.00 0.00 0.00 0.00 
Chocolate 
cake, 
brownies, 
cookies 10.03 0.00 0.00 0.00 10.03 0.00 0.00 0.00 
Chocolate 
candy 23.39 0.00 0.00 0.00 23.39 0.00 0.00 0.00 
Beer 0.10 0.10 0.00 0.00 0.00 0.00 0.00 0.00 
Wine 12.27 0.85 0.00 0.00 6.64 4.63 0.00 0.16 
Tea, 
including 
herb tea (hot 
or iced) 118.06 3.89 0.00 0.00 111.41 0.00 0.03 2.72 
Whole-wheat 
or other 
whole grain 
bread 0.97 0.00 0.00 0.00 0.00 0.00 0.09 0.88 
Cantaloupe 0.19 0.00 0.00 0.00 0.00 0.00 0.00 0.18 
Watermelon 0.05 0.00 0.00 0.00 0.00 0.00 0.00 0.05 
Winter 
squash, baked 
squash 0.38 0.00 0.00 0.00 0.00 0.00 0.00 0.38 
Sweet 
potatoes, 
yams 0.30 0.00 0.00 0.00 0.00 0.00 0.00 0.30 
Alfalfa 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.03 
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Sprouts 
High fiber, 
bran or 
granola 
cereals 0.11 0.00 0.00 0.00 0.00 0.00 0.00 0.11 
White rice 0.04 0.00 0.00 0.00 0.00 0.00 0.02 0.02 
Brown Rice 0.32 0.00 0.00 0.00 0.00 0.00 0.03 0.30 
Potato chips, 
corn chips, 
popcorn 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.02 
Coffee, 
regular or 
decaf 0.72 0.00 0.00 0.00 0.00 0.00 0.00 0.72 
White bread, 
rye, 
pumpernickel 
bread, 
sandwiches, 
bagels 0.58 0.00 0.00 0.00 0.00 0.00 0.50 0.09 
Peanuts, 
peanut butter 1.28 0.00 0.00 0.00 0.00 0.00 0.87 0.41 
Low-fat, 
frozen tofu 16.87 0.00 0.00 0.00 0.00 0.00 16.87 0.00 
Corn bread, 
corn muffins, 
corn tortillas 0.07 0.00 0.00 0.00 0.00 0.00 0.00 0.07 
Other cooked 
cereals and 
grits 0.05 0.00 0.00 0.00 0.00 0.00 0.00 0.05 
French Fries 
and Fried 
Potatoes 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.02 
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Table 2.  Distribution of flavonoid intake among a representative sample of women 
without breast cancer (n = 1500) in the Long Island Breast Cancer Study Project 
 #In milligrams (mg) per day.   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Mean# Median#  Minimum# Maximum# Standard 
Deviation# 
Total Flavonoids 230.43 148.95 0.83 902.03 216.49 
Flavonols 10.44 8.39 0.39 37.74 7.47 
Flavones 0.15 0.12 0.00 1.44 0.13 
Flavanones 31.43 22.90 0.00 227.69 33.97 
Flavan-3-ols 173.82 100.77 0.00 685.19 199.67 
Anthocyanidins 3.51 1.46 0.00 139.57 8.35 
Isoflavones 4.90 1.49 0.01 106.41 8.24 
Lignans 6.36 4.84 0.04 20.30 4.68 
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Table 3.  Major contributors of flavonoids by flavonoid class among the control 
women in the LIBCSP  
Rank Food Aggregate Percent Cumulative 
Percent 
 Flavonols   
1 Tea, including herb tea 56 56 
2 Green salad 8 64 
3 Broccoli 7 71 
4 Mustard greens, turnip greens, collards, kale 1 72 
 Flavones   
1 Green salad 41 41 
2 Tomatoes, tomato juice, V-8 juice 30 71 
3 Red or green peppers 10 81 
4 Spinach (raw) 6 87 
5 Cauliflower or brussel sprouts 5 92 
 Flavanones   
1 Orange juice or grapefruit juice 52 52 
2 Grapefruit 35 87 
3 Oranges 13 100 
 Flavan-3-ols   
1 Tea, including herb tea 97 97 
2 Apples, applesauce, pears 1 98 
 Anthocyanidins   
1 Cherries (fresh, in season) 73 73 
2 Wine 26 99 
3 Hamburgers, cheeseburgers, meat loaf, tacos 1 100 
 Isoflavones   
1 Low-fat, frozen tofu 85 85 
2 Tofu 7 92 
3 Peas 1 93 
 Lignans   
1 Tea, including herb tea 99 99 
2 Strawberries 0.5 99.5 
3 Whole-wheat or other whole grain bread 0.3 99.8 
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